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Integrating -Omics For Studying Functional Role Of Ulcerative Colitis Risk Associated Loci. 
Lauma Ramona 
Abstract	
Background: Ulcerative Colitis is chronic inflammatory condition of unknown etiol-
ogy.  Genome Wide Association Studies have successfully identified large number of 
UC risk associated loci, majority of which are located in non-protein-coding DNA re-
gions and been showed to be enriched within regulatory elements, such as enhancers.  
However, the function of these UC risk associated variants is still unknow.  
Aim: To delineate the functional role of GWAS risk associated loci in UC relevant cell 
types. 
Method: We assessed chromatin activity (ATAC seq) and transcriptional behavior 
(RNA seq) of primary cell types extracted from intestinal biopsies and blood from dis-
eased and healthy participant. Next, to pinpoint the mechanistic of how UC associated 
loci contributes to disease risk, we intersected our disease and cell type specific dif-
ferential expression and differential chromatin accessibility data with GWAS dataset. 
Results: Unfortunately, due to technical and financial reasons we failed to reach the 
target sequencing depth for both ATAC seq and RNA seq experiments. In addition, 
when combined with very low participant numbers, our data sets were not strong 
enough to reliably identify the functional role of GWAS variants. However, for prac-
tice, we proceeded with slightly simplistic proximity-based modeling and showed that 
intersecting the 3 -omics studies allowed us to identify 10 regions where the lowest p-
value associated SNP was in proximity to differentially expressed gene and differen-
tially accessible chromatin region.  
Conclusion: We were able to compare the first time the expression levels and chro-
matin conformation in purified immune cell populations from intestinal tissue and pe-
ripheral blood. Unfortunately, due to poor experimental design this study was mark-
edly underpowered and any findings from RNA seq and ATAC seq experiments should 
be further validated before any biological conclusions are made or used for reliable 
prediction of functional role of UC associated risk variants.  
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PCA - Principal Component Analysis  
pIgR - Polymeric Ig Receptor  
PRRs - Pattern-Recognition Receptors 
RhArt - Rheumatoid Arthritis  
RIN - RNA Integrity Number  
RPKM - Reads Per Kilobase Million  
rRNA - Ribosomal RNA  
S1PR1 - Sphingosine 1-Phosphate Receptor Type 1  
SC - Sigmoid Colon  
SEMA4A - Semaphorin 4A 
SNP - Single Nucleotide Polymorphism  
SNX27 - Sorting Nexin Family Member 27 
SPRED2 - Sprouty Related EVH1 Domain Containing 2 
T1D - Type 1 Diabetes  
T2D - Type 2 Diabetes  
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TCM - T Central Memory  
TE - T Effector Cells  
TEM - T Effector Memory Cells  
TEMRA - T Terminal Effector Memory  
TF - Transcription Factor 
TFBSs - Transcriptional Factor Binding Sites   
TH - T Helper Cells  
TI - terminal ileum  
TLRs - Toll Like Receptors 
TM - T Memory Cells  
TNF-α -Tumour Necrosis Factor Alpha  
TRAFD1 - TRAF-Type Zinc Finger Domain Containing 1 
TSS - Transcription Start Site  
TTRM - Tissue Resident Memory T Cells  
TXNIP - Thioredoxin Interacting Protein 
UC - Ulcerative Colitis  
UCi - UC With Inflammation In The Sigmoid Colon  
UCn - UC Without Inflammation In The Sigmoid Colon  
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1.1 Ulcerative	Colitis	
Ulcerative colitis (UC) is chronic, idiopathic inflammatory disorder characterized by 
relapsing inflammation within the gastrointestinal tract. UC is one of two most com-
mon forms of Inflammatory Bowel Disease (IBD). The other main form of IBD is a dis-
order known as Crohn’s disease (CD) (Mozdiak et al., 2015).  
In 2012 Molodecky et al. reported the highest IBD incidence rates among 20 - 29 year 
old’s (Molodecky et al., 2012). However, there are growing number of publications 
highlighting an increasing incidence of UC in pediatric (Sýkora et al., 2018) and elderly 
(Zammarchi et al., 2020) populations. It was reflected in recent report by National In-
stitute for Health and Care Excellence showing the highest UC incidence rates among 
15 - 25 year old’s, with second smaller peak between 55 - 65 year old’s (NICE 
guidelines 2019). 
With better therapies becoming available, UC have transitioned from disease being 
associated with high mortality rates into condition characterized by lifelong disability 
(GBD 2017 Inflammatory Bowel Disease Collaborators 2020). Being a lifelong condi-
tion, UC can lead to emotional distress, anxiety and depression, particularly among 
young adults. Moreover, with the standard care being extremely costly, UC is becom-
ing increasingly larger economic burden on the healthcare system. Associated 
healthcare costs of IBD in the UK in 2013 was £470 million (The IBD Standards Group, 
2013) and Burisch et al reported that direct healthcare costs of IBD in Europe was 
approximately €4.6 - €5.6 billion per year (Burisch et al., 2013).  
The prevalence of UC is highest in Northern America, Northern Europe and UK (also 
referred as regions with high socio-demographic index; Figure 1.1) (Ananthakrishnan, 
2015; Ng et al., 2017). The estimated prevalence of UC in the UK is 1 in 420 (Crohn’s 
and Colitis UK, no date). Although UC incidence rates are stabilizing in countries asso-
ciated with historically high UC occurrence, new cases have been rising in former low 
incidence areas, making UC emerge as a global disease (Loftus, 2004; Kaplan and Ng, 
2017). The exact reason behind this phenomenon is still unknown, however it has 
been hypothesized that introduction western-like-diet (Lerner and Matthias 2015) 
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and increase in hygiene might be some of the risk factors contributing to observed 
increase. Nevertheless, the availability of better diagnostic tools and standardized di-
agnosis in former low incidence regions should not be excluded. 
 
Figure 1.1 GEOPOLITICAL REPRESENTATION OF WORLDWIDE INCIDENCE OF UC EXPRESSED 
PER 100’000 PERSON-YEARS (Ng et al. 2020). 
 
1.2	Clinical	Presentations	And	Available	Treatments		
The clinical presentation of UC includes abdominal pain, increased frequency in bowel 
movement - often with blood in the stool (Baumgart and Sandborn, 2007; Ford, 
Moayyedi and Hanauer, 2013).  
UC almost always involves rectum (proctitis) and progresses proximally in a continu-
ous manner with variable extent of involvement of the colon. Early stage UC is char-
acterized by inflamed, erythematous mucosa that bleeds easily (Figure 1.2 B). In se-
vere cases extensive ulceration with pseudopolyps can be seen (Figure 1.2 D). UC in-
volves only the mucosal and submucosal layers of the intestinal wall. Inflammation is 
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superficial and there is marked infiltration of neutrophils, macrophages and lympho-
cytes in the lamina propria layer.  Neutrophils can intrude into the epithelial cell layer 
and cross into the intestinal lumen causing tissue damage resulting in loss of crypt 
architecture and goblet cell depletion (Gramlich and Petras, 2007; Fatahzadeh, 2009). 
Fraction of UC patients will develop secondary condition outside gut named external 
manifestation, including inflammation in joints, skin problems and inflammation of 
different parts of eye (Levine and Burakoff 2011). Moreover, UC patients have in-
creased risk of developing colorectal cancer when compared to the general population 
(Olén et al., 2020). 
 
Figure 1.2 ENDOSCOPIC OUTLOOK OF B. MILDLY, C. MODERATELY AND D. SEVERELY AF-
FECTED INTESTINAL TISSUE OF UC PATIENTS IN COMPARISON TO A. HEALTHY SUBJECT (Ko-
bayashi et al., 2020).  Endoscopy is irreplaceable in diagnosis and management of IBD. It plays 
a fundamental role in helping to distinguishing between UC and CD, yet, in some cases the 
histopathological and morphological features of UC and CD can overlap making clear diagno-
sis impossible.  
 
Currently there is no cure for UC. Instead therapy is focused on achieving clinal remis-
sion (Kobayashi et al., 2020). UC management is depended on the disease severity and 
its evolution over time. For mild to moderate disease, 5 - aminosalicylate (5-ASA) are 
the first line of choice. If no improvement is seen, corticosteroids are added to the 
treatment (corticosteroids can be used only till the remission is achieved).  If there is 
still no sign of improvement (thus the failure of conventional therapy) use of biologics, 
such as Infliximab, Adalimumab, Golimumab Vedolizumab and small molecule inhibi-
tors, such as Tofacitinib, are tried (NICE guidelines 2019). However, there is risk that 
with time patient will either develop an immunological reaction or stop responding to 
biologic in use.   
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In acute severe UC, intravenous corticosteroids are tried first. However, in case of se-
vere UC with no signs of improvement - surgical management is the only currently 
available lifesaving option left (NICE guidelines 2019; Kobayashi et al., 2020).   
 
1.3		Pathogenesis	Of	UC		
Despite the major effort invested into understanding the disease cause, UC remains 
an idiopathic condition. Though, the exact aetiology of UC is still unknown, current 
hypothesis is that UC is result of uncontrolled immune response to environmental 
stimulus in genetically susceptible individuals (Figure 1.3) (Turpin et al., 2018). 
The main risk factor associated with IBD is a positive family history (Santos, Gomes 
and Torres, 2018). Having a first degree relative with CD or UC increases the risk of 
developing the same condition 8-fold and 4-fold, respectively (Moller et al., 2015). 
This observation was supported by twin studies, where the concordance of IBD be-
tween monozygotic twins (20% - 55% in CD and 6.3% - 17% UC) was higher than con-
cordance between the dizygotic twins (0% - 3.6% in CD and 0% - 6.3% UC ) (Gordon et 
al., 2015).  
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Figure 1.3 RISK FACTORS CURRENTLY BELIEVED TO HAVE SOME POSSIBLE IMPLICATIONS IN 
DEVELOPMENT OF IBD (Turpin et al., 2018). 
Indeed, genetic studies have identified more than 240 IBD risk associated loci, includ-
ing risk variants falling into protein coding genes involved into innate and adaptive 
immunity, epithelial function and microbial clearance (Wellcome Trust Case Control 
Consortium, 2007; Anderson et al., 2011; Jostins et al., 2012; Liu et al., 2015; de Lange 
et al., 2017).  However, individual effect size of associations discovered are modest 
and many healthy individuals carrying a risk associated variant never develop disease. 
In addition, in comparison to family studies, heritability explained by significant asso-
ciations is much smaller. Chen et al., 2014 showed that SNP-heritability accounts for 
19% in comparison to 70% of pedigree heritability of UC (Chen et al., 2014). 
Since then, there have been multiple hypothesis, including polygenicity, gene-gene 
interaction, missing variants and questioning the adequacy of calculation itself, to ex-
plain the missing heritability (Génin 2019). However, immigration studies showing 
that children of immigrants from some of the low risk countries had the same inci-
dence risk to develop IBD as children from non-immigrants (Li et al., 2011; Benchimol 
et al., 2015) and that the younger age of migrants themselves were associated with 
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the increased risk of developing the IBD (Benchimol et al., 2015) suggests that the 
environmental exposure of possibly genetically predisposed individuals might be the 
key in IBD pathogenesis. Indeed, the presence of additional environmental triggers 
would help to explain the rapid increase in IBD epidemiology, particularly, the rise of 
IBD in newly developing countries. However, currently, there are many missing details 
concerning the most relevant environmental factors and their relative contributions 
to disease pathogenesis (Ananthakrishnan et al., 2018).   
1.4		Genetics	Studies	Of	Common	Disease	
Early epidemiology studies showing strong family history of IBD paved the way to  ge-
netic studies desperately trying to identify causal variants.  The first studies to identify 
a genetic locus predisposing to development of IBD used linkage disequilibrium anal-
ysis. These family pedigree studies assess the co-segregation of marker loci with the 
trait of interest (Ott, Kamatani and Lathrop, 2011). However, it soon become came 
clear that linkage disequilibrium analysis lack in power to identify causal genes for 
common diseases including UC  (Altshuler, Daly and Lander, 2008). For immune medi-
ated disease, including UC, CD, Rheumatoid Arthritis (RhArt) and Type II Diabetes 
(T2D), so-called “common disease / common variant” hypothesis suggests that multi-
ple genetic mutations that occur with relatively high frequency in the general popula-
tion may be associated with increased predisposition to disease development, but 
with each mutation having a relatively low relative risk (Kruglyak, 2008). 
In order to identify such common but low penetrance variants, genotyping across mul-
tiple loci in large numbers of individuals is required. A major technical advance in this 
regard came with the development of large-scale genome-wide association studies 
(GWAS). These studies make use of simultaneous genotyping of multiple single nucle-
otide polymorphisms (SNPs), to compare DNA sequence variation between disease 
bearing individuals and the healthy population in a “hypothesis-free” manner that 
scans the entire genome for SNPs associated with increased risk of disease develop-
ment (Wang et al., 2005). Due to low rates of recombination between SNPs that are 
located close together across much of the genome, there is a strong probability for 
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groups of SNPs to be passed together through generations - a phenomena known as 
linkage disequilibrium (LD). Testing of relatively few SNPs (called tag SNPs) can there-
fore allow assessment of the association of much of the most common genetic vari-
ants across the whole genome, without the need for direct sequencing (Bush and 
Moore, 2012). Thus GWAS performed on large numbers of healthy and diseased indi-
viduals permit the identification of common genetic risk factors underlying complex 
genetic diseases or traits.  
Currently there are more than 240 IBD risk associate loci identified (de Lange et al., 
2017), yet, the most aspects of disease pathogenesis remain unclear. It turned out 
that the main strength of GWAS design, which allowed to test from hundreds of re-
gions simultaneously, become the Achilles heel of the study. GWAS allow the identifi-
cation of risk regions centred on SNPs with the highest disease association signals (fo-
cal SNPs). However, these are typically in strong LD with other SNPs, thus, one cannot 
assume that focal SNP is a causal SNP without further study, including further charac-
terization of potential functional roles for both the focal SNP and SNPs in LD (Schaub 
et al., 2012).  
1.5	Difficulties	With	GWAS	Interpretation			
Understanding and translating GWAS findings into causal regulatory pathways would 
provide an important stepping stone into development of better therapeutic strate-
gies and diagnostics. However, despite the increasing attempts to dissect the causal 
variants and assign functional roles to UC risk variants and/or regions, progress to-
wards understanding pathogenic mechanisms has been limited. 
Fine-mapping is perhaps the most established computational approach used for refin-
ing evidence for a focal SNP in an LD block with multiple SNPs. Fine-mapping allow the 
assignment of probability of causality, where the ability to discriminate the causal var-
iant depends on the effect of the variant and the sample size.  The SNP showing the 
strongest probability is pronounced to be causal (Spain and Barrett, 2015). Dense gen-
otyping in a further 67,852 individuals allowed pinpointing of 18 of 94 SNPs studied, 
with IBD risk statistically linked to a single causal variant. In an additional 27 cases, 
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SNPs were linked to a single variant with at least 50% probability of being causal 
(Huang et al., 2017).   
However, candidate variant identification alone does not typically provide biological 
insights into how the associated variant contributes to the studied phenotype. In rare 
instances, focal SNPs are associated with changes in the protein-coding sequence. For 
example, GWAS have demonstrated a non-synonymous mutation in Autophagy Re-
lated 16 Like 1 (ATG16L1) gene as a strong risk factor for the development of CD 
(Hampe et al., 2007). However, such instances of non-synonymous changes in protein-
coding sequence are relatively rare (Jostins et al., 2012; Liu et al., 2015; de Lange et 
al., 2017a). Majority of UC associated risk loci are in the non-protein-coding part of 
genome.  
IBD is not unique in having the majority of the underlying genetic risk described so far 
associated with non-protein-coding changes. In fact, 93% of GWAS disease- or trait- 
associated variants lie within non-protein-coding DNA regions and, thus, understand-
ing the functional role of these non-protein-coding regions in general may help deter-
mine the potential biological role of disease or trait associated risk loci (Maurano et 
al., 2012).  
1.6	GWAS	Risk	Variants	Enrichment	On	Cis-Regulatory	Regions		
In parallel to early genetics studies, large consortium named the ENCODE was formed 
with a goal to systematically map all functional elements in DNA. The ENCODE consor-
tium defined functional elements as “discrete genomic segments that encode defined 
products or display a reproducible biochemical signature”. Together these data have 
transformed our understanding of the role of non-protein-coding DNA, by showing 
that 80.4% of the human genome has apparent biochemical functions and functional 
elements which are important in determining the cell identity (Ecker et al., 2012). 
These therefore govern cell-type specific gene expression.  
As part of the 2012 ENCODE consortium publication release, came the first detailed 
analysis of the human regulatory network (often divided into cis- and trans- regions 
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depending on their spatial locations). Cis-regulatory regions are DNA sequences 
(mainly non-protein-coding) involved in controlling transcriptional activity on the 
same chromosome and contain various cis-regulatory elements, including collections 
of binding sites for transcriptional factors (TFBSs) (Mathelier, Shi and Wasserman, 
2015). Broadly, cis-regulatory elements may be recognized as acting in different func-
tional categories. These include: 
• Promoters - DNA regions where the pre-initiation complex (DNA-binding protein 
complex whose assembly governs mRNA transcription) binds (Riethoven, 2010);  
• Enhancers - DNA segments that potentiate transcriptional activity of associated 
genes (Riethoven, 2010); 
• Silencers - DNA segments that hinder expression of associated genes (Riethoven, 
2010); 
• Insulators - DNA regions that maintain discrete inter-domain boundaries when 
placed between enhancer-promoter or opened-closed chromatin (Riethoven, 
2010);   
Cis-regulatory regions, in particular enhancer regions, are enriched with GWAS risk 
variants (Ernst et al., 2011; The ENCODE Project Consortium, 2012; Farh et al., 2015; 
Kundaje et al., 2015a). Intriguingly, variable DNA regions, such as SNPs, can modulate 
gene expression in a genotype specific manner (Dimas et al., 2009; Fairfax et al., 2012; 
Lee et al., 2014). Moreover, variant can lead change in expression by modulating a 
function of cis-regulatory elements. Taken together, these observations could poten-
tially explain and provide with mechanistical insights of how does UC risk associated 
variants located on non-protein-coding part of genome contributes to disease patho-
genesis.  
Indeed, experimental work by Musunuru et al., 2010 showed that SNP located at the 
non-protein-coding region on 1p13 locus (previously identified as GWAS risk locus for 
Myocardial Infarction) alters the function of regulatory elements by creating a TFBSs  
which in turn increase the expression of SORT1 gene.  Follow up in mice gain-of-func-
tion studies showed that increase SORT1 expression correlates with decrease levels of 
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low-density lipoprotein cholesterol, which is well established risk factor for Myocar-
dial Infarction (Musunuru et al., 2010).  
In summary, study combining GWAS data with predictions of regulatory element ac-
tivity and gene expression data may dissect how risk variants located on non-protein-
coding regions increase risk for UC development.  
1.7	Determining	Activity	Of	Regulatory	Regions	
One of the methods used to predict location and activity of potential regulatory re-
gions utilizes chromatin accessibility landscape. Thurman et al., 2012 showed that  
most TFBSs identified by the ENCODE Chip-seq were located within accessible chro-
matin regions (Thurman et al., 2012). 
Chromatin is the filamentary assembly of DNA and proteins in which only very short 
stretches of the naked helix are revealed. The fundamental unit of chromatin is the 
nucleosome which is made up from DNA twice wrapped around an octamer of core 
structural proteins known as histones (Lawrence, Daujat and Schneider, 2016). The 
topological distribution of nucleosomes across the genome is dynamic and reflective 
of chromatin functions. Chromatin accessibility is the extent by which DNA-binding 
factors are able to form a physical contact with the genomic region they would act on 
(Klemm, Shipony and Greenleaf 2019).  Active promoters are associated with accessi-
ble chromatin, where binding of RNA polymerase II require rearrangement of chro-
matin structure (due to polymerase size) (Felsenfeld et al., 1996). In addition, nucleo-
somes as well as other chromatin binding factors can provide steric hindrance to tran-
scription factors (TF) binding and increase TF dissociation rates (Allis and Jenuwein 
2016).  
Chromatin accessibility can be assessed, at least in part, by mapping the sensitivity of 
chromosomal regions to enzymatic cleavage. An example of this approach involves 
assessing the sensitivity of isolated nuclear DNA to enzymatic cleavage by Deoxyribo-
nuclease I (assay named - DNase seq) or Transposonase (assay named - Assay for 
Transposonase Accessible Chromatin Using Sequencing; ATAC seq).  
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ATAC seq allows fast and reliable assessment of the chromatin accessibility, nucleo-
some position and TF occupancy simultaneously. The underlying principle of ATAC seq 
is the use of an engineered hyperactive Tn5 transposase, which is loaded with adap-
tors for PCR amplification and sequencing. Exposure of nuclear DNA to this transposes 
under rate-limiting conditions therefore results in fragmentation of nuclear DNA and 
simultaneous tagging of the resulting DNA sequence in a manner that permits ampli-
fication and subsequent sequencing (Figure 1.4 A) (Buenrostro et al., 2013, 2015). By 
integrating preferentially into open chromatin (steric hindrance in less accessible 
chromatin hinders access of the transposase), the engineered enzyme can thus be 
employed to allow for the amplification and preparation of sequencing libraries from 
small numbers of target cells previously not amenable to DHS methods (Figure 1.4 B).  
In addition, since TF binding to DNA sequence protects it from cleavage, ATAC Seq 
“footprints” may be analyzed for evidence of active TFBS (Buenrostro et al., 2013). 
 
 
Figure 1.4 A. GRAPHICAL REPRESENTATION OF ATAC SEQ WORKING PRINCIPLES, B. TIME 
AND INPUT MATERIAL REQUIREMENTS DEPENDING ON SELECTED METHOD FOR OPEN-
CHROMATIN ANALYSIS (Buenrostro et al., 2013).  
ATAC seq has already successfully provided with meaningful insight into areas, such 
as cancer and developmental biology (Corces et al., 2018, Berg et al., 2019), neuronal 
biology (Fullard et al., 2018) and complex disease, including, Systemic Lupus Erythem-
atous (Scharer et al., 2016) and Type 2 Diabetes (Bysani et al., 2019). Ludwig et al., 
2019 employed ATAC seq to study the transcriptional factor dynamics through the 
erythropoiesis. When combined with GWAS data for erythroid cell treats, they 
showed that 19.4% of fine-mapped variants fell within accessible chromatin suggest-
ing a potential for regulatory activity (Ludwig et al., 2019). 
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1.8	 Computational	 Models	 For	 Functional	 Interpretation	 Of	
GWAS	Data	
Possibly the greatest challenge in interpretation of GWAS data is the realization of 
endless complexity in transcriptional regulatory networks and functional diversity of 
different cell types. It is an important roadblock in a way of understanding the complex 
disease, such as UC, CD, T2D, RhArt, variety of cardiovascular and neurological condi-
tions, where the pathogenesis goes beyond easily “studiable” Mendelian single-gene 
disorders. Instead, scientist is often faced with hundreds of risk regions, majority lo-
cated in non-protein-coding part of genome and seemingly requiring one or more 
stimulus from an unknown environmental risk factors to initiate the disease develop-
ment.  Just the sheer quantity and the complexity of these data seem to exceed the 
capacity of what a conventional functional study could answer in any given amount of 
time (de Souza, Fiocchi and Iliopoulos 2017). 
Computational analysis has proved itself to be capable of handling large data output 
genomic technologies returns. In the heart of computational analysis is a predictive 
model constructed by researcher, which usually is based on prior scientific observa-
tions (often created from large training data sets) and that could be applied other data 
sets (Brodland 2015).  
Indeed, other functional genomics technologies, not just GWAS, is benefiting from 
computational biology. As an example, transcriptomics, proteomics, metabolomics of-
ten returns hundreds of hits. The common approach was to select only a handful of 
hits (often defined by p-value or log fold change) to follow up in functional studies. 
Whilst the functional studies are vital in validating the findings, selecting only a hand-
ful of hits is wasteful when the cost of experiment and clinical sample availability is 
considered. In addition, there is no guarantee that hits with the highest p-value or log 
fold change are relevant to treat studied. Computational analysis in turn maximizes 
the scientific output by allowing to iterate whole data set. In addition, single data 
layer, being it GWAS data or functional genomics data, on its own often fall short in 
providing full biological story. It has been recognized that combinatorial analysis of 
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multiple layers of -omics data have potential to further increase the functional under-
standing (Cano-Gamez and Trynka 2020; Nature Research Custom Media and Illumina 
2020). 
In summary, in complex disease space, predictive learning models could potentially 
unlock the genetic data penitential and translate these finding into the actionable 
knowledge, thus, understanding the functional consequence of these variants will in-
crease the clinical translation. The few of most used computational models developed 
to assign the variant specific functionality are briefly discussed below.  
1.8.1	GWAS	SNP	Enrichment	Analysis	 
Currently there are number of different methods for enrichment calculation available, 
including ones aimed to dissect the disease specific cell types (SNPsea (Hu et al., 2011), 
CHEERS (Soskic et al., 2019)), propose the functional role of GWAS variants (GREGOR 
(Schmidt et al., 2015)) and to partition the SNP heritability (LDSC Finucane et al., 
2015)). All with an underlying theme to deepen our understand regarding the possible 
functional role of risk variants. 
The underlying assumption behind the enrichment analysis aimed to predict disease 
associated cell types and specific cell state, is that disease relevant cell types/states 
will have more pathogenicity/disease associated transcripts and genomic annotations 
and, hereby, they will be enriched for the disease associated variants. In this case ge-
nomic annotation refers to the functional genomic elements that has a regulatory ac-
tivity (Cano-Gamez and Trynka 2020). 
Farh et al showed that most of risk variants for autoimmune disease, including CD and 
UC, are enriched in enhancers and promoters active in CD4+ T cells subpopulations. 
Notably, causal variants associated with UC were also increased in cis-regulatory ele-
ments from colonic mucosa (Farh et al., 2015). 
Enrichment methods looking to understand the functional role of risk variants, work 
under similar assumption as ones used to prioritize the disease related cell types, thus 
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if disease associated risk variants act via altering the function of regulatory regions, 
then they should fall within the corresponding genomic annotations. 
Maurano et al., 2012 mapped chromatin accessibility (DNase seq) in 349 cell-types 
and showed that GWAS identified disease associated variants were enriched in in ac-
cessible chromatin sites, whereas proportion of the GWAS SNPs overlap with DHS in 
disease relevant cell types, thus showing cell type contribution to phenotype 
(Maurano et al., 2012). Altogether supporting the hypothesis that GWAS identified 
disease associated variants act by altering the function of the non-protein-coding re-
gions in a cell type specific manner.  
1.8.2	Colocalization	Analysis	 
Variable DNA regions, such as SNPs, can modulate gene expression in a genotype spe-
cific manner (Albert and Kruglyak, 2015). Following this observation, presence of the 
SNP should be reflected within expression of target gene as well as the functional ge-
nomic elements which activity variant affects.  Statistical model used to link the gen-
otype with the functional data (expression, exon splicing, chromatin accessibility and 
marks) is called quantitative trait locus (QTL) analysis (Miles and Wayne 2008). For this 
approach, no prior knowledge of the functional mechanisms is required (Albert and 
Kruglyak, 2015). However, large numbers of donors are required.   
Colocalization analysis aims to integrate the GWAS data with QTL data and identify if 
the same variant is causal in both GWAS and QTL studies (Wen, Pique-Regi and Luca 
2017). The analysis is markedly complicated by the LD and possibility of multiple causal 
variants in loci (Cano-Gamez and Trynka 2020). Moreover, variant can have different 
functional roles in different cell types or in the same cell type under different stimulus 
(Gerrits et al., 2009; Fairfax et al., 2012).  Therefore, it is important to note that colo-
calization analysis cannot establish causality, but can be used for hypothesis genera-
tion.  
Chun et al., 2017 looked to determine if autoimmune and inflammatory diseases, in-
cluding Multiple sclerosis (MS), IBD, UC, CD, Type 1 diabetes (T1D), Celiac disease and 
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RhArt, risk associated variants colocalized with cis-expression QTLs identified in CD4+ 
T cell, CD14+ monocytes and lymphoblastoid cell lines (Chun et al., 2017). Together 
they showed that only minority of the risk associated loci colocalized with eQTLs and 
concluded that proximity between GWAS risk variants and QTLs is not enough to pro-
pose the function of variant. However, the same as other studies, they showed that 
fraction of overlaps observed were cell type specific.  
Currently majority of computational models created to propose functional role of 
GWAS data integrates risk variants with only a single layer of functional data. This ap-
proach has been proven to be great for gaining some insight into variant functionality. 
However, it does not provide with full mechanistic insight of how risk variant could 
lead to disease pathogenies. Multi-dimensional data sets that combine multiple ele-
ments are required in order to correlate the nucleotide variations with change in near-
by regulatory functions and gene expression.  
MOLOC is a colocalization analysis aimed to integrate GWAS summary statistics with 
multiple QTLs from functional -omics data (Giambartolomei et al., 2018). Authors used 
expression QTL and methylation QTL to identify regulatory effects of Schizophrenia 
risk loci. MOLOC does not detect causal relationships among the associated traits, yet 
they showed that addition of an extra layer of functional data increased the gene dis-
covery by 1.5 times. However, the interpretability got more complex than from pair-
wise comparison, with single locus having 15 different possible hypotheses.  
In summary, the integration of GWAS data with functional genomics data has been 
successful for new hypothesis generation and translation of genetic findings into 
something easier to follow up. However, integration of pairwise dataset alone has 
proven to be extremely challenging and the difficulty is only increasing with more layer 
added. Hereby, conventional functional studies in vital to fully validate the findings 









 The importance of understanding non-coding DNA changes within the context of dis-
ease relevant cell types is highlighted by the fact that single variant can have a differ-
ent (even opposing functions) in different cell types (Dimas et al., 2009, Fairfax et al., 
2012). It is mirrored by the cell type specific action of regulatory elements, particularly 
enhancers. Ernst et al 2011 showed that enhancer activity is correlated with regula-
tion of tissue dependent gene expression (Ernst et al., 2011). Thus, cell type specific 
studies are vital for correct interpretation of regulatory element function and under-
standing how risk loci alter their function and lead to increased risk for disease devel-
opment.  
However, to date most attempts to annotate UC risk associated GWAS data have re-
lied upon data from peripheral blood, tissue and  ex vivo cultured primary cell lines 
from healthy individuals (Kabakchiev and Silverberg, 2013; Singh et al., 2015; Peloquin 
et al., 2016; Momozawa et al., 2018).  Considering the above, we identified a need for 
functional genomics data in UC relevant cell types.  
In time of experimental design, it was unclear which cell types are UC relevant, there-
fore we reasoned that due to the inflammatory nature of the disease and due to its 
intestinal location, purified cell populations from intestine would be the most attrac-
tive target to use in our study. In addition, previous data from our lab showed that   
GWAS risk loci for CD and UC where enriched in genes upregulated in intestinal lym-
phocytes when compared to T cells from peripheral blood (Raine et al., 2015). Further 
highlighting the possibility of intestinal immune cells being disease specific. In addi-
tion, by looking at that time available literature we reasoned that intestinal epithelium 
(due genetic studied linking epithelial malfunction with IBD) and blood lymphocytes 
(due enrichment studies showing IBD risk associated variant enrichment in CD4+ T 
cells) could be an interesting and possibly disease relevant cell populations as well.  
The intestinal cell types used in this study are briefly discussed below.  
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1.9.1	Intestinal	Epithelium	
Both large and small bowel are in constant exposure to luminal contents and tight 
regulation is necessary to maintain the symbiotic relationship between the external 
environment and self. The intestinal epithelium, coated in layers of mucus, provides 
the most basic physical barrier between the microbiome and underlining lymphoid 
tissue (Chelakkot, Ghim and Ryu, 2018). (The microbiome is term given for all micro-
organisms, such as, bacteria, fungus, protozoa and viruses that inhibits specific envi-
ronment, in this case the human gastrointestinal tract (Barko et al., 2018)).  
The epithelium is in constant dynamic biochemical communication with the microbi-
ome and other cells located within the mucosa, and thus contributes to immunomod-
ulatory, metabolic and digestive functions (Okumura and Takeda, 2017; Allaire et al., 
2018).  Intestinal epithelia cells express key receptors of the innate immune system: 
Toll like receptors (TLRs) and nucleotide binding oligomerization domain-like recep-
tors (NODs). These direct the cells to elicit both pro- and anti- inflammatory signals. 
TLR and NOD belongs to the pattern-recognition receptors (PRRs) family and recog-
nize foreign bacterial, viral and fungal structures in highly context specific manners 
(Peterson and Artis, 2014).  
Any impairment in epithelial cell function could potentially lead to disruption in ho-
meostasis and result in inflammation.  This has been supported by various murine 
models where disruption of both – the physical barrier and/or epithelial function -  led 
to spontaneous inflammation (Nenci et al., 2007; Johansson et al., 2008; Wirtz et al., 
2017).  Mucin 2 (MUC2) is one of the main mucins of colonic mucus. Mice with MUC2 
-/- deletion suffer from increased contact with intestinal microbiota which leads to 
spontaneous colitis by 7 weeks of age (Johansson et al., 2008).   
1.9.2	Intraepithelial	Lymphocytes	
Above the basement membrane, interspersed between epithelial cells, is a specialized 
subclass of T lymphocytes, known as intraepithelial lymphocytes (IEL) (Guy-Grand, 
Griscelli and Vassali, 1974). Although a range of immunocytes may be present in this 
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layer, the dominant and best characterized population is intra-epithelial T cells and in 
further text we use IEL to denote these epithelial resident T cells only. Despite their 
early discovery and extensive studies, understanding of the role of human intestinal 
IELs is still limited with most information arising from studies in rodents. Intestinal IELs 
are heterogeneous and the number and subtype profile of IELs vary between different 
parts of intestine (Mowat and Agace, 2014; Mayassi and Jabri, 2018).  
1.9.3	Lamina	Propria	Residing	T	Cells		
Below the intraepithelial layer lies the lamina propria layer. This is bounded by the 
thin basement membrane of epithelial cells above and the muscularis mucosae below 
and is home for variety of immune cells including LPL (Reed and Wickham, 2009). 
These LPLs are numerically more abundant that IELs and appear to possess distinct 
biology.   
In humans,  naïve T lymphocytes travel to distal regions, where after antigen priming 
they develop into T effector cells (TE), from which subpopulation persists as T memory 
cells (TM) (Kumar, Connors and Farber, 2018). The fundamental benefit of immunolog-
ical memory is a faster response upon reencountering of an antigen. TM can be further 
divided into smaller functionally and phenotypically distinct subsets. The heterogene-
ity of human TM has been defined based on differential expression of costimulatory 
and adhesion molecules, such as, CD45 isoforms (CD45RO, CD45RA) and lymph node–
homing receptors Cluster of differentiation 62 L and  CC-chemokine receptor 7 (CD62L 
and CCR7) (Sathaliyawala et al., 2013).  
Thome et al 2016 showed that both ileum and colon of young adults (15 – 25 years of 
age) are predominantly occupied by T effector memory cells (TEM) whereas the rest of 
TM subsets, such as, T central memory (TCM) and T terminal effector memory (TEMRA) 
are almost absent (Thome et al., 2016). However, recent studies in mice have led to 
the identification of yet another TM subset, which does not recirculate and, thus, is 
named tissue resident memory T cells (TTRM) (Klonowski et al., 2004; Masopust et al., 
2010). It is not yet clear if the same populations persist in human, but ex vivo studies 
of human T cells have showed that non-lymphoid tissue residing TEM express Cluster 
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of differentiation 69 (CD69), a marker also expressed by majority of murine TTRM 
(Sathaliyawala et al., 2013).  CD69 is an early T cell activation marker which can block 
T cell exit from tissue by suppressing the sphingosine 1-phosphate receptor type 1 
(S1PR1), a molecule required for cell emigration (Sheridan and Lefrançois, 2011). Ku-
mar et al 2017 showed that a considerable majority (<90%) of intestinal TEM cells ex-
press CD69, which is not expressed by the TEM located in blood (Kumar et al., 2017).  
In common with type a IELs, lamina propria T cells and B cells are associated with a 
“classical” immune response, undergoing priming within in secondary lymphoid tis-
sue. Typically, evading pathogens breaching the mucosal surface are captured by An-
tigen Presenting Cells (APCs), which then migrate to secondary lymphoid tissue and 
induce T cell activation and imprinting (Iwasaki and Kelsall, 2001; Mowat et al., 2003). 
Naïve CD8+ T cells, on activation, differentiate into CD8+ T cytotoxic T cells, whereas 
naïve CD4+ T cells, differentiate into distinct T helper subsets based on the stimulatory 
cytokines (Szabo et al., 2000; Mullen et al., 2001; Fields, Kim and Flavell, 2002; Mangan 
et al., 2006; Veldhoen et al., 2008). Once priming and imprinting has occurred effector 
T cell enter efferent lymphatics and subsequently return to bloodstream (Girard, 
Moussion and Förster, 2012). In the circulation, T cell homing molecules interact with 
adhesion ligands expressed by endothelium and hold lymphocytes in place thus facil-
itating their extravasation into intestinal tissue (Berlin et al., 1993; Lefrançois et al., 
1999). However, in light of the recent discovery that most LPL resident T cells belong 
to the TTRM population, which do not recirculate, it is yet to be determined if these T 
cells can be reactivated in lymphoid tissue independent manner, and what the biolog-
ical consequences might be.  
1.9.4	Lamina	Propria	Residing	B	Cells	
Lamina propria B cells differentiate into plasma cells and together with a transmem-
brane epithelial glycoprotein receptor known as the polymeric Ig receptor (pIgR) 
maintain luminal immunoglobulin A (IgA) and M (IgM) levels. IgA is the predominant 
immunoglobulin produced in intestinal tissue, is protected from protease cleavage 
and prevents antigen encounter with the epithelial cell surface and, thus, contributes 
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to immune exclusion (Brandtzaeg et al., 1999). In human, IgA is dimeric and consist of 
both IgA1 and IgA2 subclass. The ratio of IgA1 to IgA2 changes along the bowel, where 
IgA1 is preferentially produced by plasma cells in the small intestine. In colon the ratio 
is almost equal. In addition to pIgR, enterocytes also express the transferrin receptor 
Cluster of differentiation 71 (CD71) which can bind to IgA1 and facilitate luminal anti-
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We hypothesize that UC risk variants can alter the function of regulatory elements in 
disease relevant cell-types and thus contribute to disease pathogenesis. We specu-
lated that by combining GWAS data with transcriptomics data and cis-regulatory ele-
ment activity (measured by chromatin accessibility) we may be able to understand the 
functional role of UC associated risk variants.  
The specific goals for this project were: 
1) To assess performance of commercially available anti-GPR15 antibodies. 
(Side project) 
2) To compare the chromatin state and transcriptional activity between 
healthy volunteers and UC patients at purified single cell population level. 
3) To combine functional genomics and/or GWAS data to assess: 
• How much of the chromatin conformational changes are reflected by gene ex-
pression and vice versa.  
• GWAS immune disease and treat associated loci enrichment with differentially 
accessible chromatin regions and differentially expressed genes.  
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Human Biological Samples were sourced ethically and their research use was in accord 
with the principles of the informed consent.  
3.1	Recruitment	Of	Healthy	Donors	And	UC	Patients		
The main study had a two stages of participant recruitment: at the first stage samples 
were collected for both ATAC Seq and RNA Seq analysis, whereas later recruitment 
was purely to increase sample numbers for the RNA Seq study.  All samples for this 
study were collected at the Addenbrookes Hospital – Endoscopy Unity. 
A total of 39 individuals, undergoing medically indicated colonoscopy, were recruited 
for biopsy and blood collection as part of this study. Eight pinch biopsies were taken 
from the SC and TI respectively. Biopsies were collected into the RPMI medium 1640 
(Life Technologies, 11875-093) on ice, along with 5-10ml blood (into tubes containing 
15mg EDTA). Only biopsies taken from SC were used in this PhD project. All TI biopsies 
were processed till sequencing library stage and frozen in -800C.   
Prospective volunteers (UC cohort) were approached if they either had previously 
been diagnosed with UC (identified from health records stored on hospitals electronic 
data base) or if their symptoms during the time of endoscopy were ones of the UC. 
Control samples were obtained from healthy subjects undergoing colonoscopy for 
screening purposes. Donor fit for this study was re-evaluated after the results from 
the gastrointestinal endoscopy and histological examination were added on their 
health record. The main exclusion criteria for the study were old age and presence of 
other immune mediated disease.  
After careful review of medical history and sequencing quality metrics, 29 participants 
(15 UC patients and 14 healthy controls, Table 3.1) passed all study requirement and, 
thus, were used for downstream analysis. The final UC cohort was heterogeneous in 
their disease history, in particular with regard to disease duration and severity.  To 
control some of this variation, for further analysis, UC patients were split into two 
subgroups - UC with microscopically and/or macroscopically inflamed SC (UCi) or UC 
without inflammation in the SC (UCn). 
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3.2	Volunteer	Demographics	
Additional factors that could potentially contribute to the inter-individual variation 
were also recorded. These included patient age, sex, smoking history, other conditions 
diagnosed by time of sample collection and medication (Table 3.1). As part of this 
study we did not collect any supplementary clinical information.  
Since only a subset of the initially collected samples were used in the final analysis, as 
shown in Table 3.1, the mean age ± standard deviation and gender ratio was calcu-
lated for each population individually, based upon only those samples that contrib-
uted to the final analysis (Table 3.2). The mean age of controls ranged from 47.7 – 
57.6 years, whereas for UCi it was from 35.5 – 42.5 years. The oldest population was 
UCn, where mean age varied from 59.2 -64.3 years. Due to low sample numbers in 
each category it was not possible to conduct reliable significance estimations. Just by 
looking at crude age ranges, it seems that each individual condition is very well 
matched in the inter-individual age. Moreover, UCi falls into the expected age for dis-
ease onset in adults. However, for very heterogenous disease, such as IBD, study eval-
uation based on age alone might be very mis-informative.  Hereby, to understand how 
age affect the data, it should be evaluated in light of accompanying factors, including 
the disease onset, duration, severity and remission-relapse.  
 With respect to gender, there was a marked female dominance seen in all the groups. 
The sex effect on chromatin accessibility and ncRNA has been reported (Qu et al., 
2015). Though we excluded both sex chromosomes, we could not completely eradi-
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3.3	Purification	Of	Individual	Cell	Types		
Cells were first purified from peripheral blood and pinch biopsies following the proto-
col already established in lab and detailed below.  
Flow cytometry was selected for final cell type purification. First, all identified markers 
were tested, multicolor panels and sorting strategy developed and optimized (Figure 
3.1).  
Figure 3.1 SUMMARY OF CELL POPULATIONS AND THEIR SORTING MARKERS. IEL – Intraepi-
thelial lymphocytes; LPL – Lamina Propria; MF – Monocytes and macrophages; TEM – T effector 
memory. 
 
   
 
3.3.1		Peripheral	Blood	Mononuclear	Cell	Isolation	
Human blood was diluted 1:1 in Dulbecco’s Modified Eagle’s medium (DMEM) Gluta-
MAX (Life Technologies, 31966-021) + 0.5% Bovine Serum Albumin (BSA, Sigma 
A3912). Lymphoprep (Axis-Shield) was used for density-based separation (800xg, 
20min, 4 oC). Interface was collected in 15ml Falcon tube and washed with 10ml 
DMEM + 0.5% BSA, twice (250xg, 5min, 4 oC).  Peripheral blood mononuclear cell 
(PBMCs) were stained with an antibody panel designed.  
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3.3.2	Lamina	Propria	And	Intraepithelial	Cell	Separation	
Biopsies were incubated in calcium and magnesium free Hank’s Balanced Salt Solution 
(HBSS, Life Technologies 14170088) with 2mM EDTA (Sigma E5134) and 0.5% BSA.  
Samples were agitated at 900rpm for 32 min (20 min on shaking platform + 12 min by 
vortex) at room temperature. 2 x 6.5 µl 1M DL-Dithiotheritol (DTT) was added at 0 min 
and 10 min respectively. Media was changed at 24 min, 28 min and 32 min, and the 
supernatants containing the IEL fraction were filtered via 70μm cell strainer (Falcon 
352350). The flow through containing IEL was spun down at 250xg for 7min at 4oC and 
resuspended in 200μl HBSS + 0.5% BSA + 2mM EDTA and left on ice. 
Remaining tissue patches were washed with 10ml DMEM + 0.5% BSA, resuspended in 
1ml of the same media and incubated for 1.5h at 37o C after addition of 10μl type IV 
collagenase (at 128U/ml, Sigma C1889) and 10μl type V DNAse II (10U/ml, Sigma 
D8764). Tissue fragments were then further fragmented via grinding through a 70μm 
cell strainer. The flow through containing LPL was spun down at 250xg for 6min at 4o 
C and resuspended in 200μl DMEM + 0.5% BSA.  IEL and LPL were stained with anti-
body panel designed.  
3.3.3	Cell	Staining		
Cells were incubated with an antibody cocktail (final volume = 100µl) for 20 min on ice 
in dark. Cells were then washed by adding 2ml-3ml media and spun at 250xg for 4min, 
pipetted through 70µm cell-strainer and resuspended in 200µl fresh, cell type com-
patible, media for Fluorescence activated cell sorting (FACS) or FACS Analysis. All an-
tibodies used in study, including test runs, are showed in Table 3.3. Unfortunately, the 
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Table 3.3 LIST OF ALL ANTIBODIES USED DURING THE SEQUENCING STUDY. Table show all 
markers used in either sorting strategy development or in actual study and the distributer, 
catalogue number, clone, fluorochrome and concentration used for staining lamina propria, 
intraepithelial and peripheral blood mononuclear cell suspensions. LP - Lamina propria; IEL - 






We used BD Fortessa and BD Fortessa 2 cell analyzers to develop a sorting panel and 
strategy for both RNA seq and ATAC seq experiments. Instruments were located at 
the NIHR Cambridge BRC Cell Phenotyping Hub.  
For our anti-GPR15 antibody validation experiments we used FACS Canto and BD For-
tessa, located at the MedImmune, Granta Park. 
For data analysis FlowJo_VX (FlowJo LLC, Ashland) software were used.  
3.4.2	Cell	Sorting	
For both - sequencing and anti-GPR15 antibody validation experiments, BD Aria III – 
Fusion and BD Aria III cell sorters were used. Sorting was performed by the NIHR Cam-
bridge BRC Cell Phenotyping Hub. 
49 | P a g e  
 
First, populations of size of 1000-5000 events intended for ATAC Seq were sorted into 
350μl DMEM + 0.5% BSA. Then, if there were enough leftovers for a given sample, 
same populations were sorted for transcriptomics study. Cells for RNA Seq were 
sorted into either 350μl of RLT Buffer (Qiagen, 79216) or RLT plus Buffer (Qiagen, 
1053393). The RLT Buffer was used for all phase 1 recruitment samples, where RLT 
plus Buffer for all latter samples. Figure 3.2 shows the FACS gating strategy for Blood, 
IEL and LPL samples, where each dot is representing a single cell.  
 
FIGURE CONTINUED IN NEXT PAGE 




FIGURE CONTINUED IN NEXT PAGE 
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Figure 3.2 AN EXAMPLE OF FACS GATING STRATEGY USED TO PURIFY INDIVIDUAL CELL POP-
ULATION FROM A. BLOOD, B. LPL AND C. IEL SAMPLES, ALL OBTAINED FROM A SINGLE DO-




RNA from all samples sorted for transcriptomic analysis was extracted by the Qiagen 
RNeasy micro plus kit (Qiagen, 74034), following the manufacturers instruction. How-
ever, instead of mainstream extraction guidelines, the protocol in Appendix D for Total 
RNA, including small RNA, purification was selected. Extracted RNA quality and quan-




SMARTer Stranded Total RNA seq Kit- Pico Input Mammalian (Clontech, 635006) was 
used for all RNA Seq library generation. RNA input was standardized to 800pg, but 
there were a dozen samples that had less than 800pg of total RNA. In this case, librar-
ies were generated from all RNA available. With exception to fragmentation time, li-
braries were constructed following the exact manufacturer’s instructions. We de-
creased fragmentation time for samples with RNA integrity number >7 to 3 minutes, 
as 4 minutes (specified in manual) resulted in over-fragmented inserts.  
Sequencing library quality, in terms of insert size distribution and adapter contamina-
tion was assessed on Agilent Bioanalyzer via High Sensitivity DNA kit (Agilent, 5067-
4626). In addition, mean fragment size for each sample was recorded.  
For quantification KAPA Universal Library Quantification kit (KAPABIOSYSTEMS, 
KK4824) was used following the manufacturer’s guidelines.  All libraries were diluted 
10,000 and 20,000 fold to fall into dynamic range of assay. To ensure the highest ac-
curacy each dilution was run in triplicate with H20 included as negative control. 
52 | P a g e  
 
QuantStudio 12K Flex Real-Time PCR System (ThermoFisher Scientific, Massachusetts) 
was used for fluorescence signal (Cq) and melt curve detection.  Finally, sample Cq 
values and associated fragment size were imputed in KAPA Library Quantification Data 
Analysis Template and concentration of each library calculated.  
3.5.3	Library	Multiplexing,	Pooling	and	Quality	Control	
4 to 6 RNA Seq libraries were carefully matched, so that both - UC and Control samples 
- are represented in one pool. Unfortunately, T cells and B cells were only partially 
randomized between pools with some residual potential for batch effects.  
In addition, extra care was taken to design primer usage and reaction conditions such 
that all nucleotides at each position of barcodes gets equal representation in each 
sequencing cycle.  
All libraries were normalized to 10nM concentration in Illumina RSB buffer (Kindly pro-
vided by sequencing facility) and 10µl of each sample transferred to new tube. Pool 
quality was assessed on Agilent Bioanalyzer by High Sensitivity DNA kit (Agilent, 5067-
4626). 
3.6.	ATAC	Sequencing	Library	Construction	And	Quality	Control		
ATAC Seq assay was modified from the S John et al Current Protocols in Molecular 
Biology 2013 (John et al., 2013) and Buenrostro et al Current Protocols in Molecular 
Biology 2013 (Buenrostro et al., 2013). Due to these modification steps taken, we pro-
vide a full procedure description below.	Reagents used and buffer recipes are summa-
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Table 3.4 LIST OF ALL REAGENTS REQUIRED FOR ATAC SEQ LIBRARY CONSTRUCTION. 
 
 
Table 3.5 ATAC SEQ BUFFER RECIPES. Table summarizes all buffers needed for successful li-
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First, lysis buffer was made by mixing 0.1% IGEPAL solution 1:1 with Buffer A. Cells 
were spun at 4oC for 5min at 200rcf and supernatant gently removed from cell pellet. 
Cells were resuspended in 200µl lysis buffer and left on ice for 8 min exactly to incu-
bate.  Following incubation, nuclei were spun at 4oC for 5min at 500rcf. Now, super-
natant was gently removed from nuclear pellet, nuclei resuspended in 30µl Tagmen-
tation solution and placed in heating block (at 37oC) for 30 min exactly to incubate. 
Tagmented DNA was cleaned-up with Quiagen MinElute Reaction Cleanup Kit (elute 
in 10µl Buffer EB). Tagmented samples were stored at -80oC. 
 
3.6.2	ATAC	Seq	Library	Construction	and	Quantification			
Tagmented DNA samples were removed from freezer and thawed on ice. Next, PCR 
amplification mix was made by pipetting 37.5 µl of PCR reaction master mix, 2.5µl 
25µM Primer 2 (Ad2.1-Ad2.24) and 10µl of transposed DNA in each 1.5 Eppendorf 
tube. PCR reaction was run as follows:  
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1 cycle  5min  72oC 
30 sec  98oC 
5 cycles 10 sec  98oC 
30 sec 63oC 
60 sec  72oC 
Hold at 4oC 
Sample was removed from PCR machine and keep on ice. qPCR mix was made by com-
bining 9.5 µl of qPCR reaction master mix, 0.5µl 12.5µM Primer 2 (Ad2.1-Ad2.24) and 
5µl mix from 1st PCR in each individual pPCR tube. qPCR reaction was run as follows: 
1 cycle  30 sec  98oC 
19 cycles 10 sec  98oC 
30 sec 63oC 
60 sec  72oC 
Hold at 4oC 
 
Additional cycles for PCR was calculated by plotting Rn vs. cycle. Cycle number that 
correspond to 25% of maximal fluorescence intensity was used to finish PCR amplifi-
cation. Libraries were purified using MinElute PCR Purification Kit and stored at -80oC 
till further analysis. 
For ATAC Seq library quantification KAPA Universal Library Quantification kit (KAPABI-
OSYSTEMS, KK4824) was used. Samples were diluted 1: 10,000 and run in triplicate on 
QuantStudio 12K Flex Real-Time PCR System (ThermoFisher Scientific, Massachu-
setts). Concentrations were calculated using constant mean fragment size of 120bp 
(in line with previous experiments from our lab). 
After library submission all concentrations were re-estimated by qPCR-based method, 
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3.7	Data	Analysis		
Initial sequencing data from RNA Seq experiments was processed by the Medimmune 
Bioinformatics facility, whereas pre-processing of raw ATAC Seq data was performed 
by Dr. J. Gutierrez-Achurry (postdoctoral research associate in Dr Carl Anderson’s 
group, Wellcome Trust Sanger Institute).  
All downstream analysis was performed by the author using either R Studio or Python 
programming environments. Due unique nature of each analysis pipeline, the detailed 




















Algorithms Web-access Published 
FASTQC https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ Simon Andrews  
BWA http://bio-bwa.sourceforge.net/ (Li and Durbin, 2009) 
KEGG https://bioconductor.org/packages/release/bioc/html/KEGGprofile.html (Zhao, Guo and Shyr, 2019) 
Samtools http://www.htslib.org/doc/samtools.html (Li et al., 2009) 
Bamtools https://github.com/pezmaster31/bamtools (Barnett et al., 2011) 
Bedtools https://bedtools.readthedocs.io/en/latest/ (Quinlan and Hall, 2010) 
MACS2 https://github.com/taoliu/MACS/ (Zhang et al., 2008) 
Cutadapt https://cutadapt.readthedocs.io/en/stable/ (Martin, 2011) 
PICARD https://broadinstitute.github.io/picard/command-line-overview.html - 
Sailfish https://github.com/bcbio/bcbio-nextgen (Patro, Mount and Kingsford, 2014) 
MultiQC https://multiqc.info/ (Ewels et al., 2016) 
Bcbio-nextgen https://github.com/bcbio/bcbio-nextgen - 
Bcbio-variation https://github.com/chapmanb/bcbio.variation - 
Novosort http://www.novocraft.com/products/novosort/ Novocraft Technologies Sdn Bhd  
Qualimap http://qualimap.bioinfo.cipf.es/ (García-Alcalde et al., 2012) 
IPA  https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/ - 
Cufflinks http://cole-trapnell-lab.github.io/cufflinks/ (Trapnell et al., 2010) 
FeatureCounts  (Liao, Smyth and Shi, 2014) 
Sleuth + Wasabi https://github.com/COMBINE-lab/wasabi/ - 
Hisat2 https://ccb.jhu.edu/software/hisat2/index.shtml (Kim, Langmead and Salzberg, 2015) 
Htseq https://htseq.readthedocs.io/en/release_0.11.1/ (Anders, Pyl and Huber, 2015) 
Kraken  https://ccb.jhu.edu/software/kraken/ (Wood and Salzberg, 2014) 
R package DiffBind https://bioconductor.org/packages/release/bioc/html/DiffBind.html (Stark and Brown, 2011; Ross-Innes et al., 2012) 
R package DESeq2 https://bioconductor.org/packages/release/bioc/html/DESeq2.html (Love, Huber and Anders, 2014) 
R package fdrtools  http://www.strimmerlab.org/software/fdrtool/ (Strimmer, 2008) 





(Bioconductor Core Team, 
2019) 
R package org.Hs.eg.db https://bioconductor.org/packages/release/data/annota-tion/html/org.Hs.eg.db.html (Carlson, 2019) 
R package DOSE https://bioconductor.org/packages/release/bioc/html/DOSE.html (Yu et al., 2015) 
R package ReactomePA https://bioconductor.org/packages/release/bioc/html/Reac-tomePA.html (Yu and He, 2016) 
R package clusterProfiler https://bioconductor.org/packages/release/bioc/html/clusterPro-filer.html (Yu et al., 2012) 
R package RColorBrewer https://cran.r-project.org/web/packages/RColorBrewer/index.html - 
R package ggplot2 https://cran.r-project.org/web/packages/ggplot2/index.html (Ginestet, 2011) 
R package rgl https://cran.r-project.org/web/packages/rgl/index.html - 
R package IRanges https://bioconductor.org/packages/release/bioc/html/IRanges.html (Lawrence et al., 2013) 
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R package factoextra https://cran.r-project.org/web/packages/factoextra/index.html - 
R package tximport https://bioconductor.org/packages/release/bioc/html/tximport.html (Soneson, Love and Robinson, 2016) 
R package pheatmap https://cran.r-project.org/web/packages/pheatmap/index.html - 
R package Hmisc https://cran.r-project.org/web/packages/Hmisc/index.html - 
R package biomaRt https://bioconductor.org/packages/release/bioc/html/biomaRt.html (Durinck et al., 2005, 2009) 
R package AnnotationDbi https://www.bioconductor.org/packages/release/bioc/html/Annota-tionDbi.html 
(Pagès, Carlson and Falcon, 
2019) 
R package genefilter https://bioconductor.org/packages/release/bioc/html/genefilter.html (Al, 2019) 
R package RnaSeqSampleSize https://bioconductor.org/packages/release/bioc/html/RnaSeqSam-pleSize.html (Zhao et al., 2018) 
R package topGO https://bioconductor.org/packages/release/bioc/html/topGO.html (Alexa A, 2019) 
R package plyr https://cran.r-project.org/web/packages/plyr/index.html - 
R package Rgraphviz https://www.bioconductor.org/packages/release/bioc/html/Rgraph-viz.html (Hansen et al, 2019) 
R package Gviz  http://bioconductor.org/packages/release/bioc/html/Gviz.html (Hahne and Ivanek, 2016) 
Resource Identifier  
Human Genome GRCh38 http://www.ensembl.org/Homo_sapiens/Info/Index  
Human Genome GRCh37 https://genome.ucsc.edu/cgi-bin/hgLiftOver  
RStudio https://www.rstudio.com/  
GraphPad Prism 7 https://www.graphpad.com/scientific-software/prism/  
Flow Jo  https://www.flowjo.com/  
Inkscape  https://inkscape.org/  
Python 2 and 3  https://www.python.org/  
Microsoft Office https://products.office.com/  
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4.1	Introduction		
Therapies based on the blockade of the intestinal trafficking have shown success in 
treatment of both - UC and CD (Feagan et al., 2013, Sandborn et al., 2013, Targan et 
al., 2007, Vermeire et al., 2017). Recently a new G-protein coupled receptor named 
GPR15 has been reported as an intestine-homing receptor for both human and mice ( 
Fischer et al., 2016, Kim et al., 2013, Nguyen et al., 2015). Despite the efforts,  the full 
functional role of GPR15 has not been yet understood. 
Antibodies are immunoglobulin molecules produced by the immune system (Kanya-
vuz et al., 2019). Antibodies structure allows it to bind to the antigen in a highly spe-
cific manner, making them into the one of the most powerful research tools on the 
market. Antibody production is a very time-consuming process and has a high cost 
component.  
As part of my PhD we asked if any of commercially available anti-GPR15 antibodies 
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4.2 Aim 
To compare existing commercially available anti-GPR15 antibodies and validate their 
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4.3 Materials	And	Methods	
4.3.1	 Generation	 Of	 Jump-In	 T-REx	HEK293	 Cell	 Lines	Which	 Over-Ex-
presses	Human	GPR15		
Jump-In T-REx HEK293 cells were obtained from Medimmune Cell culturing team. 
Plasmids were designed and given by Matthew Robinson, Medimmune. The full list of 
reagents and buffers used for transection experiments are summarized in Table 4.1 
and Table 4.2, respectively.  




Table 4.2 SUMMARY OF BUFFER RECIPES NEEDED FOR JUMP-IN T-REX HEK293 TRANSFEC-
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4.3.1.1	Stable	Transfections	
At Day 1 of transfections, old media was removed and cells incubated with 5ml Ac-
cutase at 37°C for 5 minutes. Following incubation, flask was gently taped to dislodge 
cells and suspension transferred to 50ml Falcon tube, topped up with PBS, spun for 
5min at 400g and, finally, resuspend in Opti-MEM for counting. Cells were seeded in 
6 well plates at ~1e6cells/well and left overnight to adhere.  
At Day 2 - old media was aspirated and replaced with 2ml DMEM Mix without antibi-
otics (Table 4.2). Cells were transfected using Lipofectamine 2000, where 300ml of 
transfection mix (Table 4.2) was gently added in each well dropwise. Finally, plates 
were gently swirled to mix and returned to incubator for next 24h.  
At Day 3 - transfected cells were harvested and transferred to new T75 flask containing 
25ml of selection median (DMEM Mix + 1mg/ml Geneticin, 5ug/ml Blasticidin). Selec-
tion media was changed every 7 days. Once visible colonies had appeared, cells were 
passaged as normal and used for GPR15 antibody comparison.  
4.3.1.2	Transient	Transfections	
At Day 1 - Jump-in HEK293 were seeded into 6 well plates, so that  625’000cells/well 
in 2ml DMEM Mix (Table 4.2).  
At Day 2 - 500ml of transfection mix (Table 4.2)  was gently added in each well drop-
wise. Finally, plates were gently swirled to mix and returned to incubator for next 24h.  
At Day 3 - cells were used for assessment of GPR15 and Flag expression. 
4.3.1.3		Plating	For	Antibody	Staining	 
Old cell media was removed and cells washed with PBS, and incubated with Accutase 
at 37°C for 3 minutes. Cell suspension was transferred to 15ml or 50ml Falcon tube, 
topped up with PBS + 1% FCS, spun for 5min at 400g and resuspend in PBS for count-
ing. Cells were seeded in 96 well V-bottom plate at 5.5x104 cells/well/100µl.  
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4.3.2	Peripheral	Blood	Mononuclear	Cell	Isolation	From	Blood	Cones.		
Ethically sourced blood was purchased from the commercial vendor. Donations were 
made in day before and blood received in cone-like plastic containers.  
Upon arrival, blood cone was cut open and 10ml of blood was run into the 50ml Falcon 
tube and mixed with the 30ml PBS (Gibco, 10010023). Next, 20ml of the Blood-PBS 
mix was layered on 20ml of Ficoll (Sigma-Aldrich) and spun for 40min at room tem-
perature at 400g (no brake). PBMC layer was sucked-up via Pasteur pipette, resus-
pended in 30ml PBS and spun for 10min at 200g. Cell pallet was resuspended in 30ml 
PBS and spun again for 10min at 200g. As final step, cell pallet was resuspended in 
10ml DMEM, counted and seeded at 2e5 cell/well in 96-well U-bottom plate and used 
for GPR15 antibody assessment.  
4.3.3	Antibody	Staining		
As first step, the eFluor780 viability marker was added into each well (final concentra-
tion of 1 in 2500). Plate was wrapped in foil and incubated at either a room tempera-
ture (HEK293) or on ice (PBMCS) for 20min. Plate was washed by adding either 100 µl 
of PBS (HEK293)  or cell media (PBMCS) to each well (final 200 µl /well), spun for 5min 
at 400g and supernatants discarded. Wash step was repeated twice. Figure 4.1. sum-
marizes staining strategy, time and concentrations for all GPR15 experiments. Table 
4.3 lists all antibodies used in anti-GPR15 antibody comparison, validation and evalu-




FIGURE CONTINUED IN NEXT PAGE 




Figure 4.1 DIAGRAMS SHOWING THE STEP BY STEP STAINING STRATEGY  FOR EACH INDI-
VIDUAL ANTI-GPR15 ANTIBODY COMPARISON, VALIDATION AND EVALUATION EXPERI-
MENT. Staining strategy for A. commercially available antibody comparison using engineered 
HEK293 cell lines, B. MAB3654 staining assessment on PBMCs, C. MAB3654 and D. Goat-anti-
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Blood CD4+ TH and CD8+ TC  cells were FACS sorted into RLT Buffer (Qiagen, 79216). 
After cell lysis, RNA was extracted following RNeasy Plus Mini kit (Qiagen, 74134) guid-
ance with extra on column DNase digestion. Next, the High Capacity RNA-to-cDNA Kit 
(Applied BiosystemsTM, 4388950) was used to convert RNA into cDNA and gene ex-
pression assessed by real-time PCR with TaqMan Gene Expression Master Mix (Ap-
plied BiosystemsTM, 4369016) following the manufacturer’s instructions. Both, GPR15 
and GAPDH TaqMan probes were kindly given by colleagues in MedImmune. Samples 
were run and analysed on QuantStudio 12K Flex Real-Time PCR System (ThermoFisher 
Scientific).  
4.3.5	Flow	Jo	Analysis		
For data analysis FlowJo_VX (FlowJo LLC, Ashland) software was employed. Separation 
Index, calculated as showed below, was used to evaluate the strength of partition be-
tween the positive and negative population. 
𝑆𝑒𝑝𝑎𝑟𝑎𝑡𝑖𝑜𝑛	𝐼𝑛𝑑𝑒𝑥 =
𝑀𝑒𝑑𝑖𝑎𝑛𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 − 𝑀𝑒𝑑𝑖𝑎𝑛𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒










We first compared four, at that time commercially available, anti-GPR15 antibodies 
for their performance on flow cytometry application.  
Jump-In HEK293 cell line was engineered to over-express human GPR15 with and with-
out a Flag tag. Transfected cell lines were stained with either MAB3654, FAB3654, 
AB8104 or AB188938 antibodies followed (where appropriate) by PE-conjugated goat-
anti-mouse or goat-anti-rabbit secondary antibodies. Figure 4.2. A shows the initial 
gating strategy.  
AB8104 and AB188938 anti-GPR15 polyclonal antibodies failed to produce any signal 
when incubated with Jump-In HEK293 cell lines engineered to over-express either hu-
man (Figure 4.1. B, n experiment = 2, n transfection attempts = 2) or mice (results not shown) 
GPR15 with and without Flag tag.  
MAB3654 and FAB3654 showed weak signal when incubated with cell lines trans-
fected with GPR15 alone (Figure 4.1.B, n experiment = 2, n transfection attempts = 2), yet no 
signal was observed when cell lines engineered to overexpress both GPR15 and Flag 
tag was tested.  
However, the Flag tag expression was very low (~10%) (Figure 4.1 B) suggesting that 
there are underlining issues with transfection itself. Therefore, the strength of signal 
produced by any of four anti-GPR15 antibodies cannot be used as definitive quality 
assessment.  
 




FIGURE CONTINUED IN NEXT PAGE 





Figure 4.2 COMPARISON OF COMMERCIALLY AVAILABLE ANTI-GPR15 ANTIBODIES (n experiment 
= 2, n transfection attempts = 2). Flow cytometry plots showing the A. initial gating strategy and B. 
anti-GRP15 antibody (AB8104, AB188938, MAB3654 and FAB3654) and anti-Flag staining per-
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4.4.2	Assessment	Of	MAB3654	Staining	On	Peripheral	Blood	T	Cells	
Antibody performance is subject to both - an application its intended to be used and 
the cellular context.  At this stage, before investing time in an extensive antibody val-
idation, we wanted to see if MAB3654 would show any binding that could be detected 
by flow cytometry  when incubated with immune cells isolated from the blood.  
PBMCs were stained with MAB3654 followed by PE-conjugated goat-anti-mice sec-
ondary antibody. Gating was set by looking at the signal produced by the secondary 
antibody alone (2nd alone contains all markers, except the MAB3654). Figure 4.3 A 
shows the initial gating strategy.  
Flow cytometry analysis showed that MAB3654 has an ability to bind both - CD4+ and 
CD8+ T cells. However, there was a marked inter-donor variation in GPR15 expression 
by CD8+  Tc  (Figure 4.3 B) and CD4+ TH (results not shown) cells.  
In summary, both CD8+ and CD4+ T lymphocytes stained positive for GPR15 when in-
cubated with MAB3654. 
 




Figure 4.3 FLOW CYTOMETRY PLOTS SHOWING THE ANTI-GRP15 ANTIBODY MAB3654 
STAINING PERFORMANCE (n experiment = 2, n donor = 4). Flow cytometry plots showing the A. initial 
gating strategy and B. GPR15 expression by blood CD8 T cells. Histograms show PE fluores-
cence normalized to the mode.  





In our previous experiment we asked if MAB3654 would show any signal when incu-
bated with blood resident T cells. Indeed, we observe some binding, but it displayed 
large inter-individual variation. Here we set out to assess if by tweaking the experi-
mental design a more reproducible stain could be achieved. Figure 4.4 A shows initial 
gating strategy used for all optimization experiments. 
To determine an optimal antibody staining concentrations, we performed serial dilu-
tion of both MAB3654 primary and PE-conjugated goat-anti-mice secondary antibod-
ies. Separation between the positive and negative populations was measured by SI.  
The best distinction between GPR15 positive and negative population was achieved 
when MAB3654 (conc. = 17.5mg/ml). However, all 3 concentrations tested produced 
visually easy-to-separate dot-plots with almost equal % of GPR15+ events (n experiment = 
1, n donor = 1, Figure 4.4 B). PE-conjugated goat-anti-mice secondary antibody showed 
the best performance at conc. = 0.2ug/100ul. Higher concentrations (≥0.6ug/100ul) 
of goat-anti-mice secondary antibody, in the absence of MAB3654, resulted in an un-
specific binding (n experiment = 1, n donor = 1, Figure 4.4 C). The amount of unspecific bind-
ing of goat-anti-mice secondary antibody, when MAB3654 was present, was very hard 
to estimate as all 3 concentrations had similar % of GPR15+ events.  
To further evaluate if goat-anti-mice secondary antibody shows some unspecific bind-
ing when in prescience of MAB3654, we performed side by side comparison of staining 
quality when the same anti-GPR15 antibody clone was used already conjugated with 
a PE (FAB3654) or biotin (produced in MedImmune). Very similar GPR15 expression 
levels were detected by all three methods (n experiment = 1, n donor = 3, Figure 4.4 D), but 
the “indirect” staining method with MAB3654 followed by PE-conjugated anti-mice 
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In addition to determining the optimal antibody staining concentration, we assessed 
if longer incubation times would lead to better distinction between the positive and 
negative populations. PBMCs were stained with MAB3654 for 20min, 1h or 24h (at 
dark on ice). Even though MAB3654 incubation time of 1h showed the best SI (SI = 92), 
both 20min and 1h stains were visually easy to separate and returned almost identical 
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FIGURE CONTINUED IN NEXT PAGE 







FIGURE CONTINUED IN NEXT PAGE 




Figure 4.4 FLOW CYTOMETRY PLOTS SHOWING THE A. INITIAL GATING STRATEGY, B. 
MAB3654 PRIMARY AND C. GOAT-ANTI-MICE SECONDARY ANTIBODY TITRATION, D. TAG 
COMPARISON AND E. MAB3654 INCUBATION TIME COMPARISON. Histograms show PE flu-
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4.4.4	MAB3654	Staining	Validation	Using	Blood	Resident	T	Cells	
Probably the most fundamental characteristics of an antibody is its ability to bind se-
lectively to its  antigen. It was crucial for us to determine if GPR15 positive population 
is truly expressing GPR15. We used flow cytometry to sort GPR15-, GPR15LOW and 
GPR15HIGH T cells. GPR15 expression (at mRNA level) was assessed by TaqMan gene 
expression assay, normalized against the GAPDH and ratio calculated by 2B∆∆DE .  
The GPR15LOW and GPR15HIGH populations had 10.591 and 446.389 times higher GPR15 
expression than the GPR15- negative population, showing that MAB3654 truly binds 
to the GPR15 (n experiment = 1, n donor = 4, Figure 4.5 A).  
Next, we used an isotype control to assess the level of non-specific binding. PBMCS 
were stained with either MAB3654 or IgG 2b isotype controls (two different clones 
were given by colleagues in MedImmune), followed by goat-anti-mice secondary an-
tibody. Both isotype controls showed very little signal (n experiment = 1, n donor = 1, Figure 
4.5 B).  
Unfortunately, due unforeseeable reasons project was stopped at this stage and no 
other validation experiments carried out.  
In summary, we showed that cells bound by the MAB3654 were enriched for GPR15 
expression. 
 






Figure 4.5 MAB3654 STAINING VALIDATION WITH A. qPCR (n experiment = 1, n donor = 4) AND B.  
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4.5	Discussion 
In early experiments from our laboratory (carried out by Josquin Nyce) we used GPR15 
positive (HDLM-2) and negative (MOLT4) cell lines, selected based on information in 
The Human Protein Atlas. Only very faint shift in GPR15 expression was detected and 
it could not be distinguished from an artefact. We reasoned that HDLM-2 expresses 
too little GPR15 at protein level and, therefore, a cell line engineered to over-express 
GPR15 would be more informative for further evaluation of antibody performance.  
In the first part of this study, we transfected Jump-In HEK293 cell lines to over-express 
GPR15 alone or with Flag tag. We performed both stable and transient transfections 
with aim to ensure that we achieve noticeable over-expression of our target protein. 
Only MAB3654 and FAB3654 produced any signal when incubated with cell lines trans-
fected to over-express GPR15 alone. As expected the signal from transiently trans-
fected cell line was much higher than from stable transfections, yet still below to the 
expected transfection efficiency. Indeed, the very low expression of Flag tag (~10%) 
by cell lines engineered to over-express the GPR15 with the Flag tag suggest that there 
is an underlying issue with the transfection itself. Therefore, the signal levels produced 
by any of the four antibodies could possibly be attributed to an experimental downfall 
and not the antibody. We currently do not know why transfections did not work and 
it was not in scope of our immediate goals to investigate it further.  
Our main goal was to have an anti-GPR15 antibody that could be used for immuno-
phenotyping applications. From antibodies tested, only MAB3654 had shown some 
degree of signal in both HDLM-2 and transfected HEK293 cell lines. However, before 
proceeding to time-consuming MAB3654 validation experiments, we wanted to see if 
MAB3654 would produce any signal when incubated with blood resident T lympho-
cytes.  The initial experiments showed high inter-individual variation in GRP15 expres-
sion by both CD8+ Tc and CD4+ TH cell. Closer assessments of Flow Jo dot plots showed 
that for some of the donors’ “negative” population has become elongated, which 
could be indicative for either - a cell subpopulation that has very low GPR15 expres-
sion or an issue with the staining protocol itself.  
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Therefore, we proceeded to investigate if further optimization of our staining protocol 
could resolve variation in MAB3654 staining. We observed that higher concentration 
and longer incubation time of MAB3654 resulted in better SI. However, visual assess-
ment of flow cytometry graphs showed no noticeable difference in staining quality 
between the optimized experimental settings and our initial staining protocol. We 
would like to acknowledge that our antibody titration experiments were not compre-
hensive. Our goal was to see if substantial increase in antibody concentration would 
increase the target detection. Therefore, if MAB3654 passed the performance assess-
ment, more extensive titration should be carried out.  
Interestingly, all further experiments including the optimization experiments showed 
very consistent anti-GPR15 staining (% GPR15+ Tc = 2.58 ±	0.85, % GPR15+ TH = 6.5 ± 
1.83; n experiment = 5, n donor = 8). The only difference we could identify between our 
initial PBMC staining and optimization experiments was new batch of the goat-anti-
mice secondary antibody.  
Our results are supported by recent publication by Adamczyk et al., 2017. They used 
FAB3654 to immunophenotype T lymphocytes from the peripheral blood of healthy 
donors and UC patients.  Similar to us, they showed that only small percentage of 
healthy CD4+ and CD8+ T cells expresses the GPR15  (% GPR15+ Tc = 1.9 ± 1.0, % GPR15+ 
TH = 4.0 ± 2.7). However, it is important to highlight a paper form Bauer et al  where 
they showed that history of tobacco-smoking can have a severe effect on GPR15 abun-
dance. In their study, current smokers had a markedly higher proportion of GPR15 
positive T cells (10%-30%) than the healthy non-smokers (median 5%) (Bauer et al., 
2017). The smoking history of blood donors was not provided. However, it would be 
interesting to determine if the high inter-individual variation in GRP15 expression ob-
served in initial experiments was due the tobacco-smoking. 
In the light of ongoing concerns about data reproducibility, it is of high importance to 
ensure that reagents, such as antibodies are subjected to rigorous application valida-
tion, before use in research. For antibody to be used in research it should be specific, 
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selective and reproducible. As a final part of this study, we sought to get an experi-
mental proof that MAB3654 is suitable for immunophenotyping application. 
 We first performed a qPCR on FACS sorted T cell (binned by different levels of GPR15 
expression) and showed that MAB3654 truly separates GPR15 positive events (at 
mRNA level). Next, we used an isotype control to assessed the level of non-specific 
staining, such as, antibody binding to the FC receptors. We showed that there is very 
little non-specific binding. However, as only a small percentage of blood resident TC 
and TH cells expressed GPR15, even very little of non-specific binding could lead to 
large proportion of false positives.  We have been pre-incubating our cells with Human 
serum for 10min before staining, but it should be tested if increase in blocking time 
could reduce the non-specific binding to even lower levels.   
Unfortunately, project needed to be stopped and we could not do any further valida-
tion or protocol optimization experiments. However, if more time would be given, we 
would like to test MAB3654 specificity for GPR15. The one of experiment that could 
be done to evaluate MAB3654 specificity, is to transfect a cell line to express closely 
related family members of GPR15. However, the antibodies selectivity for GPR15 in 
over-expressed system might be different from one in physiological expression densi-
ties. Hereby a different approach to assess the MAB3654 specificity and sensitivity 
would be to use gene editing tools to knock-down the expression of GPR15.  
In summary, we evaluated performance of four commercially available anti-GPR15 an-
tibodies and rough assessment showed that MAB3654 has the most potential to be 














5. Assessment	 Of	Differences	 In	Tran-
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5.1	Introduction	
To date most attempts to describe the transcriptional landscape in UC have relied 
upon data from whole tissue samples (Costello et al., 2005; Planell et al., 2013; 
Bjerrum et al., 2014; Van der Goten et al., 2014; Taman et al., 2018; Haberman et al., 
2019), where cell heterogeneity and dynamic ratios hinders identification of transcrip-
tional changes associated with disease and subsequent gene – risk associated variant 
interplay. In this context, it is important to consider studies such as those by Fairfax 
et al and Dimas et al which have highlighted that the impact of genetic variants on 
gene expression may be cell-type dependent and also depend upon inflammatory 
state (Dimas et al., 2009; Fairfax et al., 2012, 2014).  Nevertheless, for most of im-
mune-mediated diseases, including UC, the pathological cell types are unknown. The 
observations that IBD associated causal variants impair genes acting in various inflam-
matory pathways (Pidasheva et al., 2011; Rivas et al., 2011a; Bouzid et al., 2013; Zhu 
et al., 2017) and disease pathology is driven by an uncontrolled immune response, 
support a key role for immune cells. 	
In this chapter, we employed RNA Seq to investigate transcriptional changes associ-
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5.2	Aims	  
• To compare the transcriptional activity in purified immune cell populations from 
healthy volunteers and UC patients with or without active inflammation in their 
sigmoid colon. 
• To assess how does the transcription profile changes in the same cell type depend-




















Before sequencing all samples collected during the study, we decided to perform op-
timization experiments to assess the sequencing library quality and identify the opti-
mal sequencing design (For more detail see Appendix 1). We found that libraries made 
from samples low in RNA quantity showed poor alignment to the human genome and 
introduced RNA quality and quantity-based library pre-filtering (for more detail see 
Appendix 2). 
92 libraries were sent for sequenced to SMCL Next Generation Sequencing Hub, Ad-
denbrookes, Cambridge. Samples were sequenced on Illumina HiSeq 4000 at 110M 
75bp PE reads/library. 15% Phix spike in was added for each run.  
5.3.2	RNA	Seq	Data	Analysis	Pipeline			
Initial quality assessment and read mapping was performed by the MedImmune Bio-
informatics facility, whereas further downstream analysis was carried out by the au-
thor. 	
5.3.2.1	Pre-Processing	Of	Raw	Sequencing	Data		
The initial analysis was performed using the bcbio open resource python toolkit. The 
initial analysis step by step included:  
§ Raw sequencing read quality control by FastQC quality metrics tool; 
§ Removal of left-over adapters; 
§ Raw read alignment to the human reference genome (hg38) by Hisat2 (Kim, 
Langmead and Salzberg, 2015) and pseudoalignment to the human reference tran-
scriptome by Sailfish (Patro, Mount and Kingsford, 2014); 
§ Alignment quality control by Samtools (Li et al., 2009) and Qualimap (García-
Alcalde et al., 2012); 
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The end product of this initial pipeline was Sailfish files, containing transcript level 
alignment for each RNA library sequenced along with a MultiQC report summarizing 
results from all individual QC steps included in workflow.  
5.3.2.2	Downstream	Analysis	
5.3.2.2.1	Creation	Of		Gene-Level	Count	Datasets		
The tximport package (Soneson, Love and Robinson, 2016) was used to summarize 
Sailfish generated transcript level abundance into gene-level expression count matri-
ces. Next, newly generated gene-level count matrices and associated metadata were 
passed to the DESeq2 R package (Love, Huber and Anders, 2014) selected for differ-
ential expression calculation. Finally, genes with no counts or single count across all 
samples were removed. 
5.3.2.2.2	Gene	And	Sample	Sub-Setting	
Protein coding and lncRNA gene lists were obtained from Ensemble data base using 
biomaRt R package (Durinck et al., 2005). Then, both lists, one by one, were used to 
filter our data set and create two new data matrices. One with only protein coding 
genes and second with both lncRNA and protein coding  genes.  
Data QC showed that all cell populations extracted from LPL had much higher intra-
group variance than their blood relatives (Appendix 3). Disproportionate variance 
could introduce a bias in the test statistics if the differential expression call would have 
been made on the whole dataset. Therefore, both protein coding and protein coding 
+ lncRNA data sets were split into smaller data matrices. Samples in each newly cre-
ated object are listed below. 
• LPL CD4+ TEM from UCi and UCn and C  
• LPL CD19+ B cells from UCi and UCn and C 
• Blood CD4+ TEM from UCi and UCn and C  
• Blood CD19+ B cells from UCi and UCn and C 
• Blood CD4+ TEM from C and Blood CD19+ B cells from C 
• Blood CD4+ TEM from C and LPL CD4+ B cells from C 
• Blood CD19+ TEM from C and LPL CD19+ B cells from C 
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5.3.2.2.3	Sample	Quality	
We put large emphasis on data quality assessment. An extensive pre- and post- differ-
ential expression QC was performed, including the Power calculation to assess if our 
data set is sufficient in size to confidently reject the null hypothesis.  For in-depth de-
scription of the QC, Power calculation and assessment of main challenges encoun-
tered please refer to Appendix 1-5. 
5.3.2.2.4	Call	For	Differential	Expression	
During QC we noticed that many of smaller data matrices were below the Independ-
ent filtering threshold. Meaning that genes with very low counts were retained. There-
fore, we introduced 2 different gene-count pre-filtering functions for protein coding 
and protein coding + lncRNA data sets, respectively.  
Protein	Coding	Data	Set	
Before calling for differential expression, all sample subsets were filtered to remove 
genes where there were less than n number of samples with normalized counts 
greater than or equal to 10. n was unique for each subpopulation and defined by tak-
ing a half of sample number available within the phenotype with lowest sample num-
bers. 
For differential expression analysis of protein coding genes, a design formula was set 
on either: 
§ RNA sample collection time and disease state (e.g. C vs UCi, C vs UCn) 
§ RNA sample collection time and anatomical location (e.g. blood vs LPL) 
§ RNA sample collection time and cell type (e.g. CD4 vs CD19)  
Protein	Coding	+	lncRNA	Data	Set	
The gene-count pre-filtering threshold was increased so that genes would be retained 
if all samples from a given subset expressed more than 10 normalized counts each. 
Sex was added to design.  
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Protein	Coding	And	Protein	Coding	+	LncRNA	Data	Set	
After calling for differential expression, test statistics in terms of p-value distribution, 
outlier removal, independent filtering and differentially expressed gene count distri-
bution was checked. fdrtool R package (Strimmer, 2008) was used to determine if pop-
ulations compared showed different null variance than expected by statistical tests 
implemented in DESeq2. For full details please see the Appendix 3. 
AnnotationDbi and org.Hs.eg.db R packages (Carlson, 2019; Pagès, Carlson and Falcon, 
2019) were used to assign the gene symbols and Entrez ID to all genes used for differ-
ential expression calculation. 
5.3.2.2.5	Pathway	Analysis	
We performed Ingenuity Pathway Analysis (IPA) (Qiagen) and Gene Ontology (GO) en-
richment analysis of differentially expressed genes.  For IPA analysis background was 
set to all genes expressed by population of interest, obtained from DESeq2 expression 
matrix.  GO enrichment was determined by topGO R package (Alexa A, 2019). The GO 
background was set so that only comparison specific genes which matched in expres-
sion strength with DEG was used.  In both cases enrichment was determine by Fisher’s 
statistical test. For GO analysis the node size was set to 5. 
5.3.2.2.6	Overlay	With	Published	Literature		
We compared the DEG list identified in our study to already published studies by Ta-
man et al and Van der Goten et al (Van der Goten et al., 2014; Taman et al., 2018). 
First, lists of differentially expressed genes was downloaded from supplementary in-
formation attached to the publication. Next, we used biomaRT to convert the gene 
symbols (Taman et al., 2018) and Affymetrix GeneChip Human Gene 1.0St probe IDs 
(Van der Goten et al., 2014) to human Hg38 Ensemble IDs. Finally, we used Ensemble 
IDs to filter out the matching genes pairs.  
Manual PubMed search for each DEG (with median normalized count >100) was car-
ried out. Search criteria was set to either gene symbol + Ulcerative colitis, gene symbol 
+ Inflammatory Bowel Disease or gene symbol + cell type (e.g. T cells/B cells). A hit is 
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term given for a DEG that returned at least one publication. However, the literature 


























We hypothesised that UC associated risk variants indirectly lead to the cell type spe-
cific transcriptional changes, which could be potentially associated with disease path-
ogenesis and/or pathology. To investigate how disease state affected expression in a 
cell type specific manner, 94 samples from Blood CD4+ TEM, Blood CD19+ B cells and 
LPL CD4+ TEM and CD19+ B cells were sequenced on the Illumina Hiseq400 and Illumina 
HiSeq2500 platforms. Sequenced data were processed in collaboration with Medim-
mune Bioinformatics facility.  
 A total of DEG 688 genes were identified (Table 5.1), from which 5 included lncRNA. 
DEG with highest counts (and confidence) are summarized in Table 5.2.  
Blood CD4+ TEM population displayed higher differences in expression profile between 
UCn than UCi when compared to controls. During the library generation only 3 Blood 
CD4+ TEM samples from UCn passed quality checks, resulting in the smallest sample 
sub-population in our RNA study. To investigate this further a post-differential expres-
sion QC assessment were carried out. We noticed that an overwhelming majority of 
DEG were represented by very low gene counts. Unsurprisingly, we observed that 
large proportion of DEG that were associated with low counts also suffered from very 
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Table 5.1 NUMBER OF DEG IDENTIFIED IN SELECTED IMMUNE CELL POPULATIONS FROM 
HEALTHY SUBJECTS AND UC PATIENTS WITH DIFFERENT EXTENT OF DISEASE (for n donor for 
each subset please see Table 3.2). Column headings show the cohorts that were compared, 
whereas population column shows the cell type compared.  Direction and DEG columns de-
scribe: total number of DEG, DEG number upregulated or downregulated in UC (i or n) samples. 
LPL - Lamina propria; TEM – T effector memory; UC(I) - Ulcerative colitis patient with inflamed 
Sigmoid colon; UC(N) - Ulcerative colitis patient with non-inflamed Sigmoid colon; C - Control; 
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Table 5.2 LIST OF DEG IDENTIFIED IN SELECTED IMMUNE CELL POPULATIONS FROM 
HEALTHY SUBJECTS AND UC PATIENTS WITH DIFFERENT EXTENT OF DISEASE. Table shows all 
DEG that passed the filtering threshold of median count > 100. BaseMean represents mean 
normalized count over all samples in subgroup, p-adjusted shows p-value after corrected for 
multiple testing.  LPL - Lamina propria; TEM – T effector memory; UC(I) - Ulcerative colitis pa-
tient with inflamed Sigmoid colon; UC(N) - Ulcerative colitis patient with non-inflamed Sigmoid 
colon; C – Control. 
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Since we were not able to acquire additional samples for laboratory-based validation 
experiments (due the shortage of time), we decided to use computational methods. 
We would like to acknowledge that methods chosen are based on pre-existing expec-
tations and provided with quick and superficial assessment of general data quality.  
First, we manually screened the LPL CD4+ TEM (C vs UCi) DEG lists for well-known and ex-
pected genes. LPL CD4+ TEM was selected as it is known to be a key cell population in 
IBD and it returned the highest number of differentially expressed genes. Previous 
studies in LPL CD4+ T cells have showed elevated levels of IL17, RORC and IL23R pro-
duction from patients with UC and proposed strong Th17 involvement in disease pa-
thology (Kobayashi et al., 2008). In addition, increased numbers of Treg is another char-
acteristics of active UC  (Holmén et al., 2006; Yu et al., 2007).  
We saw that, as expected, our LPL CD4+ TEM (C vs UCi) DEG lists was enrichment for genes 
associated with Th17 signalling (↑RORC, ↑IL17A, ↑IL17F, ↑IL1R1, ↑IL21, ↑IL21R) 
and Treg /T cell activation associated genes (↑CTLA4, ↑ IL2RA, ↑ TNFRSF18, ↑CCL20). 
Second in silico-based method we used for data validation was an overlap assessment 
between newly identified DEG and already published transcriptomics studies. We se-
lected one RNA Seq and one microarray-based study from PubMed literature search 
partially based on their expression data availability. Van der Goten et al used Affymet-
rix Human Gene 1.0ST array to detect the difference in transcriptional activity be-
tween control and UCi, whereas Taman et al employed RNA Seq to look at expression 
differences between treatment-naïve UC patients and controls (Van der Goten et al., 
2014; Taman et al., 2018). 
Of the 65 DEG from LPL CD19+ B cells (C vs UCi), 19% showed overlap with Van der Goten 
et al and 22% overlapped with Taman et al. Overlap for LPL CD4+ TEM was 20% and 
26%, respectively. Finally, genes identified by Van der Goten et al and Taman et al 
were tested against each other and only 50% agreement was reached.  
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Next, we screened LPL CD4+ TEM (C vs UCi) for genes which were identified as significantly 
different in all 3 studies. Genes that were shared and showed the same direction 
(↑UC) were associated with cell growth and proliferation (RRM2, S100A9, MYBL2, 
IL21R, BHLHE40) and Treg signaling/T cell activation (IL2RA, CTLA4, CD80, CCL20). In-
terestingly, DUOX2 showed strongest upregulation in UCi (Fold ChangeTaman = 53.08, 
Fold ChangeGoten = 32.87, Fold ChangeLPL CD4 = 63.62) than any other shared genes. 
Moreover, in our study DUOX2 was associated with relatively high counts (median 
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5.4.3	 Determining	 Biological	 Meaning	 Behind	 The	 Disease	 Specific	
Change	In	Expression	Profiles	
To dissect biological processes and molecular pathways, enrichment analysis was per-
formed using the annotations from GO and IPA.  For these analyses, the higher the 
number of DEG called, the more informative the analysis, so enrichment was deter-
mined only for populations that contained more than 50 DEG. In addition, we used all 
genes, including ones with very low counts, reasoning that identification of molecular 
pathways might help to separate real signal from noise.  
IPA analysis revealed that LPL CD4+ TEM cells (C vs UCi) were significantly enriched for T 
helper cell differentiation and T helper 2 pathways (Table 5.3). Interestingly Blood 
CD19+ B cells (C vs UCi) where significantly enriched for endoplasmic reticulum stress 
pathway and unfolded protein response. Both observations were backed up by Gene 
Ontology, where LPL CD4+ TEM cells (C vs UCi) where enriched for immune and inflamma-
tory response and Blood CD19+ B cells (C vs UCi) for protein folding and ER-nucleus sig-
nalling pathways (Table 5.3).  
As expected, DEG from Blood CD4+ TEM (C vs UCn) showed no-enrichment for any path-
ways. The initial differential expression calculation returned 150 genes, yet, no path-
way-based clustering (± significant) was observed, strongly stating that despite large 
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Table 5.3 IPA PATHWAY ENRICHMENT ANALYSIS OF GENES DIFFERENTIALLY EXPRESSED IN 
BLOOD CD19+ B CELL (CONTROL VS UCI), LPL CD19+ B CELL (CONTROL VS UCN) AND LPL CD4+ TEM (CONTROL VS 
UCI) COHORTS. Enrichment was calculated by Fishers-Exact test and adjusted for multiple test-
ing. Pathway column reveals the pathway enriched for, -log(p-value) column shows negative 
log of p-value after adjustment for multiple testing, Ratio represents the proportion of all 
genes in pathway covered by DEG. Finally, DEG in Pathway displays the DEG which were en-
riched in pathway. LPL - Lamina propria; TEM – T effector memory; UC(I) - Ulcerative colitis 
patient with inflamed Sigmoid colon; UC(N) - Ulcerative colitis patient with non-inflamed Sig-
moid colon; C – Control. 
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To further explore the functional role of genes identified as significantly different, 
manual PubMed search for each DEG (with median normalized count >100) was car-
ried out. Table 5.4 shows the number of genes that had a PubMed hit when searched 
for IBD and/or UC. 
From all differentially expressed genes in LPL CD4+ TEM (C vs UCi) - MKI67, CTLA4, CCL20, 
CD2, RORC, FOS, LCN2, MUC1, CCL5, CD38 were top 10 genes in terms of publication 
count when searched criteria was UC. MKI67 is good representation of downfalls of 
term-based literature search. MKI67 (also known as Antigen KI-67) is well established 
marker for cell proliferation and despite large number of publications returned, in 
most of cases, has no direct association with study itself. Other genes with high num-
ber of publications returned were: 
v CASP3 and XBP1 for Blood CD19+ B cells (C vs UCi); 
v MKI67 from LPL CD19+ B cells (C vs UCn); 
v MDM2, CD38 and DMBT1 for LPL CD19+ B cells (C vs UCi); 
We further looked for genes with less defined connection to UC (based on publication 
record). TXNIP (Thioredoxin Interacting Protein) encodes a protein of major im-
portance in redox balance (Spindel, World and Berk, 2012) and was detected as sig-
nificantly decreased in LPL CD4+ TEM cell in UC patients with active inflammation.  
Takahashi et al 2007 showed that colonic tissue from UC patients had reduced TXNIP 
expression in comparison to healthy controls. However, they mainly attributed the 
decrease in TXNIP levels due loss of topical epithelial cell layer in inflamed tissue 
(Takahashi et al., 2007).  
SEMA4A (Semaphorin 4A) returned only two publications in PubMed search for its 
role in IBD.  SEMA4A encodes a protein with broad functionality, including T-cell me-
diated immune response (Ito and Kumanogoh, 2016).  In contradiction to  Vadasz et 
al 2015, who reported increase in SEMA4A levels in patients with both - UC and CD 
(Vadasz et al., 2015), we observed significant decrease in SEMA4A transcript levels in 
LPL CD4+ TEM from UCi.  
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Another, interesting gene was KSR2 (Kinase Suppressor of Ras 2) - here identified as 
significantly downregulated in LPL CD4+ TEM from UCn. Even thought, KSR2 itself has 
no associations with either UC or IBD, Xue et al 2013 showed that micro RNA miR-31 
(which is significantly dysregulated in UC (Gwiggner et al., 2018), downregulates KSR2 
and facilitates IL-2 secretion and T cell activation (Xue et al., 2013).  
Finally, in addition to genes with already established functions and/or associations, 
substantial part of DEG had no known functional role at all. Such genes included his-
tone proteins (HIST1H2AB, HIST1H2AI, HIST1H2AJ, HIST1H2AL, HIST1H2AM, 
HIST1H3B, HIST1H3C, HIST1H3F, HIST2H3A) and zinc finger proteins (ZNF282, 
ZNF417/ZNF587, ZNF471, ZNF571, ZNRF1) which were identified as differentially ex-
pressed between UCi and control in LPL CD4+ TEM cells.  
Table 5.4 PUBMED LITERATURE SEARCH FOR DEG IDENTIFIED IN STUDY. Table shows the 
number of DEG for each cell population which were used for search and number of hits. Hit 
represents a gene which returned at least one publication associated with either UC or IBD. Hit 
table shows the symbol for all genes that had any previous record. LPL - Lamina propria; TEM – 
T effector memory; UC(I) - Ulcerative colitis patient with inflamed Sigmoid colon; UC(N) - Ul-
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5.4.4	 Determining	 Anatomical	 Location	 Specific	 Change	 In	 Expression	
Profiles	In	Purified	CD19+	B	Cells	And	CD4+	TEM	Immune	Cell	Populations	
We next attempted to establish how anatomical location might affect the transcrip-
tional landscape for cells of the same sub-type. The cell type was defined by the same 
surface marker expression. Transcription profiles of blood and SC LPL resident CD4+ 
TEM and CD19+ B cells from healthy individuals were compared. The same pipeline as 
for disease specific differential expression profiling was used.   
A total of 520 and 839 genes were identified as significantly different between blood 
and SC LPL residing CD4+ TEM and CD19+ B cells.  A substantial proportion of DEG from 
CD19+ B Cells (Blood vs LPL) were associated with low counts and, non-surprisingly, high 
log2fold change. DEG between Blood and LPL CD4+ TEM cells had higher median nor-
malized counts than CD19+ B cells. The top 10 genes from both comparisons are sum-
marized in Table 5.5.  
Biological pathway identification by IPA showed that differentially expressed genes 
between Blood and LPL in CD19+ B cells were enriched for unfolded protein response  
(p = 3.84e-05 ; ATF4; CALR; CANX; DDIT3; DNAJB9; DNAJC3; HSP90B1; HSPA5; 
HSPA1A/HSPA1B*; OS9; P4HB; PDIA6; PPARG; PPP1R15A; SEL1L; XBP1), PI3K signaling 
in B lymphocytes (p = 7.57e-05  ;  AKT3; ATF3; ATF4; ATF5; BLK; CARD10; CD180; 
CD79B; FCGR2B; FOS; FOXO3; IL4R; ITPR1; ITPR3; JUN; LYN; NFKBIA; PDIA3; PIK3AP1; 
PLCB4; PLCL2; PLEKHA2; PRKCB; PTPRC) and antigen presentation pathway (p =7.57e-
05 ; CALR; CANX; CD74; CIITA; HLA-DMB; HLA-DOB; HLA-DPA1; HLA-DBP1; HLA-DQB1; 
HLA-DRA; HLA-DRB1; PDIA3) (Table 5.6). 
Significantly different genes from CD4+ TEM (Blood vs LPL) was enriched for protein kinase 
A signalling (p = 3.62e-05 ; ADCY6; AKAP9; ATF4; CALM1; CDC25B; CREM; DUSP1; 
DUSP2; DUSP4; DUSP8; HIST1H1C; HIST1H1D; HIST1H1E; ITPR3; LEF1; MAP3K1; 
MYL12A; NFKB2; NFKBIA; PDE4A; PDE4B; PDED; PLCB3; PLCD3; PPP1R10) and integrin 
linked kinase pathway (p = 2.83e-03 ; ATF4; CDH1; DOCK1; DSP; FOS; IRS2; ITGB1; 
ITGB4; JUN; KRT18; LEF1; MYC; NACA; NFKB2; PDGFC; RND3; TMSB10/TMSB4X; 
VEGFA) (Table 5.6). 
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Table 5.5 LIST OF TOP 10 DEG (BY LOG2FOLDCHANGE) IDENTIFIED IN SELECTED IMMUNE 
CELL POPULATIONS FROM PERIPHERAL BLOOD AND SIGMOID COLON LAMINA PROPRIA  
Table shows all DEG that passed the filtering threshold of median count > 100. BaseMean rep-
resents mean normalized count over all samples in subgroup, p-adjusted shows p-value after 
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Table 5.6 IPA PATHWAY ENRICHMENT ANALYSIS OF GENES DIFFERENTIALLY EXPRESSED IN 
CD19 B CELL (BLOOD VS LPL) AND CD4+ TEM (BLOOD VS LPL)  COHORTS. Enrichment was calculated by 
Fishers-Exact test and adjusted for multiple testing. Pathway column reveals the pathway en-
riched for, -log(p-value) column shows negative log of p-value after adjustment for multiple 
testing, Ratio represents the proportion of all genes in pathway covered by DEG. Finally, DEG 
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5.5	Discussion		
Here, we successfully purified and sequenced CD4+ TEM cells and CD19+ B cells from 
peripheral blood and LP of SC colon. This allowed us, for first time, to dissect the tran-
scriptional differences between healthy and UC at cell type specific level. In total we 
identified 688 and 1359 genes significantly affected by disease state and origin, re-
spectively.  
Apart from Blood CD4+ TEM populations, patients with active inflammation had greater 
differences in their expression profiles than UC patients with no inflammation, when 
compared to control. Though it is expected for patients with active disease to bear 
larger differences, the interpretation is challenged by the fact that the recruitment 
rate for UCn were markedly reduced when compared to UCi. Thus, lower rates of ob-
served DEG may also reflect differences in experimental power, as well as genuine 
biology. 
Rigorous pre- and post- differential expression QC allowed us to identify that a large 
proportion of DEG were called based upon very low on gene counts. Moreover, when 
combined with low sample numbers, as in case for Blood CD4+ TEM UCn, this proved 
insufficient for reliable assessment of underlying biological difference in expression 
profiles. Power calculations showed that our current data set can be used to identify 
prognostic genes that are associated with high average counts (hereby lower disper-
sion) and fold change. However, further validation with qPCR or other expression-
based method, such as, RNA scope, is crucial but was not possible at current time 
frame.  
Instead to build a confidence in our results, while keeping in mind the time limitations, 
we screened our newly discovered data sets for already known and published mark-
ers. We confirmed that our LPL CD4+ TEM (C vs UCi) DEG lists had increased expression for 
genes associated with Th17 signalling. Yet, only around 1/5 of genes identified be-
tween LPL CD4+ TEM (C vs UCi) or LPL CD19+ B cells (C vs UCi) showed an overlap to DEG from 
other already published expression studies. We speculated that the fact that both se-
lected studies used whole tissue instead of purified lymphocytes might be one of the 
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main factors behind low overlap observed. Other discrepancies between or study and 
published data were heterogeneity in biopsy collection site (Van der Goten et al., 
2014) and disease activity (Taman et al., 2018).  
Finally, we proceeded to investigate the biological meaning behind the disease spe-
cific change in expression profiles. We showed that DEG between LPL CD4+ TEM cells (C 
vs UCi) were significantly enriched for TH2 pathway (p = 1x10-3.25). For a long time, UC 
has been strongly associated with TH2 response. Early in vitro stimulation of UC de-
rived LPL T cells showed increased expression of IL-5 (Fuss et al., 1996) and, later, IL-
13 (Fuss et al., 2004), both known to be markers for TH2 cells. Since then, a substantial 
number of papers has been published and even drug trials, targeting TH2 associated 
cytokine – IL-13, carried out. The results of these studies has been rather contradict-
ing, with one camp showing reduced secretion of IL-13 in UC (Vainer et al., 2000; 
Kadivar et al., 2004; Biancheri et al., 2014) and questioning the importance of TH2 
pathway in UC.  The additional fuel to TH2 importance in UC came from observation 
that there was no significantly beneficial effect by IL-13 blockade  (Danese et al., 2015; 
Reinisch et al., 2015). Expression of Interleukin-4 (IL-4) - another signature cytokine 
produced during the TH2 response – is low and does not change in response to disease 
(NIESSNER and VOLK, 2008). Meanwhile, other labs showed increased IL-13, IL-5 ex-
pression in active UC when compared to UCn (Reinisch et al., 2015), inactive UC (Inoue 
et al., 1999) and control (Nemeth et al., 2017).  
Even though we showed significant enrichment for TH2 pathway (p = 1x10-3.25), neither 
of the abovementioned TH2 signature cytokines nor two main TF - GATA3 and STAT6 - 
showed differential expression in LPL CD4+ TEM (C vs UCi). Instead the enrichment was 
based on chemokine receptor (↑CXCR6, ↑CCR1), IL receptor (↑IL12RB1, ↑IL2RA) 
and TCR subunits (↑CD3D, ↑CD247), TH2 associated TF (↓JUN, ↑MAF), co-stimula-
tor (↑ICOS) and even APC associated proteins (↓HLA-DOA, ↑CD80) and hepatitis vi-
rus cellular receptor (↑HAVCR1). Moreover, five of these DEG enriched for TH2 path-
way were also associated with TH differentiation (p = 1x10-5.84). Hereby, we feel that 
we lack the evidence to reliably infer evidence of increased TH2 activity status in our 
UCi samples.  
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Both HLA-DOA and CD80 are expressed by APCs and should not be present in our TEM 
data set. However, for pathway analysis we used all DEG, including DEG associated 
with very low counts. Indeed, after closer look we saw that both HLA-DOA and CD80 
and HAVCR1 were far below our threshold for reliable expression and most likely rep-
resent the sequencing noise. However, we would like to acknowledge that when look-
ing at the population purity based on negative sort marker expression, possible con-
tamination was noticed.  
Th17 activity was supported by enrichment for both - TH Differentiation and Differen-
tial Regulation of Cytokine production in Macrophages and T Helper Cells by IL-17A 
and IL-17F pathways. Even though, there was no difference in ether STAT3 nor IL23R 
expression, Th17 associated TF (↑RORC), secreted IL (↑IL-17A, ↑IL-17F and ↑IL-21) 
and IL17A target molecules (↑CCL3, ↑CXCL1, and ↑CSF2) where enriched amongst 
the DEG. With exception to RORC, all other genes associated with Th17 function were 
below the counts threshold. However, due the larger number of DEG present, we be-
lieve that increase in Th17 activity in UCi is real. Our observation is in agreement with 
other published studies showing increased IL-17 expression by intestinal T cells iso-
lated from UC patients (Fujino et al., 2003; Kobayashi et al., 2008).  
In conclusion, our study identifies disease state specific changes in transcriptional 
landscape in purified CD19+ B cells and CD4+ TEM immune cell populations from pe-
ripheral blood and sigmoid colon. Due to low gene counts (high variance) and small 
number of samples results should be interpreted with caution. In addition, the initial 
QC metrics looking at the expression of negative sort markers showed that there 
might be some cross-contamination. Therefore, to increase confidence in current find-
ings, further validation is essential.   
All wet laboratory-based validation experiment still faces problem of limited material 
availability, possibly in suboptimal quality. Thus, to validate all DEG lists single cell se-
quencing has the highest probability to yield good results. However, for only a few 
interesting hits, verification based upon qPCR might be method of choice. For genes 
with large expression differences, RNA scope might be more beneficial as it does not 
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require any nucleic acid extraction or manipulation; instead whole tissue can be 
stained for as many as 12 RNA species allowing easy visual comparison.  
Expression comparison of other published studies would be an alternative dry-lab 
based method for data validation. With support from large expression studies, such 
as Human Cell Atlas, single cell data from healthy and UC patients from blood and 
colon have become available (unfortunately only after our experimental work was fin-
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6.1	Introduction	
Measurement of chromatin organization permits the capture of the physical accessi-
bility of regulatory elements at individual cell type resolution (Lee et al., 2004; John et 
al., 2011; Thurman et al., 2012). Degner et al 2012 showed that single genetic variants 
can alter both the chromatin conformation and magnitude of gene expression. In ad-
dition, they showed that these genetic variants are enriched in TFB sites (Degner et 
al., 2012), and thus possibly reflects the allele-specific effects on TF binding.  
We hypothesized that IBD risk associated variants could contribute to disease devel-
opment by altering the function of regulatory elements, such as TFB sites, which in 
turn would be reflected in chromatin accessibility. Indeed, the observation that some 
of the SNPs fine mapped in IBD are enriched for transcriptional factor binding sites 
and tissue specific epigenetic marks further supports our hypothesis (Huang et al., 
2017).  
In this chapter, we performed chromatin profiling of purified cell populations from 
peripheral blood and Lamina propria and Intraepithelial layers of the SC. We at-
tempted to estimate the differential openness between similar cell types taken from 
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6.2	Aim	
• To decipher the chromatin landscape in purified cell populations from healthy vol-
unteers and UC patients. 
• To investigate differences in chromatin accessibility on a cell type specific and an-




















All ATAC Seq libraries were sequenced at Wellcome Trust Sanger Institute, Hinxton. 
Illumina HiSeq 2500 instruments with v4 chemistry was used for sequencing, with 10 
samples per line. 75bp PE reads with 5% Phix spiking was selected. 
6.3.2	ATAC	Seq	Data	Analysis	Pipeline			
Initial analysis on raw ATAC Seq data was performed by Dr. J. Gutierrez-Achurry (post-
doctoral research associate in Dr Carl Anderson’s group, Wellcome Trust Sanger Insti-
tute), whereas further downstream analysis was carried out by the author. 	
6.3.2.1	Pre-Processing	Of	Raw	Sequencing	Data		
The initial analysis in a stepwise manner:   
§ Raw ATAC Seq read QC by FastQC quality metrics tool;  
§ Adapter trimming and short read (<25nt) removal; 
§ Second QC by FastQC quality metrics tool; 
§ Trimmed read alignment to human reference genome (hg38) using BWA (Li and 
Durbin, 2009); 
§ Removal of mitochondrial and duplicate reads and ENCODE black listed regions by 
Bedtools (Quinlan and Hall, 2010) and Picard;   
§ Sequencing quality evaluation based on alignment using Bedtools; 
§ Peak calling with MACS2 algorithm (--nomodel --shift -25 - - extsize 50) (Zhang et 
al., 2008);  
The final result of this initial pipeline was peak coordinates and refined read files ac-
companied by a set of QC reports from each stage of initial analysis. 
 
 




The term “peak” is used for an identified region of open chromatin, identified by an 
excess of sequencing reads relative to a threshold determined by the background rate 
observed in any given region of chromatin. 	
Use of the MACS2 algorithm allowed de-novo identification of peaks in each individual 
sample, yet careful consideration is needed to separate the peaks representing un-
derlying biology from the individual noise. It is very intricate process as in a given phe-
notype, peak might be present only in fraction of samples within a group. In addition, 
additional technical challenges, such as differences in sequencing depth, introduce in-
ter-sample variation. The most straight forward way would be to select all peaks that 
are open in at least one sample per phenotype, yet it would result in excessive list of 
peaks which would lead to massive burden on multiple testing and introduction of 
false positives. In contrast, setting stringent filtering criteria will lead to loss of true 
positives. Moreover, MACS2 identified peaks have unique coordinates in each of the 
samples, making peak validation and uniform coordinate establishment more com-
plex.  
Unfortunately, at time there was no ATAC Seq specific analysis pipelines written that 
can tackle these challenges.  Instead, in line with common practice, we adapted algo-
rithms generated for other sequencing data analysis. To this end, we selected DiffBind 
(Stark and Brown, 2011) and DESeq2 (Love, Huber and Anders, 2014) R packages and 
modified their associated workflows to fit our dataset. DiffBind provides the user with 
a flexible peak filtering algorithm where the user can manually specify the percentage 
of samples in which a peak must be present to classify the chromatin as unfolded.  
In our case, we considered a region truly open if a peak was present in at least 50% of 
samples for any given group, where the genomic coordinates for that peak was set to 
include the entire region covered by all peaks in individual samples that overlapped 
by at least 1 base pair (Figure 6.1)  
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We grouped samples based on the cell type and disease state they represented. For 
each of group we generated a consolidated peakset containing peaks with highest 





Figure 6.1. GRAPHICAL ILLUSTRATION OF STEPS INVOLVED IN PEAK FILTERING AND UNIFIED 
COORDINATE ESTABLISHMENT. In this example a region is considered open if >50%  from total 
of 8 samples have an open region that overlaps by at least 1 base pair. The consensus peakset 
is a name given to the object that contains genomic coordinates for all peaks which passed 
filtering criteria.	
6.3.2.2.2	Peak	Annotation		
ChipSeeker R package (Yu, Wang and He, 2015) was used to assign annotations to all 
peaks present.  
Before annotation all peak-containing objects were filtered to exclude both sex chro-
mosomes (e.g. chrX and chrY). Next, Transcription start site (TSS) region was set to 
±1Kb from TSS and TxDb.Hsapiens.UCSC.hg38.knownGene transcript level annotations 
(Bioconductor Core Team, 2019) used to assign the genomic features and genes inter-
secting or closest to peaks. Following priority was adopted for genomic features:  
1. Promoters 
2. 5’ UTRs  
3. 3’UTR,  
4. Exon,  
5. Intron,  
6. Downstream  
7. Distal Intergenic 
 
In addition, we used ChipSeeker to obtain list of genes flanking (±5Kb) each peak.  
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6.3.2.2.3	 Counts	 Matrix	 Generation	 Based	 On	 Peak	 Coordinates	 In	 Consolidated	
Peaksets	
As next step in our analysis we generated counts matrices based on the regions clas-
sified as truly open. To define a region as differentially accessible, a comparison of 
normalized counts between populations of interest is carried out. Establishment of a 
unified coordinate system between all samples to be compared is crucial as read 
counts are dependent on peak width.  
Consolidated peaksets contained peaks and their associated coordinates unique for 
disease state, anatomical location and cell type. We further combined these peaksets 
to create new objects that would contain all peak coordinates necessary for either 
exploratory analysis or differential accessibility calculation.  
After construction of objects containing unified peak coordinates, the dba.count func-
tion (from DiffBind) was evoked. It counts how many reads overlap each interval for 
each unique sample. The result of counting was a counts matrix in DiffBind called bind-
ing affinity matrix. We named the count matrix which represented all peaks in study 
Global binding affinity matrix. We used the Global binding affinity matrix to assess the 
sample reproducibility. 
The count matrix for the differential accessibility calculation were called individual 
binding affinity matrix. A total of 10 individual binding affinity matrices were con-
structed and included open regions from: 
• SC Epithelium UCi and UCn and C 
• SC IEL CD4+ TEM UCi and UCn and C 
• SC IEL CD8+ TEM UCi and UCn and C 
• SC LPL CD4+ TEM UCi and UCn and C 
• SC LPL CD8+ TEM UCi and UCn and C 
• SC LPL CD19+ B cells UCi and UCn and C 
• Blood CD4+ TEM UCi and UCn and C 
• Blood CD8+ TEM UCi and UCn and C 
• Blood CD19+ B cells UCi and UCn and C 
• Blood CD14+ MF UCi and UCn and C 




The same as for RNA seq data, we performed an extensive ATAC seq data QC. For in 
depth details of QC and major challenges encountered during ATAC seq analysis 
please see Appendix 6 and Appendix 8.   
6.3.2.2.5	Call	For	Differential	Accessibility		
For initial attempts to investigate differences in chromatin opening between control 
and UC patients, the DiffBind package was used. DiffBind allows a choice of method 
by which the differential accessibility analysis will be calculated, and in this case, we 
selected the same model as DESeq2 use. To assess if DESeq2 function inherit data 
normalization method would be suitable for ATAC seq data series of simulation exper-
iments was performed (For more detail please see Appendix 7). 
After selecting the median ratio method as the most suitable for our ATAC Seq nor-
malization, all individual binding affinity matrices, to be used for differential accessi-
bility calculation, were filtered to remove all peak regions with geometric mean of 
normalized read count below 30. Finally, significance was calculated by DESeq2 algo-
rithm.  
After calling for differential accessibility in this manner, the call performance was eval-
uated using a range of quality control metrics (For more detail please see Appendix 6).   
For second attempt to determine differences in chromatin conformation DiffBind class 
objects were transformed into DESeq2 specific objects. Each counts matrix was fil-
tered so that peaks would be retained only if all samples had more than 10 counts 
each. design was set on condition (e.g. UCi, UCn and C) and analysis for differential 
accessibility repeated.  
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6.4	Results		
6.4.1	 Determining	 Chromatin	 Landscape	 In	 Purified	 Cell	 Populations	
From	Peripheral	Blood	And	Sigmoid	Colon	Lamina	Propria	And	Intraepi-
thelial	Layers	From	Healthy	Volunteers	And	UC	Patients	
Our first aim was to characterise chromatin landscape in terms of open and closed re-
gions. We used ATAC seq technique to profile the chromatin structure in 10 different 
purified cell populations, including, CD4+ or CD8+ TEM cells from blood, SC LP and SC 
IEL, CD19+ B cells from blood and SC LP, CD14+ MF from blood and CD326+ epithelial 
cells from SC LP.  
We identified a total of 393931 accessible regions present in at least 1 of 30 pheno-
types, where each individual phenotype was unique for either disease state or ana-
tomical location or cell type (Figure 6.2).  
Next, we asked how many of open regions observed in a cell type were shared be-
tween different disease states.  If two peaks overlapped by at least 1bp they were 
classified as shared. We observed that in average 90.77 ± 9.82%, 64.51 ± 11.74% and 
55.76 ± 9.72% of peaks identified in any given Control, UCi and UCn conditions were 
shared.  Cell types from healthy controls had less unique peaks than the other two 
categories. However, it is important to highlight that number of accessible regions 
were in moderate negative correlation with the number of samples for any given cell 
type (r = -0.517, p = 0.0034) as well as moderate positive correlation with sequencing 
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Figure 6.2 VENN DIAGRAMS SHOWING OPEN CHROMATIN REGIONS THAT WERE UNIQUE 
TO OR SHARED BETWEEN DIFFERENT DISEASE STATES IN A CELL TYPE AND ANATOMICAL 
LOCATION SPECIFIC MANNER (n phenotype = 30; For n donor please see table 3.2 ). Light blue circles 
represent the Control samples, dark blue UCi and green shows the peak distribution from UCn.  
LPL - Lamina propria; IEL – Intraepithelial lymphocytes; TEM – T effector memory; UC(I) - Ulcer-
ative colitis patient with inflamed Sigmoid colon; UC(N) - Ulcerative colitis patient with non-
inflamed Sigmoid colon. 
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Figure 6.3 SCATTER PLOTS ILLUSTRATING THE RELATIONSHIP BETWEEN THE PEAK COUNT, 
SAMPLE NUMBER AND GEOMETRIC MEAN OF COUNTS ASSOCIATED WITH THE SAME PHE-
NOTYPE (n phenotype = 30). All relationship was quantified by Spearman’s correlation. r - Spear-
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To gain better biological interpretation, all peaks were annotated to genomic features, 
such as, Promoter, 5UTR, 3UTR, Exon, Intron, Downstream, Intergenic, they showed 
overlap with. To accomplish this task ChipSeeker annotation package (Yu, Wang and 
He, 2015) was used.  
The highest percentage of peaks mapped to the promoter regions (18% - 60%), fol-
lowed by intronic (9.5% -36.5%) and distal regions (9% - 26%). Only small percentage 
of peaks mapped to the 3’UTRs, exonic and Downstream regions (Figure 6.4). 
 
	
Figure 6.4 GENOMIC ALIGNMENT OF ACCESSIBLE REGIONS. Legend shows the tissue types 
and genomic features, and their associated colour. LPL - Lamina propria; IEL – Intraepithelial 
lymphocytes; UCi - Ulcerative colitis patient with inflamed Sigmoid colon; UCn - Ulcerative co-









After successful identification of open chromatin regions in 30 different phenotypes 
of interest, we were intrigued to see if we could quantify how different disease states 
affects chromatin accessibility in a cell type specific manner. 
We acknowledge that we have very small sample size per each phenotype and that 
any outcome of our analysis must be validated before any reliable conclusions can be 
made.  We proceeded with analysis hoping to potentially find few interesting regions 
that we could follow up in less time consuming and expensive biological assays.  
For first call of differential accessibility, we used DESeq2 model integrated into 
DiffBind analysis package. During QC we found that in majority of comparisons test 
statistics had failed. We performed series of troubleshooting experiments (summa-
rized in Appendix 6) and repeated the differential accessibility analysis, this time using 
DESeq2 package. More comparisons now passed our QC pipeline (Table 6.1). How-
ever, the large number of DAR identified between healthy and UCn in Blood CD8+ TEM 
and CD19+ B cells seemed unusual, and, hereby, all DA calculations should be treated 
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Table 6.1. LIST OF DIFFERENTIALLY ACCESSIBLE REGIONS. First column shows the cell type, 
second the conditions compare; third and fourth column displays the number DAR upregulated 
and downregulated. Finally, the last column summarizes the total DAR count identified in com-
parison. LPL - Lamina propria; IEL – Intraepithelial lymphocytes; TEM – T effector memory; INF 
- Ulcerative colitis patient with inflamed Sigmoid colon; NON INF - Ulcerative colitis patient 
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6.5	Discussion	
Growing evidence has shown that chromatin accessibility is itself under genetic con-
trol and can result in changes in gene expression. Taken together with observation 
that GWAS loci are enriched with chromatin quantitative treat loci, this makes chro-
matin architecture an attractive target for understanding the molecular mechanisms 
underlying the UC risk. Here, we used ATAC Seq to profile the chromatin landscape in 
primary immune cells and epithelium from peripheral blood and SC from healthy and 
diseased.   
Together we identified thousands of accessible regions and mapped them to genomic 
features and genes they overlie or where closest to. We showed that chromatin profile 
at individual population level had the highest alignment score to promoter regions. 
Our finding goes against what other chromatin conformation studies have reported. 
First, a whole genome chromatin conformation study showed that only 16% of all 
DNase I hypersensitive sites were located on first exon or within 2kB upstream of pro-
moter region with highest mapping rates on introns (39%) and intragenic regions 
(39%) (Boyle et al., 2008). The low TSS region mapping was further supported by Thur-
man et al 2012, where only 3% (n = 75,575) of DHSs localize to TSS. However, Boyle et 
al after evaluating a variety of genome annotation resources concluded that at the 
time when these earlier experiments were carried out annotations were not complete 
and completely reliable yet. We used the latest human transcriptome annotation re-
source, which included TSS for protein coding and non-coding genes. We feel that with 
addition of protein non-coding genes the number of peaks mapping to TSS regions 
might have grown.   
We speculated that the low percentage of TSS reads reported by Thurman et al was 
consequence of analysis method employed by the researchers. The genomic annota-
tions were assigned to an object which contained all peaks present in 130 cell types 
profiled. At the same paper they showed that peaks on promoters are significantly 
more conserved between different cell types than any other genomic regions. Hereby, 
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we question in the small percentage of reads mapping to promoter regions are con-
sequence of high conservation of this chromatin region.  
Next, we attempted to quantify if and how much does disease state and inflammation 
change the chromatin profile. Unfortunately, we found that for majority of compari-
sons test statistics either failed or produced data that passed all QC but still were at 
suboptimal quality.   
We could not identify the exact reason behind poor performance of test statistics. 
However, during corrections we had a meeting with Dr Blagoje Soskic (Postdoctoral 
Fellow at Wellcome Sanger Institute) who has considerable experience with working 
with ATAC seq data. During our discussion it was shared that their team had experi-
enced the same failure in p-value distribution. They too used DESeq2 with small rep-
licate number (3-4). They had not looked for exact reason behind it, but under-se-
quencing was mentioned as one of possible reason. Following the work performed in 
Dr Dan’s Gaffney’s lab, it seems that 300M reads per sample could be the appropriate 
sequencing depth to perform the analysis of interest.   
Interestingly, very recent publication by Gontarz et al., 2020 showed that in compari-
son to other methods used for differential accessibility estimation, such as limma and 
edgeR, DESeq2 performed very poorly when sample size dropped below 7 and data 
were associated with low average counts (Gontarz et al., 2020).  
In summary, we identified open and close chromatin regions in 10 different cell pop-
ulations from peripheral blood and sigmoid colon lamina propria and intraepithelial 
layers from healthy volunteers and UC patients.  Our current sampling and sequencing 
strategy and possibly data analysis algorithm were too weak to allow us to determine 
if there is significant change in chromatin accessibility between different disease 
states with confidence. However, if we had more time, there are ways we could 
strengthen our current data sets, which could then allow us to perform differential 
accessibility analysis. One of the methods would be to go back and physically recruit 
more participants while doing much deeper sequencing.  The second method, would 
be combining our data with already published ATAC Seq data. However, we currently 
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are not aware of any human data sets assessing the chromatin landscape in gut resid-
ing immune cells. Thought, for both - blood CD4+ T cells and B cells, chromatin profiles 


























7. Combinatorial	 Analysis	 Of	




















In chapters 5 and 6 we attempted to employ a “phenotype-first” approach and iden-
tify changes in the gene expression and chromatin conformation between healthy 
control and UC patients in a cell type specific manner. We assumed that results from 
these analysis pipelines are directly related to the disease, although this association 
might be either causal or simply reflect downstream changes of underlying inflamma-
tion. However, neither expression nor chromatin profiling alone provides with a com-
prehensive view of potential regulatory processes implicated in disease development.  
As final part of my PhD we aimed to integrate GWAS results with functional genomics 
data generated during my PhD.  We hypothesized that this approach would allow us 
to gain a comprehensive mechanistic interpretation of how known disease associated 
SNPs affect UC and potentially resolve causality by linking observed differences to un-
derlying genetic elements (which by definition can be causal but never an effect of 
inflammation).  
Unfortunately, during the data analysis we discovered that both ATAC seq and RNA 
seq data are of poor quality, mostly due to the very shallow sequencing depth. More-
over, when combined with low sample numbers as for ATAC seq experiments - gives 
an incomplete survey of chromatin accessibility and, hereby, cannot be used to deter-
mine important disease biology.  However, we decided to proceed with the analysis 
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7.2	Aims	
• Determine the extent by which difference in transcriptional profiles between the 
control and diseased tissue are reflected in differences in chromatin conformation 
and vice versa. 
• Assess if differentially expressed genes and differentially accessible regions are en-
riched for genetic variants associated with autoimmune diseases or treats. 
• Combine GWAS, ATAC Seq and RNA Seq data to propose the causal links by which 
variants contained in risk loci might regulates gene expression with respect to spe-



























Lists of all genes and peaks that were used for differential expression or accessibility 
calculations and passed DESeq2 filtering were collected. Transcriptomics data repre-
sent differences in expression of protein coding genes only. Low expressed genes were 
associated with high noise in our data set. Therefore, we used an R script to remove 
all genes with mean expression value below 100 counts. 
Next, ATAC Seq peak lists were passed to ChipSeeker for annotation to overlapping 
genomic feature, such as, promoter, 5’UTR, 3’UTR, intron, exon, distal or downstream 
region, based on peak location and gene they overlapped or were closest to. It is 
known that open promoter regions in some degree reflect active gene expression 
(Boyle et al., 2008), yet there is less evidence about how other open genomic feature, 
such as peaks distal to a TSS, may impact on transcriptional activity for nearby genes. 
Therefore, we calculated correlation for each region separately. 
Some of the genes showed overlap with multiple peaks. There is no established 
method to model the way in which multiple peaks might influence expression of a 
single gene and different previous studies have used variety of methods. Due to its 
simplicity, we decided to partially follow model published and used by Scott-Browne 
et al 2016. In short, when a gene had multiple peaks, each peak was assigned to the 
same gene with the same transcriptomic expression data, but each peak retained its 
own original estimate of relative openness based upon log2fold change ATAC Seq 
data.  
The data matrix with gene-peak pairs and their associated relative expression and ac-
cessibility values in terms of Log2FoldChange was transferred to Prism Graph Pad soft-
ware and correlation calculated by Spearman Rho. The relationship between the ex-
pression and accessibility was assessed, so that:  
• DEG – DA (only significantly different genes and peaks located on genomic feature 
of interest, such as promoter, would be matched) 
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• DA - All genes (significantly different peaks with all genes expressed by the same 
populations) 
• All peaks - DEG (all peaks located on genomic feature of interest with significantly 
different genes) 
• All peaks - All genes (all peaks located on genomic feature of interest with all genes 
expressed by the same samples) 
 
7.3.2	 Calculation	 Of	Genes	And	Chromatin	Regions	 Enrichment	Within	
GWAS	Risk	Loci	 
Enrichment of DEG and DA within the GWAS risk loci associated with immune medi-
ated diseases and traits was calculated using the algorithm written by Dr Tim Raine 
(Raine et al., 2015). The modified algorithm, encoded for python (v2 and v3), is sum-
marized in Figure 7.1.  
Lists of all genes and peaks used for differential expression and openness calculation 
with their associated relative expression values in terms of Log2Foldchange and p-
value were exported as data matrices. Next, we used biomaRT R package to retrieve 
the genomic coordinates for each gene and peak mapping to Human reference ge-
nome v37 (Hg37). Gene and peak coordinates were backwards converted to a previ-
ous human genome build (GRCh37), as focal SNPs coordinates were mapped to this 
previous build.  In instances where regions or genes could not be converted to this 
build, they were excluded from further analysis.  
Lists of genetic risk loci associated with immune disease, such as, UC (de Lange et al., 
2017a), CD (de Lange et al., 2017a), Type 1 Diabetes (T1D) (Barrett et al., 2009), Rheu-
matoid Arthritis (RhArt) (Okada et al., 2014), Coeliac (International Inflammatory 
Bowel Disease Genetics Consortium (IIBDGC), 2015) and traits - Mean Corpus Volume 
(MCV) (Astle et al., 2016), Body Mass Index (BMI) (Locke et al., 2015), and Height 
(Wood et al., 2014)- were identified from studies deposited in the National Human 
Genome Research Institute - European Bioinformatic Institute (NHGRI – EBI) published 
GWAS catalogue (NHGRI-EBI, 2017). Only variants with p – value ≤5x10-8 was exported. 
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The SNP list was further filtered to remove all variants falling on sex chromosomes 
and the region around the MHC.   
The recombination map was downloaded from PLINK command-line program (Chang, 
2019) accompanying web resources. The python script, written for version 2, was run 
from Unix command line.  
All association lists were pre-filtered to remove duplicate loci keeping just focal SNPs 
with best association statistics within any given LD block. This approach does reduce 
the number of SNPs associated with any given locus (and might miss instances where 
multiple independent SNPs are associated with disease – e.g. as with NOD2 locus) but 
allows for pooling of multiple different GWAS without inappropriate duplication of 
replicated loci. In order to account for nonrandom patterns of chromatin confor-
mation extra caution was made when peak background was modeled.  
Next, an interval extending 0.1cM on either side of each focal SNP was defined. The 
frequency of DEG or DA falling within these set regions was determined and compared 
to a reference/null distribution defined by overlap testing of GWAS SNPs with re-
peated random samples of equivalent numbers of genes or open peaks drawn from 
the same cell population without restriction to those showing differential expression 
or differential openness. For expression and chromatin data, DEG and DA lists were 
further subdivided by genes/peaks up or downregulated in UC and tested for enrich-
ment separately.  
 




Figure 7.1 OUTLINE OF THE ALGORITHM USED FOR CALCULATING ENRICHMENT IN REGIONS 




First, we took the output of DA peak / SNP enrichment testing and summarized all 
peaks falling in a pre-defined window around the focal SNP. Next, we identified the 
peaks most distal to the focal SNP and generated a “dummy” peak with start and end 
points matching the start and end coordinates for most distal peaks. All peaks, includ-
ing the “dummy” peak, were annotated; real peaks were annotated to genomic fea-
ture and the gene they were closest to, whereas “dummy” peaks were annotated so 
that all genes in ±1Mb were assigned to the peak. Next, gene lists associated with 
“dummy” peak were screened for overlap with DEG.  Finally, the list of matched hits 
was filtered to exclude all genes with average >100 counts and peaks with >50 counts.  
The genomic location of each peak (i.e. if candidate gene is already known) was con-
sidered but not used as a filtering criterion. Finally, Pubmed literature searches using 
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Study by Boyle et al., 2008 showed that highly expressed genes are more likely to have 
their TSS open (Boyle et al., 2008). As first step in our multi-omics analysis we aimed 
to evaluate if disease state specific change in expression can be reproduced by the 
condition specific difference in chromatin conformation and by what extent.  
First, we estimated the relationship between the significantly different genes and sig-
nificantly different peaks. LPL CD4+ TEM showed moderate-to-low, but LPL CD19+ B 
cells strong association between DEG and DA as indicated by correlation coefficient (r 
= 0.3 & r = 0.65). However, neither of these observed coefficients reached statistical 
significance (p = 0.34 & p = 0.06) (Table 7.1 A).  Subsequent, visual assessment of scat-
ter plots revealed that there was no apparent meaningful correlation and these coef-
ficients were indeed likely arising through chance (Figure 7.2 B and C). Blood CD19+ B 
cells had no relationship between DEG and DA (Figure 7.2 A).  
We next evaluated how global difference in chromatin openness (All Peaks) correlates 
with DEG and how DA regions correlates to global change in gene expression (All 
Genes). As with the DEG - DA calculations, DEG - All Peaks correlation tests were too 
low on peak-gene numbers to result in reliable coefficients (Table 7.1 B).  
Testing for correlation between All Genes and DA resulted in better numbers of peak-
gene pairs. Very low correlation coefficients showed that there was in fact no or min-
imal relationship between differences in gene expression and DA promoter sites for 
any of the cell types studied (Table 7.1 C). Interestingly, intronic DA peaks displayed 
closer relationship with gene expression (rBlood CD19+ B cell = 0.239; rLPL CD19+ B cell = 0.2292; 
rLPL CD4+ TEM = 0.3144) than DA peaks assigned to promoter regions (rBlood CD19+ B cell = 
0.1119; rLPL CD19+ B cell = 0.1834; rLPL CD4+ TEM = 0.1008).   
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Next, we asked if global changes in gene expression are reflected by global variance in 
chromatin profile. No relationship was seen for peaks within a promoter region, nor 
any other genomic features tested (Table 7.1 D). 	
Finally, we decided to repeat the analysis using the previously estimated differences 
between control blood CD4+ TEM vs CD19+ B cell expression and chromatin profiles. 
Both control populations had higher sample number and we hoped that it would allow 
us to capture real cell type specific biological difference. 
There was a robust significant correlation between the DEG and DA (r = 0.57, p = 
0.0001) (Table 7.1 A, Figure 7.2 D). The observed correlation weakened when DEG – 
All Peaks (r = 0.3264, p = 0.0001) were compared. The association fell further when 
testing for correlation between DA and global gene expression (r = 0.208, p = 0.0001) 
and completely disappeared at the level of global expression vs global accessibility (r 
= 0.066, p = 0.0001). DA peaks within introns showed a moderate correlation with DEG 
and were stronger than promoters when assessed against global changes in gene ex-
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Table 7.1 SPEARMAN CORRELATION BETWEEN A. DEG AND DA, B. DEG AND GLOBAL 
CHANGES IN THE CHROMATIN PROFILE, C. DA AND GLOBAL CHANGES IN THE EXPRESSION 
PROFILE AND D. GLOBAL CHANGES IN THE CHROMATIN PROFILE AND GLOBAL CHANGES IN 
THE EXPRESSION PROFILE. r - Spearman’s rho; p - p-value; n - peak-gene pair number; DEG - 
Significantly different genes; DA - Significantly different accessible regions; All Genes - ± signif-
icant genes expressed by the cell type(s) under investigation; All Peaks - ± significant peaks 
belonging to the cell type(s) under investigation; C – Control; LPL - Lamina propria; TEM – T 























Figure 7.2 VISUAL REPRESENTATION OF RELATIONSHIP BETWEEN GENE EXPRESSION AND 
PROMOTER ACCESSIBILITY IN A. BLOOD CD19+ B CELL, B. LPL CD19+ B CELL AND C. LPL CD4 
TEM CELLS VARYING BY DISEASE STATE AND D. CD4+ TEM VS CD19+ B CELLS. The x-axis repre-
sents the change in gene expression, whereas y-axis is variation in assigned promoter accessi-
bility. Olive-green dots represent significantly different gene-peak 
LEGEND CONTINUED IN NEXT PAGE         
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pairs. r - Spearman’s rho; p - p-value; n - peak-gene pair number; DEG - Significantly different 
genes; DA - Significantly different accessible regions; All Genes - ± significant genes expressed 
by the cell type(s) under investigation; All Peaks - ± significant peaks belonging to the cell 
type(s) under investigation; C – Control; LPL - Lamina propria; TEM – T effector memory; UC(I) - 














































We aimed to determine if GWAS identified immune – mediated disease or trait asso-
ciated loci are enriched for the DEG and DA identified. Scripts used for enrichment 
estimation were developed by Dr Tim Raine (original method published in Gut 2015) 
and adapted by author to fit current data sets.  
7.4.2.1 Testing	For	Disease	State	Specific	Expression	Enrichment		
Immune - disease associated variants, but not trait connected SNPs, approached (pCD  
= 0.084, pRhArt = 0.06) or were significantly enriched (pUC = 0.008, pCoeliac = 0.0075) with 
genes differentially expressed between LPL CD4+ TEM (C vs UCi). Enrichment strength-
ened when only genes up-regulated in UCi were tested (Table 7.2). The majority of 
genes enriched in UC risk associated regions were either inflammatory (CCR1, CXCL1, 
IL-21, IL1R1, RORC, IL2RA, PRDM1, TRAFD1, LY75) or required for cell proliferation 
(NUSAP1, KIFF11, PIM3).   
A large proportion of immune - mediated disease risk loci are shared. Therefore, next 
we proceeded to determine how much of the enrichment observed between different 
diseases for genes upregulated in LPL CD4+ TEM UCi was due to common genetic asso-
ciations. Association was considered to be shared if immune-mediated disease focal 
SNPs were in proximity to the same gene and located in the same locus as the UC focal 
SNP.  
As result we identified that 86.67%, 60%, 28.57% and 60% of CD, Coeliac, RhArt and 
T1D risk loci, enriched for genes up-regulated in active inflammation in LPL CD4+ TEM, 
were shared with UC. TRAFD1 (TRAF-Type Zinc Finger Domain Containing 1), a gene 
associated with negative control of the immune system (Mashima et al., 2005; Sanada 
et al., 2008), was identified as overlapping SNPs for all 5 immune-mediated disease. 
IL-21, gene encoding for IL-21 - cytokine predominantly secreted by T cells and naturel 
killer T cells, was shared between CD, UC, Coeliac and T1D. CTLA4 and/or ICOS 
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(members of CD28 family of T-cell co-stimulatory receptors) – were up regulated in 
LPL CD4+ TEM upon active inflammation and associated with risk loci for Coeliac, T1D 
and RhArt but not UC and CD.  
UC associated risk loci might naturally be enriched for immune and inflammatory 
genes and, thus, the enrichment we observed might simply be due to gene expression 
data obtained from tissue under conditions of active inflammation. In this regard, DEG 
showing upregulation in quiescent UC LPL CD4+ TEM cells (C vs UCn) and approaching sig-
nificant enrichment for UC associated risk loci (p = 0.098) might be more of importance 
(Table 7.2).  We identified a total of 6 genes - YPEL1, YPEL3, HELZ2, CENPO, SNX27 and 
SPREAD2 - enriched in UC risk associated regions. However, SNX27 was associated 
with the same locus as RORC, already a well-established candidate gene involved as 
the master transcription factor for pathogenic Th17 cells (Ivanov et al., 2006). Like-
wise, the locus we assigned to YPEL3 was already associated with a credible candidate 
gene ITGAL, identified from eQTL studies in monocytes response to Lipopolysacharide 
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Table 7.2 IMMUNE-DISEASE OR TRAIT ASSOCIATED VARIANT ENRICHMENT FOR PEAKS AND 
GENES IDENTIFIED AS SIGNIFICANTLY DIFFERENT IN CELL POPULATIONS VARYING BY DIS-
EASE STATE OR ANATOMICAL LOCATION. Enrichment was determined for all DEG/DA and 
DEG/DA up or down regulated in UCi/UCn or SC LPL relative to the Control or Blood. The total 
number of risk associated regions for each condition, used for enrichment assessment after 
removal of an overlapping regions, is shown at the head of each column. The number of DEG 
and DA peak are displayed next to each comparison. p-values for are shown only for observa-
tions that were close to (0.1>p>0.05; in blue) or passed the significance threshold (0.05 > p; in 
red).  ALL - all peaks/genes identified as significantly different; UP - DEG/DA upregulated/more 
open in UCi/UCn/LPL; DOWN - DEG/DA downregulated/less open in UCi/UCn/LPL; SNP - single 
nucleotide polymorphism;  DEG - Significantly different genes; DA - Significantly different ac-
cessible regions; C –  Control; UC(I) - Ulcerative colitis patient with inflamed Sigmoid colon; 
UC(N) - Ulcerative colitis patient with non-inflamed Sigmoid colon; LPL - Lamina propria; TEM – 
T effector memory; CD - Crohn’s disease; UC - Ulcerative colitis; RhArt - Rheumatoid arthritis; 









With an exception of IEL CD8+ TEM, none of the immune-mediated disease associated 
locus showed any enrichment (Table 7.2). Peaks, more accessible in IEL CD8+ TEM in 
inflamed SC of UC patients showed significant (p = 0.035) enrichment for UC risk loci 
with 8 of 180 focal SNPs having an associated DA peak.  
Genetic loci associated with changes in MCV reached significance for overlap with 
peaks more open in Blood CD4+ TEM and LPL CD4+ TEM in UC under active inflammation.  
 
7.4.2.3	Testing	For	Cell	Linage	Specific	Expression	Enrichment		
It has been proposed that genes that are specific to intestinal lymphocytes in compar-
ison to their equivalent populations resident in other locations such as peripheral 
blood, could be of importance in their identity and function as intestinal lymphocytes, 
and variation in their regulatory regions could lead/contribute to intestine specific im-
mune disease risk.   
DEG genes between control CD4+ TEM (Blood vs LPL) were enriched in UC, CD and RhArt 
associated risk loci (Table 7.2). Further analysis showed that that genes upregulated 
in intestinal CD4+ TEM had a stronger association (p = 0.035) with UC, whereas coeliac 
enrichment weakened (p = 0.06) than for the full DEG list (that includes both up- and 
down-regulated genes). Interestingly, it was genes more expressed in Blood CD4+ TEM 
that approached significant enrichment in RhArt.  
In contrast to CD4+ TEM cells, both genes significantly upregulated and downregulated 
in intestinal B cells were enriched in risk loci associated with UC and CD, but no other 
immune-mediated disease or trait.  Further analysis showed that most of UC risk as-
sociated regions enriched for genes upregulated in either blood or LPL residing B cells 
were shared with CD (92.86% and 78.79%, respectively) (Table 7.3).  
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Table 7.3 LIST OF GENES THAT WERE IDENTIFIED AS DIFFERENTIALLY EXPRESSED IN B CELLS 
FROM PERIPHERAL BLOOD COMPARED TO THEIR GUT COUNTERPARTS AND ENRICHED IN 














As a final step in our analysis we tried to combine all 3 - omics data sets to narrow 
down the possible candidate gene list and propose mechanisms by which variants lo-
cated in the UC associated risk loci might lead to observed changes in expression. We 
hypothesized that a causal variant located in the risk associated locus might change 
the function of a regulatory region, such as an enhancer, insulator or silencer, which 
in turn might lead to change in gene expression.  We based our analysis on assumption 
that risk variants act on chromatin within their immediate proximity. Indeed, the GTEx 
consortium has showed that in tissue most of eQTLs are in less than 1Mb from gene 
which expression they affect (GTEx Consortium et al., 2017).  
In Blood CD19+ B cells, LPL CD4+ TEM and LPL CD19+ B cells (C vs UCi) we identified 9, 13 
and 12 UC associated risk regions which contained both - DA region and were near to 
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Table 7.4 LIST OF DEG AND DA WHICH EITHER FELL INTO OR WERE IN PROXIMITY TO UC 
ASSOCIATED RISK LOCUS. DA peaks and DEG that fall into the same region and share the same 
direction (in terms of Log2FC) are coloured green (more open and expressed in UCi) and red 
(less open and expressed in UCi).  
The first 2 columns show the GWAS data: 
Column 1 shows focal SNP  
Column 2 shows chromosome focal SNP is located on;  
Next 9 columns summarize the information around the DA peaks in proximity to focal SNP: 
Column 3 shows DA peak count in each newly defined region 0.1cM each side of focal SNP; 
Column 4 shows the peak-associated region overlap type;  
Columns 5 and 6 shows the start and end coordinated of each DA peak; 
Column 7 shows genomic feature (GF) and gene (in brackets) which peak is associated with 
based on its location on DNA;  
Column 8 shows peak width in bp;  
Column 9, 10 and 11 shows average concentration (AvgConc), log2foldchange (Log2FC) and 
p-value adjusted for multiple testing 
Last 4 columns present DEG associated statistics: 
Columns 12, 13,  14  and 15 shows average concentration (AvgConc), log2foldchange (Log2FC),  
p-value adjusted for multiple testing and symbol of differentially expressed gene. 
GWAS - Genome wide association study; ATAC Seq - Assay for Transposase accessible chroma-
tin; RNA Seq - Ribonucleic acid sequencing; SNP - Single nucleotide polymorphism; C - Control, 
UC(I) - Ulcerative colitis patient with inflamed Sigmoid colon; TEM – T effector memory; LPL - 
Lamina propria; CHR - Chromosome; No - Number in peaks in region around focal SNP; GF - 
Genome feature; AvgConc - Average concentration; Log2FC - Log2foldchange; bp - Base pair;  
LP - little peaks that start and end coordinates of peaks are inside the region around focal SNP; 
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LPL CD4+ TEM (C vs UCi)  
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7.5	Discussion 
We herein integrated transcriptomics, GWAS and chromatin conformation data for 
possibly IBD implicated cell types purified from Blood and SC biopsies from healthy 
controls and UC patients with and without inflammation. First, we would like to 
acknowledge that RNA seq and ATAC seq data sets are suboptimal quality. Therefore, 
data in this chapter (on their own) are not reliable to make any biological conclusions. 
Instead, we proceeded with analysis and interpretation to give author a chance to 
increase skill set.  
7.5.1	Relationship	Between	Expression	And	Accessibility			
First, we looked if difference in expression profile between C vs UCi are reflected by 
difference in peak accessibility. We used peak-gene pair model and performed a series 
of association calculations between DEG – DA, DEG – All Peaks, All Genes – DA and All 
Genes – All Peaks.  Unfortunately, due to low peak-gene pair numbers we were not 
able to properly assess if and how much significantly different changes in gene expres-
sion correlates with significantly different changes in their promoter (or other ge-
nomic region) accessibility in the same cell type varying only by disease state.  
By using cell type specific data from cell populations of different lineages from healthy 
controls, we showed that in this context DEG show the strongest correlation to DA 
regions mapped to promoters. We also demonstrated that DEG exhibit a stronger as-
sociation with differential promoter site openness than the converse (i.e. than DA pro-
moters being associated with genes showing differential expression). Whether this 
also applies to DEG and DA regions for the same cell type under different inflamma-
tory states remains unclear. The lack of correlation we observed may reflect the fact 
that regulation of gene expression under conditions of inflammation is mainly driven 
by other factors, such as transcription factor occupancy of already open regions of 
chromatin.  
The relationship between expression and chromatin profile are complex. Even though 
we modelled with the assumption that individual peaks might be responsible for 
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changes in gene expression and achieved, in the context of an unknown, non-linear 
biological system, strong correlation, it is not always the case. de la Torre-Ubieta et 
al., 2018 looked at difference in chromatin conformation and gene expression be-
tween cortical plate and germinal zone of developing human neocortex. They re-
ported only moderate correlation between DA promoters and genes with significantly 
different expressed exons (r = 0.417, p = 6.2e-60).   
Correlations between promoter accessibility and gene expression are perhaps the 
best understood model. In this system, TF binding initiates nucleosome displacement 
for transcription machinery to bind (Workman and Kingston, 1992; Svaren et al., 
1994). Even in this system the relative importance of TF binding within the promoter 
region can vary depending on the biology under investigation. The impact and mech-
anism of other regulatory regions on gene expression is less clear. In particular, recent 
studies by Alasoo et al., 2018 have shown that a large proportion of regulatory regions 
can be primed under normal conditions, meaning that allele specificity will impact the 
chromatin accessibility under normal conditions. This observation means that regions 
important for disease risk might not be identified from case control studies. In addi-
tion, Alasoo et al., 2018 revealed that some peaks act as master regulators for others. 
Gate et al., 2018 showed that a single variant can affect nearby and distal chromatin 
conformation which might partially explain why one peak can impact the accessibility 
of other peaks.  We believe with increase in information, more complex models will 
be developed which will permit the identification of the global relations between the 
gene expression and chromatin conformation. 
7.5.2	Disease	And	Trait	Associated	Locus	Enrichment	For	DEG	And	DA	Re-
gions		 
Next, we evaluated if GWAS risk variants associated with immune – mediated diseases 
or traits are enriched in genes/peaks identified as significantly different between C vs 
UC (i or n), or Blood vs LPL.   
We found that 4 out of 5 autoimmune disease associated risk variants, but not trait 
associated variants, were significantly enriched for genes up-regulated in LPL CD4+ TEM 
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upon active inflammation, whereas the 5th narrowly failed to reach statistical signifi-
cance (pT1D = 0.055). Further assessment showed that TRAFD1, a gene with expression 
upregulated in LPL CD4+ TEM UCi, was shared between all 5 autoimmune conditions.  
TRAFD1, also known as FNL29, was first identified as a IFN-γ + LPS inducible gene in 
monocytic M1 cells; mouse peritoneal macrophage and macrophage-like RAW cell 
stimulation with LPS, IFN-β and IFN-γ led to increased TRAFD1 protein levels. Further 
experiments showed that TRAFD1 overexpression attenuated NFkB signalling which 
most likely is the consequence of TRAFD1 physical interaction with TRAF6 (an adaptor 
protein with multiple functions, from which one is mediating the downstream signal 
of pattern recognition receptors, such as, toll-like receptors) (Mashima et al., 2005). 
Sanada et al., 2008 showed that Trafd1 deficient mice, challenged with sublethal dose 
of LPS or Poly(I:C) (Polyinosinic – polycytidylic acid; synthetic analogue of double-
stranded RNA, used to study anti-viral pattern recognition receptor signaling) exhibits 
much higher mortality than WT in vivo. In addition, Bone marrow-derived dendritic 
cells (BMDCs) from Trafd1 -/- mice secreted significantly higher levels of pro-inflam-
matory cytokines such as TNF-α, IL-6 and IL-12p70 (an active heterodimer of IL-12) 
upon stimulation with LPS than BMDCs from WT mice (Sanada et al., 2008). Together 
they have proposed TRAFD1 as negative regulator of immune response. TRAFD1 was 
significantly upregulated in LPL CD4+ TEM in UC patients with active inflammation, and 
even though physiological role of TRAFD1 in T cells is still unknown, T cell specific de-
letion of its proposed interaction partner - TRAF6 results in multiorgan inflammatory 
response (King et al., 2006), suggesting that TRAFD1 might act as negative feedback 
mechanism to regulate active inflammation.  
In contrast to differential expression data, none of immune-mediated disease showed 
enrichment for regions displaying higher accessibility in LPL CD4+ TEM UCi. Which might 
contradict other already published studies. Farh et al., 2015 showed that their identi-
fied, UC associated variants are enriched for acetylated cis-regulatory elements 
(which are markers of active promoters and enhancers) on stimulated CD4+ T cells and 
colonic mucosa. It was seconded by Kundaje et al., 2015b. In addition, Gate et al., 2018 
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showed that both - naïve and stimulated CD4+ T cell specific peaks, show higher over-
lap with UC associated variants than predicated by chance. 
Lack off enrichment possibly could be attributed to poor quality of our ATAC seq data. 
However, we could not exclude probability that our enrichment model was not fit for 
ATCA seq data analysis, mainly as individual gene can have multiple peaks with only 
some reaching statistical significance. Refining our enrichment algorithm might allow 
us to pick up any missing relationship, yet, we recognized that not all risk associated 
loci will be effective in all cell types. 
An additional approach to identify tissue or cell specific gene expression effects that 
could have a potential role in pathogenesis involves comparing the transcriptional 
profiles between matched cell populations (by surface marker expression) in different 
parts of the body or between case and control samples. The underlying hypothesis is 
that genes showing differential expression may be of particular importance for the 
tissue or cell type under study, and that, where these genes lie near to focal SNPs 
identified by GWAS, they represent attractive candidate genes for further study within 
that particular locus/cell type combination (Gautier et al., 2012).   
Herein we showed that genes upregulated in LPL CD4+ T cells (when compared to their 
blood counterparts) are enriched UC risk variants. In this regard, the observation that 
genes upregulated in SC CD4+ TEM but not TI CD4+ TEM (Raine et al.,2015) (in comparison 
to Blood CD4+ TEM) were strongly enriched in UC associated risk loci suggests a degree 
of anatomical specificity that matches the known disease distribution.  We therefore 
determined how many genes, which were upregulated in SC CD4+ TEM cells compared 
to blood and located in proximity to UC associated focal SNPs, were found differen-
tially expressed between C vs UC (i or n).  We found that 5 genes (PLEKHH2, OTUD3, 
FOS, TPPP and SPRED2) constituting 20% of genes examined, were identified as differ-
entially expressed between the healthy and disease. Interestingly, all 5 were down-
regulated in UC.  
 




Finally, we hypothesized that UC risk associated loci affects regulatory region function 
which subsequently leads to changes in gene expression. Gate et al., 2018 assessed 
chromatin structure in CD3 and CD28 stimulated CD4+ T cells from 105 healthy indi-
viduals with European descent. First, they showed that only 5% of SNP-containing 
peaks had associate SNP affecting chromatin state. However, these peaks were en-
riched for T cell enhancers and T cell development and activation associated TFBs. 
Moreover, peaks containing chromatin quantitative treat locus were more likely to 
overlap with GWAS autoimmune-disease associated risk variants than general SNP-
congaing peaks. 30% of local chromatin quantitative treat loci acted as eQTL to nearby 
genes. 
Here we combined ATAC Seq, GWAS and RNA Seq data to propose the causal mecha-
nistic by which variants contained in risk loci might impact the nearby (± 1Mb) gene 
expression with respect to specific cell types, namely Blood CD19+ B cells, LPL resident 
CD19+ B cells and CD4+ TEM cells.  After screening for DA peaks and DEG in proximity 
to focal SNPs associated with UC we further filtered our lists to exclude genes and 
peaks associated with low counts and known association.  We were left with 1 overlap 
region for LPL CD19+ B cells, 4 for Blood CD19+ B cells and 5 for LPL CD4+ TEM. In the 
following text, each predicated overlap region is discussed separately. 
	
Blood	CD19+	B	cells		
MIER3 (MIER Family Member 3) 
We found 3 peaks in region around rs10065637, all showing significantly less accessi-
bility in UCi. All peaks were located on gene body of ANKRD55. MIER3 expression was 
downregulated in UCi, letting us hypothesize that either of peaks could be harbouring 
an enhancer site. PubMed search for MIER3 resulted in total of 6 studies. MIER3 ex-
pression has been associated with colorectal cancer: Pitule et al., 2013 compared bi-
opsies from healthy mucosa vs cancer affected areas from CRC patients and reported 
significant reduction in MIER3 expression in tumour sites. Peng et al., 2017 further 
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revisited MIER3 with aim to better understand its role in CRC. They showed that MIER3 
downregulation is associated with more aggressive cancer growth and metastasis. 
Currently there are no studies of MIER3 in B cells, but profiling the tumor environment 
at single cell level has captured B cells and confirms MIER3 expression in these cells 
(Jerby-Arnon et al., 2018). 
 
LPL	CD19+	B	cells		
DENND1B (DENN Domain Containing 1B)  
Two separate loci contained peaks within 1 Mb of DENND1B. Each region contained 2 
peaks, from which one was located on the DENND1B promoter. Although DENND1B 
expression was increased in UCi compared to Control, all peaks showed significant de-
crease in openness. Of the other 3 peaks, one was within the promoter sequence of 
the C1orf53 gene. The other 2 were in an intergenic region distal to MIR181B1, which 
encodes a short non-coding microRNA that acts on mRNA stability. Currently, without 
any further investigation, it is hard to say if/which of peaks identified might have an 
effect on DENND1B expression, yet the decreases in DENND1B promoter accessibility 
might fit the least well. DENND1B functions as a guanine nucleotide exchange factor 
for small GTPases, specifically Rab35 which is regulator for endocytic recycling 
(Yoshimura et al., 2010). Yang et al., 2016 have recently showed that aerosolized an-
tigen challenged Dennd1b-/- mice intensified T helper 2 mediated inflammation. The 
DENND1B role in B cells is yet to be eluded. Polymorphisms in DENND1B have been 
associated with childhood asthma (Sleiman et al., 2010). 
 
XBP1 (X-Box Binding Protein 1)  
The region around focal SNP rs5763767 contains a DA peak within the UQCR10 pro-
moter. This sequence was more accessible in UCi. The peak is also around 1Mb from 
XBP1, the expression of which is also increased expression in UCi. UQCR10 encodes a 
component of the ubiquinol-cytochrome C reductase complex (Schägger et al., 1995). 
Interestingly, when Takata et al., 2010 compared gene expression in the brain cortex 
and hippocampus of Xbp1 +/− vs WT littermates, the top genes upregulated were 
Uqcr10 and Nipsnap1. However, this study was potentially flawed by possible gene 
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carry over from the 129S mice strain they used to generate Xbp1+/- mice. XBP1 is a 
transcription factor extensively studied in IBD, particularly CD (Kaser et al., 2008; 
Adolph et al., 2013). In the epithelium, accumulation of misfolded protein can induce 
endoplasmic reticulum (ER) stress and subsequently lead to the so-called “unfolded 
protein response” (UPR) (Chakrabarti, Chen and Varner, 2011). IRE1 is one of the ER 
stress sensors and splices XBP1 mRNA to induce generation of its active form, which 
now acts as transactivator for UPR target genes. In B cells XBP1 is required for plasma 
cell development (Reimold et al., 2001). 
 
 JUP (Junction Plakoglobin aka Catenin Gamma) 
The region associated with JUP contains 8 DA peaks, all on promoters showing in-
creased accessibility, whereas JUP expression was significantly reduced in UCi. JUP be-
long to the catenin family and is vital for desmosomal assembly. In addition it plays a 
role in cell adhesion and motility (Lie, Cheng and Mruk, 2011). The JUP impact on Wnt 
signalling is less straight forward than its relative β – catenin (Miller et al., 2013). Both 
proteins’ roles have been studied in IBD as both interact with E-cadherin, an epithelial 
adhesion molecule. Karayiannakis et al., 1998 stained colonic tissue from UC and CD 
patients and showed no difference in JUP expression in both disease. Koch et al., 2008 
looked at JUP and β – catenin impact on haematopoietic stem cell self-renewal and 
differentiation into other blood cells and concluded that neither are of importance. 
  
IDH2  (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial) 
There were two peaks, one on the CRTC3 promoter region, another on an intron. Both 
showed increased accessibility in UCi and were also close to IDH2, a gene upregulated 
in UCi, that encodes a protein necessary for conversion of isocitrate to α-ketoglutarate 
(Jo et al., 2001; Lee et al., 2007). IDH2 mutations have been associated with various 
cancer types, including B cell malignancies (Yang et al., 2012). Cha et al., 2017 used 
DSS to induce acute colitis in IDH2+/+ and IDH2-/- mice and showed significant drop 
in survival rate and increased neutrophil infiltration within the colon of knock out an-
imals. They proposed that IDH2-/-  exacerbated the DSS – induced colitis via alteration 
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in redox status, that leads to increase in p53 upregulated modulator of apoptosis 
(PUMA)-mediated apoptosis.  
 
LPL	CD4+	TEM	cells		
FAM53B (Family With Sequence Similarity 53 Member B) 
The risk loci around rs111456533 contained a DA open peak within the intronic por-
tion of the FAM53B gene. In parallel, expression of FAM53B was significantly in-
creased. There is little information about FAM53B in the literature currently, but the 
few existing papers have suggested that the FAM53B orthologue Smp is important in 
tissue regeneration and cell proliferation in fish (Kizil et al., 2009). Further experiments 
from Kizil et al., 2014 showed β-catenin dependence on Smp activity, where loss of 
Smp prevented the nuclear accumulation of β-catenin and blocked expression of Wnt 
target genes. They further used FAM53B siRNA transfected HEK293T cells line and 
showed reduction in β-catenin nuclear translocation in response to stimulus with 
Wnt3 conditioned medium. Ding et al., 2008 reported anti-inflammatory effect of sta-
ble β-catenin expression in T cells, particularly Tregs. The exact Treg role in UC is not fully 
understood. However, patients with mutations in FOXP3, a key gene for Treg  function, 
leading to dysfunctional Tregs are associated with intestinal inflammation (Okou et al., 
2014). Hence, FAM53B might be one of the genes necessary for Treg suppressive and 
inflammatory function and may be impacted in these cells by the disease associated 
variant.  
 
NAB1 (NGFI-A Binding Protein 1) 
NAB1 was significantly upregulated in UCi.  NAB1 acts as transcriptional repressor for 
EGR1 (Early Growth Response-1) (Thiel et al., 2000) and currently there are no associ-
ations between NAB1 and IBD.  It is located in proximity to DA promoter of STAT1 
(Signal Transducer and Activator of Transcription 1), less accessible in UCi. STAT1 acts 
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NOL4L (Nucleolar Protein 4 Like) 
NOL4L and TPX2 are two genes within the rs6142618 region.  Only NOL4L passed the 
counts threshold introduced. We observed significant upregulation in CD4+ TEM in UCi. 
NOL4L function in humans is not well understood. Guastadisegni et al., 2010 and 
Kawamata et al., 2012 have identified NOL4L as a fusion partner to RUNX1 and PAX5 
in acute myeloid leukemia and acute lymphoblastic leukemia. NOL4L and TPX2 were 
also in proximity to DA promoter of ASXL1, which was more accessible in UCi. 
 
CASP8AP2 (Caspase 8 Associated Protein 2) 
The region around rs1847472 contained two DA peaks that were intronic to BACH2. 
Within this region, lies CASP8AP2. The DA peaks showed decreased accessibility in UCi 
and CASP8AP2 was downregulated. CASP8AP2 is a multifunctional protein and has 
been associated with histone gene expression, cell death and survival. It is involved in 
Fas and TNF- α death receptor signalling, with one of the functions being activation of 
caspase 8 (CASP8) (Imai et al., 1999; Jun et al., 2005). In addition, CASP8AP2 has been 
identified as crucial for CRC cell survival (Hummon et al., 2012). Apoptotic pathways 
have been long recognized in IBD, and very recently Lehle et al., 2019  showed that 
germline mutation in CASP8 which results in reduced protein abundance, is associated 
with very early onset development of Inflammatory Bowel Disease.  
 
 
CBX3 (Chromobox 3 ) 
CBX3 expression was increased in UC patients with active inflammation in comparison 
to healthy control. The gene is located close to a DA peak that lies within the 5’UTR of 
the SKAP2 gene. This peak shows significant reduction in chromatin accessibility in UC 
patients.  CBX3 has been associated with various functions including transcriptional 
regulation (including inflammatory genes) and can act as component of heterochro-
matin. Sohn et al., 2012 used CBX3 as marker of senescence in UC and CD. Senescence 
is a process in which cells enters permanent growth arrest. IHC revealed high level of 
CBX3 in colonic tissue from IBD patients, where CD had higher levels of CBX3 then UC.  
The role of CBX3 in lymphocytes is less studied. Sun et al., 2017 looked at Cbx3 effects 
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on CD8+ TE cells. They showed that Cbx3 insufficient CD8+ T cells had increased killing 
capacity and that the cancer microenvironment of Cbx3 insufficient mice or wild type 
mice treated with Cbx3 insufficient CD8+ T cells, showed changes in T cell ratios, with 
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UC is chronic idiopathic condition, characterized by uncontrolled inflammatory re-
sponse in colon (Gramlich and Petras, 2007; Fatahzadeh, 2009). GWAS has been suc-
cessful in identification of one of the largest numbers of UC and Crohn’s disease risk 
associated regions across the entire human genome, more than for any other immune 
mediated disease. However, as for other immune mediated diseases, only a small frac-
tion of variants is located in protein-coding regions (de Lange et al., 2017). Though 
missense variants have been essential in highlighting some of disease associated 
causal genes and pathways (Pidasheva et al., 2011; Strober and Watanabe, 2011; 
Adolph et al., 2013; Lamas et al., 2016), the exact biological role of majority of loci still 
remains unclear.  
Previous attempts to understand the molecular paths leading to complex disease have 
shown that GWAS identified disease and trait associated variants are significantly en-
riched in endonuclease accessible chromatin regions (Maurano et al., 2012; Kundaje 
et al., 2015b), chromatin marks (Ernst et al., 2011; Farh et al., 2015; Kundaje et al., 
2015b), eQTLS for complex diseases (Nicolae et al., 2010) and histone-QTLs (Grubert 
et al., 2015). Taken together, these studies proposed that disease associated risk var-
iants could act by modulating the function of underlining regulatory elements, which 
in turn could lead to change in gene expression. Grubert et al., 2015 carried out a large 
scale study looking at genetic variant impacts on histone marks, DHS, gene expression 
and chromatin 3-dimensional interactions. They showed that a single QTL can affect 
multiple molecular phenotypes, and that the biggest proportion of local-QTLs affect 
the enhancer chromatin state.  Enhancers are the regulatory elements characterized 
by their cell-type and tissue specificity (Heinz et al., 2015). A number of studies have 
now showed strong GWAS risk associated variant enrichment in enhancer sites (in-
cluding IBD) (Ernst et al., 2011; Farh et al., 2015). Interestingly, it is cell type and tissue 
specific enhancers which shows the enrichment.   Weedon et al., 2014 revealed that 
homozygous mutation in distal enhancer of PTF1A gene, were associated familiar pan-
creatic cancer. Enhancer region showed marked cell-type specificity, as none of the 
cell types screened by ENCODE showed the enhancer.  
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The main goal we set with this study was to develop hypotheses around the exact 
mechanism by which the GWAS associated variants might lead to disease risk. GWAS 
on its own is good in identifying common disease susceptibility loci without prior 
knowledge of locus function, but it is unable to identify the causal variant, causal reg-
ulatory region or causal gene. From large numbers of common risk regions, we believe 
that complex networks of molecules are involved in UC pathogenesis. Each genomic 
study is limited to one particular molecular layer. Hereby, to gain a complete under-
standing of biological mechanism of disease multiple genomic studies should be em-
ployed. We selected RNA Seq and ATAC Seq methodologies for functional analysis of 
UC. On their own they can highlight certain biological differences between the healthy 
participants and UC, but we hoped that integrative approach would provide us with 
understanding of the molecular information flow. Thus, we hoped that we could con-
nect the change in underlying genomic sequence, to change in chromatin confor-
mation, which would further explain the transcriptional differences. However, as at 
the time there were no studies looking at the expression profiles and chromatin con-
formation in purified cell populations from gut of either healthy and UC patients, we 
first proceeded with individual genomic data analysis.  
RNA Seq of CD4+TEM and CD19+B cells from blood and SC allowed us to identify 2042 
DEG including 5 long non-coding RNAs, between the control and UC (i and n). However, 
it is important to note that sample QC indicated that there might have been a slight 
contamination during FACS sorting. In addition, Power Analysis showed that with our 
sample numbers and sequencing depth we have power to reject the null hypothesis 
only for genes with high expression and LogFold change. Altogether suggesting that 
data validation is crucial before any biological conclusion is made. Nevertheless, we 
successfully picked up already known transcriptional difference, such as increased ex-
pression of RORC, IL17A, IL21, IL2RA and CTLA4 in LPL CD4+TEM form UCi. Moreover, 
we were able to propose new genes which had no or little association with UC. Good 
examples are SEMA4A and KSR2. Moreover, we saw that DEG from LPL CD4+TEM (C vs 
UCi) are enriched in GWAS risk loci for UC. Interestingly, the DEG from the same cell 
populations approached significant enrichment when control was compared to UCn.  
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Next, we investigated the chromatin profile in 10 FACS-purified cell populations from 
peripheral blood and SC from healthy and diseased. We identified a total of 393’931 
accessible regions present in at least 1 of 30 phenotypes. Unfortunately, even after 
extensive trouble shooting DA calculation returned data with possible quality issues. 
Thought the small sample number is very unlikely to represent true estimate of pop-
ulation mean (assumption is based on observation that RNA seq data, which had less 
variance and higher sample counts could reliably identify only very prominent change 
in gene expression), change of differential accessibility algorithm could solve the fail-
ure in test statistics seen. 
As both RNA seq and ATAC seq data sets were of suboptimal quality, we were not able 
to use them for sophisticated computer modelling of the possible causal network, 
which was our main goal. We still proceeded with multi -omics analysis to improve 
authors skillset. Integration of all three -omics data sets allowed us to identify 10 
GWAS risk regions where the DA peak and DEG were in near proximity.  
For example, in B cells r7495132 SNP were located in close proximity to IDH2 and two 
differentially accessible peaks falling in the CRTC3 promoter and intronic regions. DEG 
and DAR showed increased chromatin accessibility and IDH2 expression in UCi. Inter-
estingly, both genes encode for protein important in the energy metabolism. CRTC3 is 
a downstream element of second messenger cAMP mediated signalling cas-
cade. CRTC3 acts as a co-activator for cAMP responsive element binding protein 
(CREB) (Liu et al., 2018). Double knockout of CRTC3 and CRTC2 is lethal, whereas 
CRTC2-/-, CRTC3-/+ resulted in splenomegaly and abnormal bone marrow functions, 
which included reduction in B cell numbers in circulation (Kim et al., 2017).  In addi-
tion, CRTC3 regulates mitochondrial biogenesis in response to rotenone induced mi-
tochondrial stress (Than et al., 2011). 
The similar multi -omics approaches have been successfully employed in studying the 
GWAS SNP effects in pancreatic cell subtypes isolated from human donors. Arda et al., 
2018  showed that cell type specific DAR are enriched for diabetes associated genes 
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and that genes expressed in cell type specific manner can be associated with multiple 
DAR (Arda et al., 2018).   
In conclusion, we aimed to study the expression profiles and chromatin accessibility 
in purified, possibly UC relevant cell populations, with main goal to use these data to 
propose the functional role of UC associated risk loci. We have generated valuable 
data sets, which when combined with other data sets, could provide with reliable bi-
ological insights. However, we fell that the main impact of this study was many tech-
nical findings regarding sample processing and analysis. Since our early work, there 
have been several publications highlighting the same challenges we have seen, such 
as read alignment with ribosomal library preparation and ATAC seq data analysis 
guidelines. Hereby, our work could be used as guidance of how to design better ex-
periments using clinical samples of suboptimal quality.  
Unfortunately, we did not have any time to fully validate any of our findings.  If we 
had more time and funds available we would try to overcome some of the biggest 
limitations in the study - small sample numbers and low sequencing depth. The best 
starting point would be in silico validation of the expression data. Smillie et al., 2018 
compare the expression profiles of UC vs Control at single cell level and, hereby, this 
dataset could form a resource of first choice.  
 As for the next steps, we are not aware for any ATAC or DNase Seq assay in purified 
populations from human intestinal tissue. Unfortunately, currently the only method 
to validate the ATAC seq data would be the performance of more ATAC seq, DNase 
seq or Chip Seq for histone marks.  
In addition, by end of project there were some ATAC seq libraries leftovers, therefore 
with more money available, we could increase sequencing depth to the 300M 
reads/sample suggested, which would allow to gain better insight of chromatin con-
formation and perform the TF “foot printing” and identify the TFBS occupancy in these 
samples, which from our current knowledge currently is not available anywhere else.  
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There is no gold standard for sequencing design. An optimal sequencing depth is highly 
dependent on the aims of each individual experiment (Conesa et al., 2016).  Sequenc-
ing depth in this case refers to the total number of sequenced reads in a sample.  
Before venturing into a large-scale sequencing project, we first set out to determine 
the optimal sequencing depth, which could provide us with sufficient level of infor-
mation to carry out the intended analysis. In addition, as it was our first-time con-
structing RNA seq libraries, we wanted to assess sample quality before further com-
mitting to high in cost sequencing experiment. 
Initial sequencing parameters were selected based on recommendations from experts 
in the Medimmune Bioinformatics facility and Dr. Bergamaschi (Postdoctoral Fellow 
in Prof Ken Smith lab). Briefly, 13 RNA Seq libraries were pooled together, quality 
checked and run on NovaSeq 500 (75bp, PE, 30M reads/Sample) located in the De-
partment of Biochemistry, University of Cambridge. Initial quality assessment and 
read mapping were performed by the MedImmune Bioinformatics facility using the 
bcbio open resource python toolkit.    
Raw	Sequencing	Read	Alignment		
Sample alignment ranged from 1.7% to 81% of total reads sequenced, with median of 
41% (Figure A1.1). Poor mapability together with GC content bias raised the question 
of possible contamination with other (non-human) genomes.  
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Figure A1.1 RAW RNA SEQUENCING READ ALIGNMENT TO THE HUMAN GENOME EX-
PRESSED AS PERCENTAGE OF TOTAL READS (n sample = 13). Each dot represents a sample. Error 
bar represents the mean and standard deviation. 
To test for potential impurities Kraken (a system for assigning taxonomic labels to 
short DNA fragments) was used. In short, after the low complexity region removal, 
unmapped reads were fragmented into the smaller fragments and passed to the Kra-
ken to test for the contamination with mammalian, viral and bacterial genomes.  
Only a small proportion (median = 19.8 %) of unmapped reds mapped to the contam-
inants selected, leaving the rest of unmapped reads unclassified (Figure A1.2).  
 
Figure A1.2 PERCENTAGE OF UNMAPPED READS THAT EITHER DID OR DID NOT REALIGN 
AGAINST ANY OF OTHER GENOMES TESTED (n sample = 13). Unmapped-Unclassified shows 
reads that failed any alignment, whereas Unmapped-Classified found their alignment after 
Kraken screening. Each dot represents a sample. Error bar represents the mean and standard 
deviation. 
 
The Unmapped-Classified reads mapped to human and bacterial genomes, but not 
viral or other mammalian genomes. Interestingly, the percentage of remapping 
strongly correlated with sample RIN (Figure A1.3), where increases in RNA quality 
showed strong negative correlation (r = -0.775, p = 0.0028) with mapping to bacterial 
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Figure A1.3 RELATIONSHIP BETWEEN THE RNA QUALITY AND PERCENTAGE OF READ RE-
MAPPING TO THE VIRAL, BACTERIAL AND HUMAN GENOME (n sample = 13). Relationship was 
quantified by Spearman’s correlation. Each dot represents a sample. r - Spearman’s rho; p - p-
value; RIN - RNA integrity number; UC - Unmapped-Classified; B – Bacterial Genome; H – Hu-
man Genome; V – Viral Genome.  
 
Taken together, these observations suggested that most of the unmapped reads could 
not be attributable to the contamination with either viral or mammalian genetic ma-
terial. Rather it seems that the samples with low RNA quality are more susceptible to 
the presence of bacterial genome.  
Read	Genomic	Alignment	
Analysis revealed that most of the mapped reads aligned to the intergenic regions 
(median = 63.8%) with the second largest group mapping to intronic regions (median 
= 25.35%) and only a small proportion of total aligned reads mapped to the exonic 
regions (median = 10.55%) (Figure A1.4). 
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Figure A1.4 GENOMIC ALIGNMENT OF MAPPED READS. Samples 1 to 13 are shown along y 
axis and the % of total mapped reads that fell on defined genomic region are shown amongst 
the x axis. 
 
We had two hypotheses to explain why a large proportion of reads mapped to the 
intergenic regions and not to the exons. We speculated that libraries could either have 
been contaminated with the gDNA or the rRNA depletion methodology used might be 
responsible for this unusual read distribution.   
To exclude gDNA as a possible contaminant, RNA purity was re-assessed. First, we re-
valuated all RNA sample associated electropherograms. None of gDNA characteristic 
peaks were seen in any of RNA samples. Second, we used Qubit benchtop fluorometer 
to accurately measure gDNA quantity in 7 of the 13 RNA samples used for library gen-
eration.  All samples were below detection range (<10pg/ul). 
At time of our Optimization experiments,  Illumina released Ribo-Zero rRNA removal 
kits, which worked in similar manner to the SMARTer Stranded Total RNA seq Kit- Pico 
Input Mammalian kit we used for our RNA seq library construction. The supplemen-
tary information published along the Ribo-Zero rRNA removal kits showed that librar-
ies constructed by rRNA depletion method shows significantly different genomic align-
ment that RNA Seq libraries made by conventional poly-A enrichment methods. 
Therefor we concluded that there was no error during library construction and the 
unusual alignment is due the new library generation technology.   
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The main finding from the first optimization experiment was that only a small fraction 
of reads aligns to the exonic regions and, hereby, sequencing depth of 30M is far too 
low for accurately determining changes in gene expression. Therefore, we decided to 
run a second optimization experiment increasing the sequencing depth to 200M PE 
reads/sample that allowed us to down sample and find the optimal sequencing depth 
(balance between the information needed and the associated costs). Finally, we se-




















From optimization experiments we learned that some of the RNA seq libraries 
showed very poor sequencing performance. Early identification and exclusion 
of these libraries would be very beneficial from the financial perspective. There-
fore, to predict which libraries will result in poor performance cell count, RIN, ex-
tracted RNA concentration and library insert size were correlated with the percentage 
of total reads mapped (Figure A2.1).   
Both - RIN and extracted RNA concentration showed strong correlation (r = 0.67, p 
=0.015 and r = 0.819, p = 0.001) with read alignment. Though cell number showed 
moderate correlation with mapping ability, the correlation coefficient was not signifi-
cant (r = 0.443, p = 0.13). However, cell number exhibited robust correlated with both 
RIN (r = 0.633, p = 0.023) and extracted RNA concentration (r = 0.575 , p = 0.043 ) (Data 
not shown).  
 
FIGURE CONTINUED IN NEXT PAGE 
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Figure A2.1 RELATIONSHIP BETWEEN THE RNA SEQUENCING LIBRARY ALIGNMENT AND 
EARLY SAMPLE/LIBRARY METRICS (n sample = 13). Relationship was quantified by Spearman’s 
correlation. Each dot represents a sample.  r - Spearman’s rho;  p - p-value; RIN - RNA integrity 
number; Conc. – extracted RNA concentration. 
In summary, we identified that libraries generated from samples low in RNA quantity 
or quality resulted in poor alignment to the human genome and showed increased 
contamination with bacterial genome. It should be mentioned that all libraries were 
generated from the same amount of RNA, thus, the impact of initial RNA concentra-
tion on library quality was not anticipated. However, it might explain the bacterial 
contamination seen, as, most likely, low amounts of RNA in tubes was not enough to 
dilute out environmental contamination, which further was successfully amplified 
during the PCR amplification step. Therefore, it was decided to exclude samples with 
RIN <7 or concentration < 100pg/ul from further study. Both thresholds were selected 
after analysis of correlation scatter plots, keeping in mind that too stringent thresh-




















In RNA and ATAC sequencing experiments large emphasis was put on the data QC. We 
believe that QC is a very important part of any experiment. It not only examines the 
presence of any technical artifacts, but also if general biological assumptions are sat-
isfied.  
Sequencing	Library	Quality	Control	
For initial quality assessment and read mapping the same pipeline as for both optimi-
zation runs was performed by the MedImmune Bioinformatics facility.  
A median sequencing depth per library of 82.5M PE reads and 98.2M PE reads for 
sequencing runs 1 and 2 was achieved (Figure A3.1 A). In comparison to the optimiza-
tion run, median read count mapped increased to 70.25M PE reads per library, with 
the lowest sample achieving 36.10M PE reads (Figure A3.1 B).   
 
Figure A3.1 RNA LIBRARY SEQUENCING DEPTH AND ALIGNMENT (n sample = 92). A. The number 
of PE reads each sample was sequenced to. B. Percentage of total sequenced reads per sample 
that mapped to the human genome. Each dot represents a sample. Error bar represents the 
mean and standard deviation. PE - Paired end sequencing; M – Million.  
 
Moreover, percentage of mapped reads moderately correlated with RIN number (r = 
0.428, p = 0.0001), and cell count (r = 0.4311, p = 0.0001), but kept very strong corre-
lation with RNA concentration (pg/ul) (r = 0.7396, p = 0.0001) (Figure A3.2).  
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Figure A3.2 RELATIONSHIP BETWEEN THE RNA SEQUENCING LIBRARY ALIGNMENT AND 
EARLY SAMPLE/LIBRARY METRICS (n sample = 92). Relationship was quantified by Spearman’s 
correlation. Each dot represents a sample.  r - Spearman’s rho;  p - p-value; RIN - RNA integrity 
number; Conc. – extracted RNA concentration. 
Despite the increase in read alignment, proportions of genomic origin stayed the same 
(Figure A3.3).   
 
Figure A3.3 GENOMIC ORIGIN OF ALIGNED READS (n sample = 92). Each dot represents a sam-
ple. Error bar represents the mean and standard deviation. 
 
Together, these data confirmed that the alignment accuracy is determined by the ex-
tracted RNA quantity. 
Pre-Differential	Expression	Quality	Control	
Before differential expression analysis, reproducibility between samples was evalu-
ated. The underlying assumption behind differential expression is that genes from the 
same sample group have similar expression pattern and quantity.  
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To evaluate read count distribution, density plots and box plots from normalized 
counts was generated. No obvious sample outliers were detected (data not shown). 
Additionally, plots highlighted that most of genes have very low counts (median = 
32.7).  
DESeq2 intrinsic functions were used for count normalization, variance stabilization 
and finaly PCA plot and hierarchical clustering generation. PC3/PC4 graphs were pro-
duced by manually altering the code used for PC1/PC2 construction. Both the total 
and protein coding data sets were clustered based on the Euclidean distance. For easy 
visual assessment of sample associated factor influence on their variance, plots are 
colour and symbol coded. In addition to colour, sample similarity is highlighted by the 
dendrograms on top and on left-hand side of heatmap.  
In all instances observed clustering was driven by a combination of sample anatomical 
origin and cell type. When sample relationship was evaluated based on all genes, one 
of the Blood CD4+ TEM samples was mixed with LPL CD4+ TEM, it was not the case when 
protein coding genes were assessed alone(Figure A3.4 A).    
PCA plots were constructed using expression data for the top 500 most variable genes, 
as genes that lack variance between samples will not contribute to sample separation. 
The principal component 1 (PC1) showed that most (48%) of variance is explained by 
the cell type, following by the anatomical location (PC2 = 27%), as expected. Interest-
ingly, when all genes were considered, as in clustering by Euclidian distance, it was 
anatomical location that contributed to greatest sample-to-sample difference, fol-
lowed by cell type (data not shown). PC3 and PC4 explained 4% and 3% of variance, 
where PC3 seemed to be cell type driven (Figure A3.4 B).  
Importantly, PCA showed that samples from LPL have much higher within-group vari-
ability than ones from blood, and so each subpopulation should be analyzed sepa-
rately, if not, LPL samples would inflate the per-gene dispersion estimates for blood 
samples.  
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Figure A3.4 EXPLORATORY ANALYSIS (n samples = 94). A. HeatMap representing sample-to-sam-
ple relationships at total gene or protein-coding gene level.  B. PCA based on top 500 protein 
coding genes with highest variance. Percentage of variance each principal component consti-
tutes are shown of left-side and bottom of each plot. F – Female; LPL – Lamina Propria; M – 
Male; PC – Principal component; TEM – T effector memory; UC - Ulcerative colitis patient with 
and without inflammation in Sigmoid colon.  
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After main sample set division into smaller aim specific subsets, PCA was applied to 
each of individual subsets. To estimate the impact of sample biological and technical 
variation, PC1/PC2 plots were coloured according to sex, batch (represents RNA sam-
ple collection time), medication and disease condition. In addition to PCA, we used 
factoextra R package to generate Scree plots. Scree plot is diagnostic plot showing the 
percentage of variance explained by each principal component (data not shown). In 
case of Blood CD4+ TEM and Blood CD19+ B cells, where each PC1/PC2 explains rela-
tively small proportion of variance, PC3 and PC4 must be evaluated too.  
PC1 and PC2 (Blood CD4+ TEM) explained 13% and 12% of variance (Figure A3.5 A) and 
were driven by individual samples; Outlier samples were removed and PCA re-esti-
mated, but again separation was based on individual samples (data not shown) so all 
samples were kept for further analysis. PC2 (Blood CD19+ B cells) accounted for 11% 
of variance (Figure A3.5 C) and seemed to separate samples by the RNA sample col-
lection time. However, in addition to sample collection time PC2 slightly correlated 
with sex, but that could be explained by fact that most of male participants were re-
cruited at second phase of sample collection.  In contrast, PC2 (12%) for LPL CD4+ TEM 
seemed to separate samples by disease state (Figure A3.5 B). The rest of variance 
could not be explained by any of factors tested (Figure A3.5 A, B, C and D).  
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Figure A3.5 PRINCIPAL COMPONENT ANALYSIS ON A. BLOOD CD4+ TEM, B.  BLOOD CD19+ B, 
C. LPL CD4+ TEM AND D. LPL CD19+ B CELL POPULATIONS. Batch represents the sample collec-
tion and RNA extraction time, where batch A marks samples that were collected 2015-early 
2016, but batch B shows samples collected from late 2016-2017. LPL - Lamina propria; TEM - T 
effector memory; PC - Principal component; F – Female; M – Male. 
 
When PCA was calculated for samples from the same cell type, but at different ana-
tomical locations, the main variance came from the anatomical location (Figure A3.6), 
as expected.  
 
Figure A3.6 GRAPHICAL REPRESENTATION OF PC1/PC2 FOR CD4+ TEM AND CD19+ B CELLS 
FROM PERIPHERAL BLOOD AND SC LPL. LPL - Lamina propria; TEM - T effector memory; PC - 
Principal component. 
For the last step of pre-differential expression quality control, subpopulation purity 
was evaluated based on their expression of sort markers (CD3, CD4, CD19, CD14, 
CD62L, CD8a). In initial FACS sort: 
• CD45 was used to separate lymphocytes from rest of cells;  
• CD3, CD19, CD14 were used to separate all T cells, B cells and MF from CD45+ pop-
ulation;  
• CD4 and CD8a was used to separate T cells from CD3+ population.  
DESeq2 was used to generate representative plots, where pseudo-count of 0.5 were 
added to each sample to fit on log axis. 
As expected, Blood CD4+ TEM and LPL CD4+ TEM subpopulations expressed more CD4 
and CD3 than Blood CD19+ B cells and LPL CD19+ B cells, which was vice versa for CD19. 
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Nonetheless, samples showed marked variation in expression levels of sort markers 
used for negative selection (Figure A3.7). This could be reflection of low background 
transcription of genes or simple noise. On the other hand, the sort itself has an error 
rate, which for samples with lot of cells would make no difference, but for low cell 
(low count) experiment it might have a rather large impact. Nevertheless, without 
having a clear understanding of actual reason contributing to heterogeneous expres-
sion of negative-sort markers data should be analyses with caution, possibly assuming 
that there is an underlying contamination.  
 
Figure A3.7. EVALUATION OF CELL POPULATION PURITY BASED ON CELL SURFACE MARKER 
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Post-Differential	Expression	Quality	Control	
After extensive pre-expression QC the call for differential expression was made. In or-
der to determine if differential expression calculations have resulted in reliable out-
put, we further examined count outliers, independent filtering, p-value and normal-
ized counts for all DEG.  
Independent filtering is a metric introduced to minimize the power reduction by mul-
tiple testing. Independent filtering works by removing genes with low expression as 
they suffer from very high Possion noise and are not reliable for estimation of true 
biological effect (Bourgon, Gentleman and Huber, 2010).  
For unknown reasons, most DESeq2 calls were below the independent filtering thresh-
old which meant that function was not performing any filtering. To overcome this and 
remove genes that had minimal expression, we introduced a manual count-based 
gene pre-filtering. For full function description please see the Chapter 5 Materuals and 
Methods section.  
DESeq2 function automatically screens for count outliers. The graphical evaluation of 
gene count outliers showed that none of the DEG had an obvious outlier, neither did 
any of samples (Data not showed).  There is major downfall to outlier identification by  
DESeq2 - it cannot detect more than one outlier per gene. To further evaluate the 
quality of DEG calling, normalized counts were plotted for visual inspection for all sig-
nificant results.   
Large proportions of DEG associated with low counts suffered from very high variance 
(Figure A3.8 A). However, whilst a substantial fraction of DEG associated with low 
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Figure A3.8 REPRESENTATIVE COUNTS DISTRIBUTION FOR A. LOW EXPRESSED GENE AND B. 
RELATIVELY HIGHER EXPRESSED GENE. To fit counts of logarithmic axis pseudo-count of 1 was 
added. UC(I) - Ulcerative colitis patient with inflamed Sigmoid colon; UC(N) - Ulcerative colitis 
patient with non-inflamed Sigmoid colon. 
 
Finally, p-value distribution for DEG testing was visualized to determine if the statisti-
cal tests employed for significance estimation gave dependable results. p-values 
should have an uniform distribution between 0 and 1 with a possible peak at 0, repre-
senting the p-values under the alternative hypothesis (Klaus et al., 2016). The p-value 
distribution model in case of little or no significance is named uniform, whereas If 
there is a significance it is called anti-conservative p-value distribution. 
All helathy vs disease comparisons had either anti-conservative or uniform p-value 
distribution indicating the robustness of our approach. However, when comparison 
was based on anatomical locations, the observed rates of the alternative hypothesis 
was exceptionally high, suggesting that majority of genes have different expression 
patterns. To reassess if high number of significant genes is not consequence of test 
statistics itself, we used fdrtool package (Strimmer, 2008) to recalculate the variance 
of the null-model. By default, test statistics use constant variance (sd = 1) for all sta-
tistical tests. Yet, if data will have variance different from 0, incorrect estimation will 
take place.  Recalculation showed that, indeed, variance was markedly higher for both 
CD19+ B cell (Blood vs LPL) (sd = 1.873) and CD4+ TEM cell (Blood vs LPL) (sd = 1.946) 
populations. Calculations was passed back to DESeq2 and p-values corrected accord-
ing to newly determined variance (Figure A3.9). 
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Figure A3.9. P-VALUE VISUALIZATION BEFORE AND AFTER CORRECTION FOR THE STANDARD 
DEVIATION FOR A. CD4+ TEM (Blood vs LPL) AND B. CD19+ B CELLS (Blood vs LPL) COMPARISONS. LPL - 
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During optimization runs it was discovered that some of the samples showed poor 
alignment to the human genome. Alignment is one of the first indicators of sample 
quality and possible contaminations. It was of major importance to identify the factor 
behind low mapability, as the nature of any confounding factors would determine if 
samples would meet study expectations and provide an accurate biological picture.  
Contaminant screening showed that most of the unmapped reads did not belonged 
to other common bacterial, viral and mammalian genomes. However, correlation with 
sample associated metrics allowed us to connect poor alignment with RNA poor qual-
ity and low yields. We therefore took measures to exclude samples from downstream 
analysis based upon these parameters. 
One critical aspect that impacted library quality related to the library preparation kit 
used. At the time of designing these experiments, we encountered a paradox. Whilst 
bulk RNAseq based upon large cell numbers was an established methodology, and 
whilst single cell methodologies for RNASeq were becoming established, surprisingly 
little existed for RNASeq library preparation using cell numbers in the range we were 
exploring. We selected a technology which would allow us to obtain good data quality 
from clinical samples, known to be limited in nucleic acid amount and heterogeneous 
in quality. At the time, available kits typically used poly-A selection to separate protein 
coding mRNA molecules from the rest of RNA species. During mRNA maturation mul-
tiple adenosine monophosphates gets added to 3’ end of mRNA molecule which is 
then called poly-A tail (Lodish et al., 2000), which is then targeted for mRNA enrich-
ment (De Klerk, Den Dunnen and ’T Hoen, 2014; Hrdlickova, Toloue and Tian, 2017). 
mRNA selection is an important step as mRNA constitutes only small fraction of total 
RNA (Conesa et al., 2016). Thus, without purification it would require very deep se-
quencing to obtain the same information level as for mRNA alone and lead to high 
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sequencing costs.   Unfortunately, poly-A selection requires large amounts of highest 
grade RNA as during degradation RNA fragments break and loose their poly-A tails 
(Conesa et al., 2016). SMARTer Stranded Total RNA Seq Kit - Pico Input Mammalian kit 
had a distinct advantages in this regard, since it employs bead based rRNA and mito-
chondrial RNA purification technology which allows kit to be used for suboptimal qual-
ity RNA samples, such as those obtained from low starter cell numbers and after some 
potential degradation during cell sorting and RNA storage. In addition, coupling rRNA 
removal technology with PCR amplification steps contributed to this kit’s unique 
picomolar RNA input requirements (Takara Bio Inc., 2018).  
In our experiments, we showed that in our hands, this kit was not compatible with 
poor quality RNA samples. To gain further understanding of why we see low quality in 
our sequencing library, I undertook further communication with Dr Bergamaschi, a 
post-doctoral fellow in Prof Ken Smith’s laboratory and who had routinely used 
SMARTer Stranded Total RNA Seq Kit - Pico Input Mammalian kit for her sequencing 
library generation. Dr Bergamaschi did not share our experience, yet, their laboratory 
used ng of only high-grade RNA (RIN > 7). Indeed, our observation was latter backed 
up by Schuierer et al 2017. They compared poly-A and rRNA removal technology back 
to back across a wide range of RNA input concentrations coupled with different RNA 
quality and showed that sample alignment decreased with reduced input amounts 
independent of RNA quality, and that highly degraded samples resulted in very poor 
alignment to human genome which was further augmented by a decrease in input 
concentration. The lower concentration of highly degraded RNA tested on rRNA de-
pletion kit in their study was 10ng (94% more than for our libraries) which produced 
only 42.78% alignment to human genome (Schuierer et al., 2017). 
Unexpected	Genomic	Origin	
In addition to poor alignment, a separate problem we observed was that for mapped 
reads, there was an unexpected pattern of genomic alignment, with the highest frac-
tion of reads mapping to intergenic part of DNA which should not be represented in 
RNA. mRNA selection-based studies usually showed high (70% - 90% of mapped reads) 
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exonic alignemnt and high intergenic mapping acted as first indicator for gDNA con-
tamination. To exclude possible gDNA contamination (Griffith et al., 2015; Conesa et 
al., 2016), a series of further tests were performed, all of which did not support the 
presence of significant gDNA contamination in our samples. However, we did not em-
ploy any further computational gDNA evaluation methods, but visualization of inter-
genic reads could be a good experiment to start with. If gDNA was responsible for 
intergenic reads uniform read distribution would be expected (Andrews, 2016b). An-
other, good in silico experiment to resolve the high intergenic alignment would be 
looking for intergenic regions unusually high in reads, which would be an expected 
result if any of random primes showed binding preference.  
However, we were aware that rRNA depletion technology might change the read dis-
tribution as it depletes only rRNA and mitochondrial RNA but preserves the rest of 
RNA species. Around the time of our observations, available data from Illumina ap-
peared to supported the effectiveness of their rRNA depletion technology that we 
employed. However, since this time, several publications have compared different 
RNA Seq technologies and have clearly shown that sequencing libraries generated by 
rRNA depletion have lower exonic read alignemnt. With that being said, there cur-
rently are no consensus of what the expected alignment pattern for rRNA depleted 
libraries is.  For example, a recent study by Herbert et al 2018 compared seven differ-
ent rRNA depletion techniques. They used the same commercially available RNA ref-
erence sample (The Universal Human Reference RNA (Agilent)) and rRNA depletion 
method as Schuierer et al 2017. Nonetheless, they were not able to reproduce the 
same genomic alignment as the other group. The final two messages conveyed by 
Herbert et al were that the same genes were detected significantly different by differ-
ent kits and that performance of the same kit in different RNA seq facilities were mark-
edly different (Herbert et al., 2018). 
Interestingly, samples of different origins (Schuierer et al., 2017; Zhao et al., 2018) and 
preservation techniques (Zhao et al., 2014) have high variance in their exonic : inter-
genic : intronic read ratios.  Zhao et al 2018 showed that in order for rRNA depleted 
blood and colon samples to reach the same protein coding gene coverage as produced 
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by poly-A selection 220% and 50% more reads would be required, making rRNA tech-
nology very cost ineffective if it is protein coding genes which are of interest (Zhao et 
al., 2018).  
 
In conclusion, based upon our experiments and those of others, we believe that cur-
rently none of the kits for sequencing library construction from bulk of RNA would 
yield good quality sequencing libraries when small clinical samples with only pg of 
suboptimal quality available.  Instead, if our experiments were to be repeated, meth-
odologies based upon single cell sequencing should be considered. Decreasing costs 
and increased throughput rates makes it this an attractive means to study the tran-
scriptional profiles in cell populations present in clinical samples. However, the down-
fall for single cell technology is the limited number of transcripts one gets when com-
pared to bulk sequencing. Indeed, during the review of the present manuscript, we 
became aware of recent related work by Smillie et al. (‘Rewiring of the cellular and 
inter-cellular landscape of the human colon during ulcerative colitis’, submitted for 
publication). These authors proceeded to generate a single-cell expression atlas from 
the colon to capture the transcriptional landscape of healthy and UC patients. To-
gether their work showed that genes with high probability of being causal share very 
cell subset- and linage- specific expression patterns, which change upon inflammation 
(Smillie et al., 2018). This observation further compliments our work, where we pro-
ceed to investigate the transcriptional changes and, later, epigenetic changes in cell 




















Next, we proceeded to estimate what sample size is needed to correctly reject the null 
hypothesis that there is no difference in gene expression between two groups. We 
used RNASeqSampleSize package developed by Zhao et al., 2018. It should be noted, 
that due to RNA seq data complexity (they represent hundreds of genes with different 
expression values, distribution and dispersions) there is no standard method for 
Power Calculation. In addition, user must provide with descriptive values for prognos-
tic genes (genes that will be differentially expressed). Therefore, to have the best pos-
sibility to accurately capture sample size needed, we used two different functions 
from RNASeqSampleSize package using our own data and publicly available large col-
orectal cancer RNA seq data set.  
First, we created power curves using dispersion values from our data. In short, we 
asked what will be the power to accurately reject null hypothesis if: 
1. Prognostic genes will have average expression of either 100 counts (lambda0 
= 100) or 250 counts (lambda0 = 250).  
2. Minimal fold change associated with prognostic gene is 2, 3 or 4 (rho = 2, 3 or 
4)  
Sample numbers used for RNA seq data analysis is showed by white interrupted lines. 
When sample numbers in each group was not equal, such as 12 vs 9, we used the 
lower value. We reasoned that it will give more realistic picture (due to higher chance 
to have estimated population mean deviated from real population mean). 
Calculations showed that Control vs UCn comparison were too low in sample size to 
accurately reject null hypothesis even if prognostic gene has 4-fold change between 
conditions compared. Whereas Control vs UCi comparison would be able to capture 
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very prominent prognostic genes that has high median cell counts and fold change 
associated with them (Figure A5.1 and A5.2).  
As power depends on dispersion we wanted to use large data set with many samples 
to give us the best chance to accurately capture intra-group variance in expression. 
We asked how many samples would be needed to have 80% possibility that we have 
accurately rejected null hypothesis in data set with minimal average gene expression 
of 10 counts, with total number of expressed genes ~8K.  
Calculations showed that if prognostic gene has minimum difference of 2 folds, 3 folds 
or 4 folds, 48, 20 and 12 samples are needed, respectively. Altogether agreeing of 




Figure A5.1 POWER CURVE FOR CD4+ T CELL DATA. x axis represents sample numbers, 
whereas y axis shows the associated Power.  Both Blood and LPL CD4+ T cell data had the same 
dispersion value of 0.6 and 0.4 for genes with average counts of 100 and 250, respectively. 
Rho shows the minimum expected fold change and lambda0 represents the average counts 
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rho = 2; lambda0 = 250
rho = 3; lambda0 = 250
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Figure A5.2 POWER CURVE FOR CD19+ B CELL DATA. x axis represents sample numbers, 
whereas y axis shows the associated Power.  Both Blood and LPL CD19+ B  cell data had the 
same dispersion value of 0.7  and 0.5 for genes with average counts of 100 and 250, respec-
tively. Rho shows the minimum expected fold change and lambda0 represents the average 
counts for prognostic gene. White lines represent sample numbers in our analysis. 
 
In summary, we showed with the current sample numbers we have up to 0%-8% prob-
ability to accurately reject the null hypothesis when Control is compared to the UCn 
populations, when prognostic gene has average counts of 250 and fold change of 4. 
However, in LPL CD19+ B cells (C vs UCn) we have identified gene HIST1H2AJ that has me-
dian counts of ~1411.04 and Log2fold change of -3.65 and has 99% probability to be 
an accurate estimation.  
When Control samples are compared to UCi populations, we have  50% LPL CD4+ T 
cells (C vs UCi), 65% Blood CD4+ T cells (C vs UCi), 34% LPL CD19+ B cells (C vs UCi) and 49% Blood 
CD19+ B cells (C vs UCi) chance of correctly rejecting null hypothesis if prognostic gene 
has 4 fold (Log2Fold of 2) difference and average read counts of 250. Altogether, we 
wanted to highlight that this calculation is highly dependent of the parameters we 
associate with prognostic genes. Hereby, we conclude that our Control vs UCi data sets 
could be used to identify prognostic genes with high average expression and/or fold 
change. However, the further validation experiments are crucial before making any 
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Initial ATAC Seq analysis was performed by Dr. J. Gutierrez-Achurry (postdoctoral re-
search associate in Dr Carl Anderson’s group, Wellcome Trust Sanger Institute).  Fur-
ther analysis was carried out by the author.  ATAC Seq Data  quality was determined 
at various stage of analysis and has been main findings has been summarized below.  
Raw	 Sequencing	 Read	 Alignment	 And	 Assessment	 Of	 ATAC	 Li-
brary	Quality		
Substantial variation in sample sequencing depth was observed with total raw PE read 
count ranging from 11.2M to 225.6 M reads/sample with median of 49.6M reads/sam-
ple (Figure A6.1). Three samples particularly separated from the rest, these all came 
from a single sequencing lane which had been loaded with only these 3 samples, re-
sulting in less competition for binding.  
 
Figure A6.1 ATAC LIBRARY SEQUENCING DEPTH (n sample = 183). Error bar represents the mean 
and standard deviation. PE - Paired end; M –  Million.  
Following initial clean-up which included adapter trimming and short fragment re-
moval, raw reads were mapped to human genome (version 38) by use of BWA aligner 
(Li and Durbin, 2009). The vast majority (89%) of samples had a mapping score higher 
than 90% (Figure A6.2 ), signifying overall sequencing accuracy and absence of other 
contaminating genomes.  




Figure A6.2 ATAC SEQUENICNG LIBRARY ALIGNMENT TO HUMAN GENOME EXPRESSED AS 
PERCENTAGE OF TOTAL RAW READS (n sample = 183). Error bar represents the mean and stand-
ard deviation. 
The human mitochondrial genome is a well-recognized contaminant of first genera-
tion ATAC Seq libraries and this requires removal from datasets. To estimate how 
much of the total read counts were taken up by reads mapping to the mitochondrial 
genome, Samtools (Li et al., 2009) command indexstats was run by Medimmune Bio-
informatician. The output file was processed by author and numbers expressed as per-
centage of total library size (Figure A6.3 ).  
Mitochondrial read counts in samples fluctuated, with some samples having only 0.11 
% of total read counts taken up, but others as high as 73.20%. High presence of mito-
chondrial reads meant that reads from nuclear origin (of interest) will have reduced 
sequencing depth in these samples and, possibly, will lead to decreased power to de-
tect the difference in chromatin conformation (hereafter referred to as differentially 
accessible regions (DAR)) between the control and UC.  
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Figure A6.3 PERCENTAGE OF TOTAL PROCESSED READS THAT MAPPED ON MITOCHONDRIAL 
GENOME (n sample = 183). Error bar represents the mean and standard deviation. 
To obtain an impression of final library depth after all filtering, total read counts from 
each purified read file was visualized (Figure A6.4). Initially we set a goal for 40M PE 
reads/sample which should result in 20M SE reads/sample, yet we only achieved a 
mean of 7.5M SE reads/sample, thus more than half of libraries had lower counts that 
had been previously determined as optimal. 
 
Figure A6.4 READ COUNT PER SAMPLE POST FILTERING THAT WAS USED FOR PEAK CALL-
ING (n sample = 183). Error bar represents the mean and standard deviation.  SE -  Single End; 
M -  Million.  
 
For further analysis samples were selected based on their Fraction of reads in peaks 
(FRiP) and total read count. FRiP was calculated by dividing the number of reads falling 
in peak regions with total mapped read count and has been established as a quality 
metric for Chip seq data interpretation (Landt et al., 2012). The recommended cut off 
threshold used in ATAC Seq studies ranges from ≤10% to ≤15% of FRiP. In this study 
we selected a less conservative cut off of ≤5%, due to the large number of samples 
falling below the 10% margin (Figure A6.5).  
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Figure A6.5 PERCENTAGE OF FRACTION OF READS IN PEAKS (n sample = 183). Red dots repre-
sent samples with FRiP less than 5%, Orange dots shows samples with FRiP higher than 5% 
and lower than 15%, whereas blue dots represent samples with FRiP higher than 15%. Error 
bar represents the mean and standard deviation. FRiP- Fraction of Reads in Peaks. 
In addition to FRiP, reads count for each sample in the group it belonged to (e.g. Blood 
CD4+ TEM) were compared to median read count for the same group. The individual 
read count per sample was expressed as percentage of median read count, and sam-
ples that fell below 10% on this assessment were removed. Applying these filtering 
criteria resulted in a total of 25 samples (from the original 183) being excluded from 
further study; interestingly 9 of these 25 samples came from the same donor, indicat-
ing on possible error in library preparation stage.  
Pre-Differential	Accessibility	Quality	Control	
Before differential accessibility calculation can commence, we performed visual data 
exploration to ensure that samples are indeed representing the expected phenotype 
and there are no other factors that would drive sample separation.   
Unfortunately, we were not able to used DESeq2 packadge inherit exploratory analy-
sis, as at the time of analysis DiffBind packadge did not provide this functionality. It is 
preferable to use the same normalized counts for significance estimation and initial 
visualization as each normalization metric influences sample to sample relations. In-
stead, pre-filtered raw read counts were normalized for sequencing depth and length 
of each peak by RPKM and log2 transformed to minimize the influence on test statis-
tics of peaks with the highest counts. Samples clustering was assessed by Spearman 
correlation and by PCA.	
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Sample correlation revealed that the main variable driving sample separation was cell 
type, where Blood CD14+ MF, LPL and Blood CD19+ B cells and CD326+ Epithelial cells 
made distinct groups with most of CD19+ B cell samples further separating based on 
their anatomical region (Figure A6.6). Yet, TEM clustering was much more heterogene-
ous with both CD8+ and CD4+ cells from all three regions combining in smaller patches. 
One of the plausible explanation for TEM patchiness would be that both- anatomical 
location and cell type had similar weights on sample clustering.  Interestingly, a small 
subset of the TEM samples were closer to epithelium. We were not sure what factors 
were behind this separation, but contamination seemed less likely as some of the sep-
arated TEM samples were of peripheral blood origin. Similar patterns were observed 
when clustering was based on top 500 and top 5000 peaks with highest standard de-
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Figure A6.6 HEATMAP REPRESENTING SAMPLE-TO-SAMPLE RELATIONSHIPS (n samples = 158). 
In colour-key 1 (the same sample) is represented by dark blue colour, which slowly transitions 
into white with samples becoming more different to each other. Samples from UCi, UCn and 
Control patients were colour-coded dark blue, green and light blue, respectively.  Light orange, 
dark violet, light violet and dark orange were assigned to Blood, LPL, IEL and Epithelium. Fi-
nally, dark blue, light blue, dark green, light green and yellow shows CD4+ TEM, CD19+ B cells, 
CD14+ MF, CD8+ TEM and Epithelium. LPL – Lamina Propria; IEL – Intraepithelial Lymphocytes; 
UC(I) - Ulcerative colitis patient with inflamed Sigmoid colon; UC(N) - Ulcerative colitis patient 
with non-inflamed Sigmoid colon; TEM – T effector memory; MF - Macrophages and Monocytes. 
To investigate how known technical and biological factors such as disease state, sec-
ondary condition, sex, medication, total PCR cycles and Tn5 enzyme volume used for 
library construction and sorter type, might influence sample clustering, PCA for indi-
vidual binding affinity matrices were calculated and samples in PC1/PC2 plots color-
coded based on feature they represented.   
In all 10 models, none of the factors tested showed any influence on PC1/PC2 (data 
not shown).  
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Post-Differential	Accessibility	Quality	Control	
In the same manner as for RNA seq data analyis, we perfomed vigorous assessment 
of test statistics.  
Data passed all but the p-value distribution QC metrics. Instead of anti-conservative 
or uniform p-value distribution these plots had conservative (“hill-shaped”) distribu-
tion with more p-values at 1 than at 0. The odd p-value distribution is first indicator 
that test statistics has failed and results are not reliable for any furter interpretation.  




Figure A6.7 P-VALUE HISTOGRAMS ILLUSTRATING CONSERVATIVE (HILL-SHAPED), UNI-









We performed rigorous search of any previously reported instances when the DESeq2 
test statistics had failed and returned hill-shaped p-value distribution. The 3 most 
common reasons we found were:  
1) If variance from the null distribution is too high (Klaus et al., 2016).  
2) Unidentified batch effect (Bergenstrahle, 2017). 
3) Overwhelming prescience of genes with low counts (in our case peaks) (Ber-
genstrahle, 2017).  
To permitted more flexibility for data assessment, we transformed all individual 
DiffBind class objects into the DESeq2 specific objects. Next, we proceeded to investi-
gate if any of 3 proposed reasons could explain failure of statistical test seen.   
First, we used the  fdrtool package to re-evaluated the null variance for all compari-
sons. However, thought the most of calls had variance different than 1, the newly es-
timated variance did not rescue the test statistics.  
Next, to test if any of known technical or biological factors influence sample relation, 
PCA was re-performed. This time PCA was calculated by DESeq2 internal function. In 
addition, we decided to use variance stabilizing transformation instead of log2 trans-
formation.  Variance stabilizing transformation accounts for both - high and low count 
impact on variance.    
Despite data pre-filtering and improvement in normalization and variance stabiliza-
tion, it was still very hard to dissect if and how much of any factors tested had an 
influence on sample variance. However, the message from newly generated PC plots 
were consistent with all previous results (Data not shown). 
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Following the PCA assessment, the raw and normalized counts for each sample were 
visualized by boxplots and density plots. This showed that some of the samples were 
so low on counts that even after normalization they failed to align with other samples.  
Observed low count dominance was not unexpected, as most samples were left with 
small library sizes after initial raw count clean-up had taken place. However, further 
sample exclusion would lead to reduced power to detect DAR. Nevertheless, keeping 
outlier samples which resist normalization appeared to have a more negative impact 
on test statistics, so these outlier samples were removed after manual inspection. In 
addition, stringent count pre-filtering was introduced, stating that each sample in 
comparison must have 10 or more counts for a given region to be retained. 
Finally, the call for the differential accessibility was repeated and test statistics evalu-
ated. Thought, now only 5 of 20 tests showed a hill-shaped p-value curves the number 
of differentially accessible regions identified between Blood CD19+ B cells  (C vs UCn)  and 
(C vs UCi)  were very high making us question if some of the calculations have truly 
worked.  
In summary, majority of samples in this experiment are under sequenced and below 
our target of 40M reads/sample. Data set can be used to identify peaks which are 
present/absent in each phenotype, yet the differential expression analysis must be 
looked with caution, particularly as our test statistics either failed or showed suspi-
ciously high number of differentially accessible regions. In addition, the inter-group 
variance is very high suggesting that very small sample numbers we have are insuffi-
cient to correctly represents estimated population mean, thus has little or no power 


















At time of ATAC seq data analyis there were no standard methodologies established 
for ATAC seq data normalization. The normalizetion method that the DESeq2 model 
uses accounts for both - differences in sequencing depth and sample composition 
(Love, Huber and Anders, 2014). In most published ATAC Seq studies authors normal-
ize for depth alone, and do not seek to correct for sample compositional bias. In order 
to evaluate if DESeq2 inherit data normalization metrics would be suitable for ATAC 
seq data, we proceeded to performed a series of data symulation experiments.  
First we looked to assess if the read count in peaks could be used as representation of 
the toatal sequencing depth. The total library size (i.e. reads used for peak calling) was 
correlated with the total read count in peaks for each library, and strong, positive cor-
relation (r = 0.74, p = 0.0001) observed (Figure A7.1). This indicated that the metric of 
total reads in peaks could be used to adjust for difference in library size. 
 
Figure A7.1  SPERAMAN CORRELATION LOOKING AT THE RELATIONSHIP BETWEEN THE TO-
TAL LIBRARY SIZE AND READS IN PEAKS (n samples = 158). Relationship was quantified by Spear-
man’s correlation. Each dot represents a sample. r - Spearman’s rho; p - p-value; M – Million. 
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Next, to investigate if DESeq2 normalization metrics are compatible with ATAC Seq 
data, both median ratio and scaling to full library size were compared head to head.	
For data symulation purpose, a new counts matrix from Blood Control CD4+ TEM and 
CD19+ B cells were generated. We worked under assumption that genes under active 
transcription should have their TSS open (Boyle et al., 2008).  Since transcriptional 
differences between healthy blood T cell and B cells are well established, looking at 
differentially accessible peaks and linking these with the TSS of nearby genes, then 
comparing these to known T and B cell DEG, represents a strategy for differential ac-
cessibility pipeline validation. In this study TSS region was set to ± 1000kb upstream 
and downstream from the actual TSS (according to the definitions used in de la Torre-
Ubieta et al., 2018). 	
A total of 15988 and 15284 DAR between blood control CD4+ TEM and CD19+ B cells 
were identified when read counts were normalized by median ratio or scaling method, 
respectively. 82.85% of all DAR peaks were identified by both methods (Figure A7.2).    
 
Figure A7.2 VENN DIAGRAM REPRESENTING THE NUMBER OF DIFFERENTIALLY ACCESSIBLE 
REGIONS IDENTIFIED FROM THE SAME DATA SET NORMALIZED BY EITHER MEDIAN RATIO 
METHOD OR SCALED TO FULL LIBRARY SIZE.  
 
To further investigate if the peaks identified were consistent with expected biological 
differences, all differentially open regions were annotated for their genomic origin 
and assigned to a gene (by proximity to nearest TSS). Associated genes were then an-
alysed using KEGG pathway enrichment analysis (Zhao, Guo and Shyr, 2019).  
DA regions were enriched for B cell receptor signalling pathways and T helper 1 and T 
helper 2 differentiation (Figure A7.3), providing reassurance that DESeq2 internal 
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normalization metrics can be used for current ATAC Seq data set and that identified 
peaks represent true biology.  
 
 
Figure A7.3 KEGG PATHWAY ANALYSIS OF CHROMATIN REGIONS IDENTIFIED AS DA BY ME-
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DA estimation was far from straightforward. First, substantial percentage of reads 
(median = 30.2%) were lost due mitochondrial contamination, which is an expected 
problem for all first generation ATAC Seq protocols (Gaspar, 2019). Mitochondrial DNA 
is nucleosome-free (Alexeyev et al., 2013) which makes it an ideal substrate for trans-
posase cleavage. Since recognition that large proportion of sequencing reads are lost 
due mitochondrial contamination various mitochondrial depletion techniques has 
been evaluated (Wu et al., 2016; Gu et al., 2016; Corces et al., 2017; Montefiori et al., 
2017).   
Assessment of Omni-ATAC Seq protocol allowed us to propose a reason behind the 
very heterogeneous amounts of mitochondrial DNA seen in our libraries. Even though 
our nuclei extraction step was adopted from DNase I hypersensitivity assay (John et 
al., 2013) the detergent and order of tagmentation steps stayed the same as in the 
ATAC Seq protocol. Both protocols use IGEPAL - a nonionic, non-denaturing detergent, 
and immediately proceed with transposition reaction. We believe that incomplete ly-
sate removal from the nucleic fraction has resulted in mitochondrial contamination. 
Due to low cell numbers the nuclei pellet was not visible after initial centrifugation 
following lysis. Thus, in order to avoid removal of nucleic material some lysate was left 
at the bottom of tube. Additionally, the lysis reaction was carried out in 1.5ml Eppen-
dorf tubes, further complicating the identification of any nuclei pellet. Therefore, the 
inconsistency in lysate removal would explain the highly heterogeneous amounts of 
mitochondrial reads seen.  
Increased	Background	Signal	
Next, 25 samples were effectively lost due low signal to background ratios. Hoverer, 
the actual number of samples with suboptimal quality (FRiP < 15%) was 71 which 
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would correspond to more than 1/3 of all samples sequenced. Currently, we do not 
know the reason behind the low signal to background ratio. However, a literature 
search has allowed us to identify 3 known factors which influence tagmentation. 
They are chromatin conformation, underlining DNA sequence (Madrigal, 2015)and 
Tn5 transposase concentration (Buenrostro et al., 2015).   
If ATAC Seq libraries have been constructed correctly, around half of post-cleanup 
fragments should be shorter than 100bp and the rest of the fragments should show a 
prominent downward laddering pattern (Buenrostro et al., 2013; Ou et al., 2018). The 
small fragments (<100bp) are representative of nucleosome free regions, whereas the 
downwards facing ladder corresponds to nucleosomes tightly wrapped in chromatin 
and, thus, protected from cleavage.  Thus, plotting the size distribution of sequenced 
fragments of ATAC Seq libraries would be a good computational approach to address 
if the low signal to background ratio is due to cell oversaturation with Tn5 transposase.  
A recently published Fast-ATAC Seq protocol (Corces et al., 2016), designed for pri-
mary blood cells, used 50µl of tagmentation mix for only 5,000 primary haemopoietic 
cells (including blood CD4+ and CD8+ T cells). With majority of our samples having more 
than 5,000 cells and use of only 30 µl - 35µl of tagmentation mix made oversaturation 
less likely. Nevertheless, we believe that for any further analysis, construction of frag-
ment size distribution plots will be crucial.  
The loss of reads due to mitochondrial contamination let us question if low sequencing 
depth has an impact on the high background noise observed. Ou et al 2018 used al-
ready published ATAC Seq data and showed that downsizing the library size to 2.6M 
uniquely mapped reads did not affect the patterns seen in quality control plots, yet 
the peak height decreased (Ou et al., 2018). Similar observation was made by 
Buenrostro  et al 2013 when they compared the assay performance between 50,000 
and 500 GM12878 lymphoblastoid cells (Buenrostro et al., 2013). Taken together, 
both studies showed that low cell counts in combination with low sequencing depth 
are naturally susceptible to higher background signal.  
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Another computational experiment to determine the ATAC Seq library quality would 
be visualization of read distribution around regulatory regions of known housekeeping 
genes. It is expected for housekeeping genes to be actively transcribed and, thus, their 
promoter sites should be opened.    
In summary, we are not sure what the was reason behind the low signal: noise rations 
observed. However, after consideration of work done by Corces et al 2017 we noticed 
that CD4+ T cells libraries showed only 10% FRiP, when libraries were prepared by first 
generation ATAC Seq protocol (Corces et al., 2017). This suggests that the poor FRiP 
seen is not due to failure of library preparation but an inherit problem with the proto-
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